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ABSTRACT 
 
FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS AND METABOLIC 
HEALTH IN PREGNANT SAUDI WOMEN 
MAY 2018 
MAYSA H. ALZAIM, B.S., KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Associate Professor Richard Wood 
 
Lifestyles have been dynamically changing in the past few years in Saudi Arabia, 
and the prevalence of non-communicable diseases (NCDs), such as obesity, diabetes, 
hypertension, high cholesterol, and other cardiovascular diseases (CVD), is notably 
increasing. In fact, NCDs are affecting a growing number of people in SA, especially 
women of childbearing age. Vitamin D deficiency has also become pandemic and a major 
public health concern among the Saudi population despite the abundance of sunlight. The 
most vulnerable groups are pregnant women and their newborns. Previous studies have 
correlated low vitamin D status with a higher risk of adverse short- and long-term health 
consequences for both mother and child. Therefore, identification of novel genetic 
markers in women at risk of adverse pregnancy outcomes could lead to earlier 
identification of at-risk pregnancies and inform possible interventions to reduce adverse 
health outcomes. 
  viii 
The fact that vitamin D receptors (VDR) are present in almost every tissue of the 
human body has led to a debate about the extra-skeletal functions of vitamin D. To date, 
numerous studies have associated VDR gene polymorphisms to serious chronic illnesses. 
One candidate gene that has attracted interest in the literature is FokI VDR 
polymorphisms. FokI VDR, is capable of altering the protein structure and produces two 
structurally different variants: a longer (f allele) and a shorter (F allele), which is more 
effective and has higher transcriptional activity than the long variant (f allele).  
Since there is scarce research regarding the potential association between FokI 
VDR polymorphism and adverse metabolic health outcomes in pregnant Saudi women, 
we hypothesized that Saudi mothers with poorer vitamin D status plus expression of the 
longer, less effective f version of the VDR protein would be at greatest risk of any 
adverse effects, such as vitamin D deficiency, gestational diabetes mellitus (GDM), and 
metabolic syndrome (MS). 
We carried out a cross-sectional study in pregnant Saudi women and compared 
the association between the FokI VDR genotype and different metabolic health outcomes. 
The participants were randomly selected from primary health care centers and 
governmental hospitals scattered around the city of Riyadh during their first and second 
trimesters check-up between December 2013 and January 2016. The FokI VDR genotype 
was assessed, and its association with different variables, including vitamin D status, 
GDM, and MS and its components, were also analyzed. 
In the first study, we investigated the association between FokI VDR gene 
polymorphism and serum 25-hydroxyvitamin D (25(OH)D) levels in 345 pregnant Saudi 
women (273 with vitamin D deficiency and 72 non-deficient subjects) in their first 
  ix 
trimester. About 79% of the women studied were vitamin D deficient (25(OH)D < 50 
nmol/L). Our findings indicated that the Ff genotype and the combined variant genotype 
(Ff+ ff) showed a significant decrease in the risk of developing vitamin D deficiency (FF 
vs. Ff, OR = 0.44, 95% CI = 0.20–0.94, P = 0.035, FF vs. Ff+ff, OR = 0.42, 95% CI = 
0.20–0.88, P = 0.022), after adjusting for confounding factors that had significant effect 
on altering vitamin D status. 
In the second study, we examined whether there was a difference in the risk of 
having GDM among the various FokI VDR genotypes in 108 GDM patients and 260 
healthy pregnant women in their second trimester. We found no significant difference in 
risk. However, within the group of patients carrying the minor ff genotype, we found that 
serum 25(OH)D was significantly and inversely associated with fasting serum glucose 
and hemoglobin A1C. Vitamin D deficiency was highly prevalent among study 
participants amounting to 85.3%. It was also significantly associated with GDM 
(P=0.016) and glucose indices such as fasting insulin, HOMA_IR and HOMA_. 
In the third study, we investigated the association of the FokI VDR genotype as a 
risk factor for MS and its components in 368 pegnant Saudi women (44 with MS and 324 
without MS) in their second trimester. We found that the minor ff genotype was a 
significant risk factor for MS (P = 0.039; OR = 2.91; 95% CI, 1.05–8.1).  
Together, the results of the previous studies suggest that FokI VDR gene 
polymorphism could be a risk factor for vitamin D deficiency, poorer glucose 
homeostasis, and MS in the Saudi population.  
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CHAPTER 1 
CHALLENGES FACING PREGNANT SAUDI WOMEN 
 
Saudi Arabia is a high-income country with a well-developed health care system, 
including free antenatal care for all pregnant Saudi women at primary healthcare centers 
as well as referral to government hospitals.1 Moreover, in the past few years there has 
been a significant improvement in the educational and employment status of the Saudi 
female population.2 These enhancements in medical care and sociodemographic 
characteristics have clearly manifested in overall pregnancy outcomes, including the 
maternal mortality ratio, which declined from 23/100,000 in 2000 to less than 13/100,000 
in 2015.2 Despite this, epidemiological studies conducted in Saudi Arabia found a high 
stillbirth rate of 12/1000 live births, which is high when compared with similar high-
income countries, with the reason attributed to a high prevalence of maternal diabetes and 
obesity.1 
The rapid urbanization and advancement in socioeconomic status has resulted in a 
significant change in Saudi lifestyle behaviors, including increased consumption of high-
energy dense foods, physical inactivity, and the subsequent emergence of non-
communicable diseases (NCDs) such as obesity, diabetes, hypertension, high cholesterol, 
and other cardiovascular diseases (CVD).1 NCDs have thus become a major public health 
problem and are now the primary cause of death among adults in Saudi Arabia.3 In fact, 
the death toll from NCDs reached 78% during 2014, and CVDs were responsible for 
about (46%) of these deaths.4 The most alarming fact is that these risk factors are 
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prevalent at younger ages,5 and it is well known that Saudi Arabia has a young 
population. More than half of the population is younger than 25 years,6,7 78.3% of 
women are under the age of 40,8 and the over-65 group constitutes only 3.7% of the total 
population.1 These health challenges are concerning in this specific group of women. 
Therefore, prevention and early detection should be prioritized to improve health in the 
Kingdom of Saudi Arabia (KSA). 
In addition to the previously mentioned health problems, vitamin D deficiency is 
highly prevalent in KSA, particularly in females and in the younger age groups.9 Al-Faris 
conducted a cross-sectional study of 160 pregnant Saudi women and found that younger 
pregnant women (aged 20–34 years) had a significantly higher prevalence of vitamin D 
deficiency compared with older women (aged 35–49 years) (P = 0.029).10 The author 
attributed this observation to unhealthy dietary patterns among younger women, 
characterized by high fast food consumption and less vitamin D intake or 
supplementation.10 
The fact that the previously mentioned health problems are more common at 
younger ages deserves immediate attention and investigation of the underlying 
mechanisms. Specifically, according to Al Quaiz et al., Saudi women are at a greater risk 
of developing CVD and diabetes compared to a decade ago, with a notable increase in 
obesity compared to men.6 Moreover, a report published by the World Health 
Organization in 2015 revealed that life expectancy among Saudi Arabian women is still 
lower than that observed in many developed countries (Japan = 86.8, Australia = 84.8, 
United Kingdom = 83, United States of America = 81.6, United Arab Emirates = 78.6, 
KSA = 76 years).11 This chapter will address the health problems prevalent among 
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pregnant Saudi women and the risk factors that contribute to adverse health outcomes for 
mothers and their newborns.   
1.1 Vitamin D Deficiency in Pregnancy  
1.1.1 Prevalence and Diagnosis  
Vitamin D deficiency is considered a public health problem around the world.12 
Vitamin D status has been investigated in numerous countries based on the concentration 
of serum 25-hydroxyvitamin D (25(OH)D).13 There is a debate in the literature regarding 
the definition of vitamin D deficiency. Most researchers agree that a 25(OH)D 
concentration < 50 nmol/L is an indication of vitamin D deficiency, whereas a 25(OH)D 
concentration of 51–74 nmol/L is considered to indicate insufficiency; concentrations > 
75nmol/L are considered to be sufficient.13 This is based on the observation that intestinal 
calcium absorption is maximized above 80 nmol/L, and parathyroid hormone (PTH) 
concentrations in adults continue to decline and reach their nadir at ≈75–100 nmol/L.13 
As there are no tailored recommendations for the diagnosis and treatment of 
vitamin D deficiency in the Middle Eastern region, the Prince Mutaib Chair for 
Biomarkers of Osteoporosis (PMCO) in King Saud University (KSU), Riyadh, KSA, 
together with local experts and in cooperation with the European Society for Clinical and 
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), organized a panel to 
resolve this issue and established a reference range for the cut-off values of serum 
25(OH)D based on the following: Vitamin D sufficiency is defined as circulating serum 
25(OH)D ≥ 50 nmol for the general population and vitamin D adequacy as serum 
25(OH)D > 75 nmol/L for the frail and osteoporotic elderly. The panel also 
recommended vitamin D supplementation of 1000–2000 IU/day (vitamin D2 or vitamin 
  4 
D3) for pregnant Saudi women, which it claimed would be feasible, safe, and could 
improve maternal and fetal outcomes.14 
In KSA, two meta-analyses were conducted to assess the prevalence of vitamin D 
deficiency across all demographics of the Saudi population.15,16 Both systematic reviews 
used the same cut-off values for determining vitamin D status and were conducted around 
the same years. Strangely, however, they reported contentious results. In the first meta-
analysis, which included 16 articles and was carried out between 2008 and 2015,15 Al-
Alyani et al. found that the overall rate of vitamin D deficiency in the healthy Saudi 
Arabian population was 63.5%.15 Meanwhile, the other meta-analysis, which was 
conducted by Al-Daghri between 2011 and 2016 and included a review of 13 articles, 
showed the overall prevalence of vitamin D deficiency to be 81.0%.16 The discrepancy 
between these numbers is relatively large and could be due to a non-unified cut-off for 
vitamin D deficiency, different diagnostic methodologies, and varying study designs and 
qualities. 17  
Although this issue seems controversial, no one can deny that KSA, the land of 
sunshine, has alarming rates of vitamin D deficiency in most of its population, across all 
ages and in both genders. Specifically, Saudi females have higher rates of severe vitamin 
D deficiency (< 25 nmol/L) when compared to males (44.6% vs. 28.3%, p < 0.000), as 
reported in a retrospective observational study of 10,709 patients.18 This issue needs to be 
highlighted and carefully addressed, especially in vulnerable groups that appear to be 
more susceptible to developing vitamin D deficiency, such as women of childbearing age, 
pregnant women, and pregnant women at risk of GDM.19 Previous studies have shown 
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that vitamin D deficiency occurs in up to 90% of pregnant women and depends on many 
factors, such as the country of origin and lifestyle.20 
In KSA, vitamin D deficiency affects approximately 78% of Saudi females among 
various age groups.21,22 Studies of women of childbearing age found a variable 
prevalence of vitamin D deficiency, from one-third22 to three-fourths23 of the population 
studied. Al-Faris found that over 90% of pregnant Saudi women were either vitamin D 
deficient (serum 25(OH)D level < 50 nmol/L) or insufficient (serum 25(OH)D level = 
50–74 nmol/L).10 In another study, which was conducted on a larger sample of 1,097 
pregnant Saudi women living in Riyadh, the capital city of KSA, Fouda et al. found that 
almost 85% of pregnant subjects and 88% of their neonates were vitamin D deficient 
(serum 25(OH)D level < 50 nmol/L).17 Similarly, Al-Wassia and Abo-Ouf and Alsheikh 
et al. reported a very high prevalence of maternal vitamin D deficiency ranging, from 
86.4% to 90.5% in pregnant Saudi women. 24,25 Al-Wassia and Abo-Ouf also found that 
86% of infants were vitamin D deficient.24 Although numerous studies have assessed the 
prevalence of vitamin D deficiency in KSA, information is still lacking regarding vitamin 
D status throughout pregnancy, as most previous studies have measured vitamin D once 
in the third trimester or at delivery. 
1.1.2 Causes  
Maternal vitamin D status varies across different pregnancy trimesters, and the 
risk of vitamin D deficiency increases due to the high maternal and fetal demands.25 
Aside from this, vitamin D levels are usually affected by several factors. The major risk 
factors associated with vitamin D deficiency in KSA have been agreed upon by several 
investigators and are related to Saudi customs.10,16,17 KSA receives abundant sunshine 
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year round, and in summer months the temperatures often rise above 50C. Therefore, 
Saudis avoid sun exposure and limit their outdoor activities during the daytime.10 In 
addition, due to cultural and religious reasons, the majority of Saudi women wear dark 
veils that cover nearly all their body parts, which block sunlight and necessitate increased 
circulating 25(OH)D production from sun exposure.16,23,26 Certainly, there are many other 
risk factors that affect vitamin D status in Saudi women, including dietary habits, dark 
skin pigmentation, pregnancy, physical inactivity, obesity, and lack of government 
regulation for vitamin D fortification of food.18, 25  
Interestingly, Hussain et al. found that vitamin D deficiency was more common 
and severe in Saudis than in non-Saudis living in the same city of Riyadh.18 This 
observation sheds light on the influence of genetic variantiations, such as vitamin D 
receptor gene polymorphisms, which might play a role in vitamin D metabolism and 
disease susceptibility.25 Sadat-Ali et al. were the first to investigate the genetic influence 
on vitamin D status in the Saudi population.27 They found that several single nucleotide 
polymorphisms (SNPs) in vitamin D-related genes were significantly associated with 
vitamin D deficiency compared to the population with normal vitamin D levels.27 
However, there have been no studies to confirm such a relationship in KSA with larger 
sample sizes and controlling for different confounders that might mask vitamin D status, 
such as the risk factors mentioned earlier in this section.  
1.1.3 Adverse Perinatal Outcomes  
Vitamin D deficiency during pregnancy has been associated with several maternal 
and offspring complications that persist later in life.28 Stores of vitamin D in newborns 
are dependent on maternal vitamin D status.20 Maternal serum and cord blood 25(OH)D 
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are highly correlated, and both maternal serum and cord blood 25(OH)D levels increase 
after maternal vitamin D supplementation.29 Indeed, two recent cross-sectional studies 
found a significant association between maternal serum 25(OH)D and neonatal cord 
blood Vitamin D levels in pregnant Saudi women.17,24  
It has been also suggested that low serum 25(OH)D in the mother might cause 
reduced transfer of 25(OH)D to the fetus, leading to impaired growth, low infant birth 
weight, delayed bone ossification and congenital rickets, abnormal tooth enamel 
formation, and lower bone mineral content.30 Case reports show that neonatal 
complications from extreme maternal vitamin D deficiency can be life threatening, e.g., 
severe hypocalcemic fits with high risks of resultant brain damage and neonatal heart 
failure.29  
Aside from causing adverse skeletal effects, vitamin D deficiency during 
pregnancy has also been linked with a number of maternal problems, including infertility, 
preeclampsia, gestational diabetes, caesarean section, bacterial vaginosis, postpartum 
depression, neonatal hypoglycemia, low birth weight, and preterm birth.10,31-33 
Fortunately, a recent study found that supplementing pregnant women with vitamin D 
and increasing maternal serum 25(OH)D levels to ≥ 100 nmol/L was associated with a 
60% reduction in preterm birth risk in a large, diverse population of women.34 
In KSA, Alsheikh et al. studied the effect of hypovitaminosis D on adverse 
pregnancy and neonatal outcomes and found that hypertensive pregnancy disorders and a 
history of miscarriage were significantly associated with vitamin D deficiency and 
insufficiency when compared to women with normal vitamin D levels.25 
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1.2  Gestational Diabetes Mellitus 
1.2.1 Prevalence and Diagnosis  
The American Diabetes Association (ADA) defines GDM as “carbohydrate 
intolerance resulting in high blood sugar (hyperglycemia) of variable severity, with onset 
or first recognition during pregnancy.”35 It is usually diagnosed between 24 and 28 weeks 
of gestation.35 GDM is recognized in the global population as ranging from 1% to 14% of 
all pregnancies, depending on the ethnicity and the GDM diagnostic tests used.36 Hence, 
GDM is considered to be one of the most common complications of pregnancy.37 When 
compared to adverse maternal outcomes, GDM is the most prevalent complication seen 
in pregnant Saudi women (11.1%).25 In fact, in their large multicenter cohort study, 
Wahabi et al. reported that the prevalence of GDM (24%) and pre-GDM (4.3%) in 
pregnant Saudi women is among the highest in the world and is associated with high 
maternal and neonatal morbidities and mortalities.1 Another study conducted in KSA 
showed that 18.7% of all pregnancies led to a GDM status.38 This alarmingly high rate 
exceeds the prevalence that is reported in the United States and Europe.39 In fact, the 
prevalence of GDM in the United States is far less than in KSA, ranging from 3.47% to 
7.15%.40  
Although GDM affects only a sub-group of the population, its prevalence is rising 
along with soaring rates of obesity and Type 2 diabetes mellitus (T2DM).41 For example, 
In the United States, Getahun et al. reported that the prevalence of GDM increased 
gradually between 1989–1990 and 2003–2004 by 122%, from 1.9–4.2%, respectively.42 
Considering the high burden of T2DM in the Saudi population and the fact that the 
occurrence of GDM is directly related to that of T2DM, a high rate of GDM is 
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anticipated to continue to increase in pregnant Saudi women.1 The prevalence of GDM is 
expected to increase fourfold in subsequent decades,43 stressing the importance of further 
research into its pathophysiology.  
1.2.2 Causes 
The most commonly reported risk factors for the development of GDM are high 
maternal age (> 35 years), obesity, ethnicity, parity, family history of type 2 diabetes 
and/or GDM, previous delivery of a macrosomic infant, and diagnosis of polycystic 
ovarian syndrome (PCOS).44 However, these well-known risk factors are only 
responsible for about 50% to 60% of the risk of future GDM.45 Other factors mentioned 
in observational studies that are independently associated with higher GDM risk include 
the following: higher triglycerides,46 inflammation,47 gestational weight gain (GWG),48 
and low vitamin D levels.19 Studies from KSA reported that the most commonly observed 
risk factors were increased maternal age, higher body weight and BMI, previous history 
of GDM, macrosomia, and multiparae.49,50 The question remains: Why are certain ethnic 
groups, such as pregnant Saudi women, at a higher risk of GDM?  
The underlying pathophysiological mechanisms for GDM are poorly understood 
and seem to be multi-factorial.51,52 Nevertheless, it is well known that gestational steroid 
hormones coupled with placental outcomes (hormones and cytokines) are altered by 
insulin secretion and resistance.53 When insulin secretion is unable to meet increased 
maternal needs, secondary to increased resistance, GDM occurs.51,53 As a result, an 
increased request for insulin during pregnancy places an additional burden on pancreatic 
β-cells, which can lead to pancreatic dysfunction.51 Previous data have linked vitamin D 
deficiency to GDM, but some studies have not found this association. A recent systematic 
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review found that vitamin D deficiency (serum 25(OH)D <50 nmol/L) in pregnancy is 
associated with a 1.61-times increased risk of GDM.54 However, this association remains 
inconclusive and requires more studies to elucidate the impact of low vitamin D status on 
the occurrence of GDM.  
1.2.3 Adverse Perinatal Outcomes  
Gestational diabetes (GDM) complicates 3–14% of pregnancies, and it is 
responsible for an important proportion of fetal and maternal morbidity and mortality in 
both the short and long term.42 Short-term effects include maternal GDM complications, 
such as pregnancy-induced hypertension, preeclampsia, urinary tract infections, and 
cesarean deliveries;55 long-term complications include a 35−80% higher risk of recurrent 
GDM,56 a 70% higher risk of developing T2DM within 10 years after delivery,53 and a 
higher risk of developing metabolic syndrome.57 In the offspring of GDM mothers, there 
can also be short-term complications, such as fetal macrosomia, birth trauma, shoulder 
dystocia respiratory distress syndrome, congenital malformation, and neonatal jaundice 
as well as an increased risk of neonatal intensive care unit (NICU) admission.42 
Meanwhile, long-term complications for the child can include childhood obesity, 
metabolic syndrome, T2DM, and CVD.58  
According to a study performed in KSA, GDM was a major contributor to 
perinatal death, congenital malformation, and neonatal jaundice.59 Similarly, most studies 
conducted in KSA reported that GDM affected both the mother and fetus. GDM mothers 
were more likely to have cesarean deliveries, and the infants born to such mothers were at 
higher risk of developing hypoglycemia, higher birth weight, hyperbilirubinemia, 
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macrosomia, and higher NICU admissions when compared to infants born to non-GDM 
mothers.49 
Interestingly, not only mothers with GDM suffered from perinatal complications; 
pregnant Saudi women with pre-GDM also experienced hypertensive disorders during 
pregnancy, induction of labor, cesarean section delivery, preterm delivery between 34 
and 36 weeks, stillbirth rate, neonatal admission to NICU, macrosomia, low APGAR 
scores, and shoulder dystocia when compared to nondiabetic women.1 
1.3 Metabolic Syndrome   
1.3.1 Prevalence and Diagnosis  
Metabolic syndrome (MS) is a cluster of risk factors for T2DM and CVD.25,60 The 
National Institutes of Health (NIH) defines MS as having at least three of the following 
risk factors: central obesity, elevated triglycerides, low high-density lipoprotein 
cholesterol, hypertension, and elevated fasting plasma glucose.61 
MS is considered an epidemic of the 21st century and a huge burden that needs to 
be carefully addressed in both developed and developing countries.60 According to the 
International Diabetes Federation (IDF), a quarter of the adult population worldwide 
suffers from MS.62 The prevalence estimates of MS differ depending on which defining 
criteria are utilized. Using the IDF’s definition of MS, according to the National Health 
and Nutrition Examination Survey (NHANES), the prevalence of MS rose significantly 
from 25.3% between 1988 and 1994 to 34.2% between 2007 and 2012 among US 
adults.63  
In KSA, the prevalence of MS is much higher than in the US, with rates varying 
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between 25.5% and 55% when using the same IDF definition.64 After reviewing different 
studies and using various defining criteria, Bahijri and Raddadi found that the overall 
prevalence of MS in the Saudi population varies from 13.6% to 57%.65 The authors 
attributed the difference in prevalence to variations in the targeted populations, 
geographical location, gender, age groups, and the criteria used to define MS.62 
Irrespective of the defining criteria of MS, the calculated prevalence is very high among 
the Saudi population, particularly among Saudi females.62 This issue raises concern for 
women of childbearing age and pregnant women in KSA, as the detection and screening 
of MS during pregnancy has not been addressed in the literature. Studies on pregnancy 
from around the world have shown that women with MS have a higher risk of having 
newborns with perinatal adverse outcomes, demanding attention and special care.60 
Therefore, diagnosis during pregnancy is essential in terms of determining the women at 
risk of cardiovascular and metabolic changes.66 
1.3.2 Causes  
Despite the fact that the pathogenesis of MS has not been studied thoroughly,67 it 
is known to be a multi-factorial disorder influenced by the synergistic effects of genetic 
and environmental risk factors.62,65 
Environmental components such as changes in diet and lifestyle explain the 
increased prevalence of MS in Saudi Arabia. 62,65 As mentioned earlier, the prevalence of 
MS is increasing worldwide and is associated with the rising incidence of obesity 
epidemic along with population aging and urban housing.57,60 Surprisingly, the overall 
prevalence of obesity in adult females in KSA has been previously reported as one of the 
highest worldwide.4,6,25 Moreover, obesity rates are higher in Saudi females than in their 
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males counterparts.5,68 A large national survey conducted in KSA revealed that 33.5% of 
women were obese and 28.7% were overweight.8 These high rates of obesity in this 
population are extremely shocking and must be addressed, especially for pregnant Saudi 
women.  
Over all, it is estimated that maternal obesity complicates 33% of all pregnancies, 
having detrimental effects on the metabolic health of the mother and offspring.61 Maternal 
obesity has been associated with macrosomia, delivery by cesarean section, pregnancy-
induced hypertension, and higher rates of early miscarriage and congenital anomalies, 
including neural tube defects, which can lead to fetal death.50,60,69  
Most studies have agreed that the high prevalence of obesity among Saudi women 
could be attributed to unhealthy dietary patterns and physical inactivity.3,8,62 Al-Quaiz 
reported a very high rate of physical inactivity, reaching upwards of 98.1% in Saudi 
females.70 
The genetic components of MS have been investigated in the Saudi population 
with relatively very small study sizes. We will elaborate more on this topic in Chapter 2.  
1.3.3 Adverse Perinatal Outcomes  
It is vital to identify women with MS, as they are at twice the risk of developing 
CVD over the next 5–10 years.57 According to World Health Organization (WHO), 
CVDs are the primary cause of death in women worldwide, accounting for 33.2% of 
female deaths in 2008.71 In KSA, the estimated prevalence of CVD is around 42%, with a 
high proportion of young women aged 30 years and above affected.72 Strangely, the mean 
age of CVD incidence was estimated to be ten years younger in the Gulf region when 
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compared to that in European countries.72 Women with MS also have a higher risk of 
developing GDM,69 and thus they have a 30% risk of developing future T2DM.57,60 
There are few studies on metabolic syndrome in pregnancy. Dane et al. found that 
pregnant women with MS had significantly higher rates of GDM and preeclampsia when 
compared with women with normal pregnancies.66 Moreover, Tavares et al. reported 
finding adverse perinatal outcomes in 14.1% of pregnancies with MS.60 
Overall, women in KSA face serious health challenges, such as vitamin D 
deficiency, GDM, and MS. These conditions are alarmingly widespread, especially at 
young ages. To develop strategies for primary prevention, more research is needed on 
younger women, and special attention should be focused on pregnancy to prevent the 
burden of disease in coming years.  
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CHAPTER 2 
FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS AND ITS 
ASSOCIATION WITH NON-SKELETAL OUTCOMES 
 
2.1 Vitamin D Metabolism Pathway 
It has been long known that the effect of genetic variation in the vitamin D 
synthesis and metabolism pathway on circulating concentrations is not clear.1 The two 
forms of vitamin D, which is either synthesized in the body from adequate exposure of 
the skin to sunlight (vitamin D3; cholecalciferol) or obtained from diet (vitamin D2; 
ergocalciferol), are both prohormones that are biologically inactive.2 Both vitamin D3 and 
D2 are hydroxylated twice to obtain their biologically active form, calcitriol, or what is 
known as 1,25-hydroxyvitamin D (1,25(OH)2D).
3 The first hydroxylation occurs in the 
liver, where the enzyme 25-hydroxylase (CYP2R1) hydroxylates vitamin D to 25-
hydroxyvitamin D (25(OH)D; calcidiol), which is the circulating form of vitamin D and 
the most reliable indicator reflecting vitamin D status.4 The second hydroxylation occurs 
primarily in the kidneys or at the local tissue level and is performed by the enzyme 
25(OH)D-1-α-hydroxylase (CYP27B1) to yield 1,25(OH)2D.4 The active hormone, 
1,25(OH)2D, is then released in the blood, where it binds to the vitamin D–binding 
protein (DBP) and arrives at the targeted cells to apply its endocrine functions through 
the vitamin D receptor (VDR; Figure 2.1).5,6 This process is vital in regulating many 
genes that play significant roles in controlling cellular growth and differentiation.5,6 Thus, 
any genetic variation or mutation in this metabolic pathway has the capability of altering 
serum 25(OH)D concentrations.1  
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Figure 2.1: Vitamin D metabolism and genes involved in vitamin D metabolic 
pathways  
(Adapted from Hossein-Nezhad & Holick, 2013)6 
 
 
2.2 Vitamin D Receptor (VDR) Gene Polymorphisms  
VDR, a member of the steroid/thyroid hormone nuclear receptor family, is 
ubiquitously expressed in nearly all nucleated human cells at fluctuating concentrations.7 
The VDR gene is considered to be a candidate for controlling responses to vitamin D.8 As 
mentioned in the previous section, VDR binds to the active form of 1,25(OH)2D and, in 
turn, the ligand-activated VDR forms a heterodimer with the retinoid X receptor.9 The 
heterodimer binds to vitamin D–response elements in the promoter regions of vitamin D–
dependent target genes and regulates the expression of various genes related to vitamin D 
metabolism.9,10 VDR is also known to be involved in bone and calcium homeostasis, cell 
differentiation, immunomodulation, and the control of other hormonal systems.11  
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The VDR gene, which is at the chromosomal locus of 12q12-14, includes 2 
promoter regions, 8 coding exons (namely, 2–9), and 6 untranslated exons (1A–1F).12 
Several single nucleotide polymorphisms (SNPs) have been identified in the VDR gene, 
including 3 SNPS located at the 3′ untranslated region (3′ UTR) of the gene, namely BsmI  
(A > G, rs1544410), ApaI (A > C, rs7975232), and TaqI  (T > C, rs731236), as well as 
another polymorphism known as FokI (C > T, rs10735810), which is located within the 5′ 
end of the coding exons near the promoter region (Figure 2.2).13 
Since VDR is found in nearly every human tissue, researchers investigated its 
functional significance and potential effects on disease susceptibility and the extraskeletal 
functions of vitamin D.9 To date, numerous systematic reviews of the literature as well 
genome-wide association studies have linked VDR polymorphisms to various disease 
outcomes, such as bone mineral density, cardiovascular diseases, metabolic syndrome 
(MS), asthma, increased risk of T2D, an unfavorable lipid profile, hypertension, obesity, 
periodontitis, risk of multiple sclerosis, and malignancy.14–16 In the next section, we will 
focus on FokI polymorphism in VDR and its association with adverse health outcomes in 
pregnancy. 
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Figure 2.2: Structure of the VDR gene and position of single nucleotide 
polymorphisms  (Adapted from Uitterlinden et al., 2004)13
 
2.2.1 FokI VDR Gene Polymorphism  
The FokI SNP (rs10735810 merged into rs2228570), which is defined by the 
restriction enzyme, is located in exon 2 of the coding region of the VDR gene (Figure 
2.3).17 It is uniquely different from the other SNPs for two reasons. First, it is the only 
polymorphism that is not linked to any of the other VDR variants.18 Second, it is the only 
known VDR polymorphism, in contrast to other variants, that is translated into two 
different VDR protein products, thus affecting the VDR protein structure and function.11 
In regards to this, VDR FokI is considered one of the most important functional 
regions of the gene.18 In fact, it is the only known VDR gene polymorphism that leads to 
the production of an altered protein.17 In other words, it can generate two structurally 
distinct isoforms: a shorter F allele or a longer f allele protein.19 In the ff FokI genotype, 
translation initiation occurs at the first ATG site, giving rise to a full length VDR protein 
comprised of 427 amino acids.17 On the contrary, in the FF FokI genotype, translation 
begins at the second ATG site instead of the first, resulting in a shortened protein with 3 
fewer amino acids (427 versus 424 amino acids).17 The mutation in the ff FokI VDR 
polymorphism results in a cytosine-to-thymine (C→T) nucleotide change in exon 2 of the 
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coding region of the VDR gene and creates a second upstream start site due to a codon 
change from ACG → ATG.13 This start codon change causes the expression of a VDR 
protein that is 3 amino acids longer and has been shown to reduce transcriptional activity 
and to be less responsive to 1,25(OH)2D than the shorter F allele version in activating 
target gene expression.20 In fact, the F allele variant is 1.7-fold more active than the f 
allele.15,21 However, various studies have shown inconsistent findings regarding the 
functional significance of the FokI polymorphism,9 although most data indicate that the F 
allele is more effective than the f allele in transactivation of the 1,25(OH)2D signal.
13–19 
Thus, women with the F allele may have better metabolic outcomes regarding bone 
health, glucose homeostasis, and inflammatory response.9 Still, the number of 
publications that have examined the role of VDR polymorphisms in pregnancy is very 
limited. The aim of this chapter is to review the association of VDR FokI polymorphism 
and metabolic disorders in the general population while shedding light on the limited 
research that has been done on pregnant women.  
Figure 2.3: Location of the VDR gene FokI polymorphism  
(Adapted from Colombini et al., 2014)17 
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2.2.1.1 FokI VDR Gene Polymorphisms and Vitamin D Deficiency  
Twin- and family-based studies have previously found that heritable factors have 
a considerable effect on vitamin D status.15,19 Depending on the VDR variant, it could 
either increase or decrease the serum 25(OH)D levels.15,19 
The VDR FokI polymorphism, either individually or in combination with other 
VDR variants, has been investigated in a few studies and showed inconsistent results 
regarding their association with serum 25(OH)D levels or vitamin D deficiency. Recent 
reports from China,1,22 Saudi Arabia,23 the United States,24 and the United Arab 
Emirates25 have failed to detect any significant association between VDR FokI 
polymorphism and circulating levels of 25(OH)D. To our knowledge, there is only one 
study that assessed the association between VDR FokI polymorphism and vitamin D 
status in Iranian women during their gestation periods.26 However, Aslani et al., who 
conducted this study, did not detect any significant differences in 25(OH)D levels 
between carriers of the F and f alleles among healthy pregnant Iranian women and GDM 
patients in their second trimester.26  
In contrast, there is consistent evidence that the VDR gene FokI polymorphism is 
significantly associated with 25(OH)D levels in adult patients with multiple sclerosis,27–29 
systemic lupus erythematosus,30 and autism spectrum disorder in children.18 The unified 
finding for all these studies indicated that the mutant ff FokI genotype had significantly 
higher levels of serum 25(OH)D compared to FF and Ff carriers.18,27–30 Some of these 
authors reported that the reason for higher levels of serum 25(OH)D in mutant f allele 
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carriers may be attributed to its compensatory response due to reduced VDR activity and 
distorted signaling pathways.18,27   
On the other hand, few studies have reported a significant association between ff 
genotype carriers and low values of serum 25(OH)D when compared to the FF genotype 
in patients with T2DM,8,31 patients with inflammatory bowel disease,32,33 and patients 
with chronic kidney disease.34 In fact, two of these studies demonstrated a significant 
association between vitamin D deficiency and the combined mutant genotype (Ff + ff) of 
FokI in the Chinese patients with Crohn’s disease32  and ulcerative colitis.33 Similarly, 
another study reported an increased risk of developing severe vitamin D deficiency (< 38 
nmol/L) among chronic kidney disease patients carrying Ff and combined Ff + ff 
genotypes compared to healthy participants in the South African population.34 
The inconclusive findings of all the studies could be attributed to their modest 
sample sizes; variability of the population and ethnic groups studied; and the failure to 
adjust for risk factors that alter serum 25(OH)D, such as vitamin D intake, use of 
supplements, latitude, seasonal variations, sun exposure, and others.1 Additionally, most 
of the research to date has assessed the association between 25(OH)D and the VDR FokI 
polymorphism on unhealthy subjects, and the lack of an association could be related to 
disease confounders.  
Future prospective cohort studies on healthy subjects are required to clarify the 
primary genetic predictors of 25(OH)D concentrations, including the assessment of genes 
involved in vitamin D metabolism. It is vitally important to consider the proper 
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adjustments to be made for important confounders that are known to alter vitamin D 
status to appreciate the effects of genotype on vitamin D levels.  
2.2.1.2 FokI VDR Gene Polymorphisms and Gestational Diabetes  
GDM is considered to be a serious public health problem associated with higher 
incidence rates of perinatal mortality and morbidity.35 As previously mentioned, VDR is 
expressed in many human tissues, including the ones involved in the regulation of 
glucose metabolism, such as pancreatic β cells.8,19 VDR is also known to alter glucose 
homeostasis via the insulin-like growth factor system.8,12  
Since T2DM and GDM are very much alike in terms of sharing a similar 
pathophysiology, polymorphisms in genes that cause a predisposition for T2DM are 
closely related to GDM vulnerability.12 Moreover, numerous studies were conducted to 
prove an association between VDR FokI polymorphism and T2DM but with rather 
equivocal results.36 Studies that have confirmed a significant association between VDR 
FokI polymorphism and T2DM were carried out on Chinese37 and Emarati38 populations. 
In fact, the latter study found that the mutant f allele and ff genotype of VDR FokI 
polymorphism were significantly associated with 85% increased risk of T2DM when 
compared to the control group (P = 0.0007),38 whereas no significant association has 
been reported in Italian39 or Indian populations.40 According to a meta-analysis, the 
inconsistent evidence in the previous studies could be due to strong intra-individual 
variability of vitamin D status, which could probably affect the expression of VDR 
variants, as well as substantial inter-ethnic variance in the samples studied.36 
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Studies have shown a potential role of FokI polymorphism of the VDR gene in 
the pathogenesis of GDM, yet they remain scarce and inconclusive. Only three studies 
were available, and one was conducted in Saudi Arabia. The first study was conducted by 
Aslani and colleagues on 303 Iranian pregnant women (142 GDM patients and 161 
healthy subjects) and found that the ff genotype was more common in GDM patients 
compared to the healthy subjects (OR = 1.783, 95% CI = 0.774–4.107). 26 Interestingly, 
healthy subjects had higher frequencies of the F allele (78.6% vs. 72.2%, [P < 0.06]), 
suggesting that the F allele may have a role in decreasing the incidence of GDM.26 The 
authors attributed the reason for the association between the mutant ff FokI genotype and 
a higher risk of GDM to the dysfunction of the f VDR variant. Because the mutant f allele 
is longer in structure and 40% less active than the shorter F allele, f allele carriers are 
therefore predisposed to a higher risk for GDM.26 The second recent study, whose results 
were in line with Aslani et al., was recently conducted on a population from northeastern 
Brazil.42 The investigators examined whether VDR FokI polymorphism was associated 
with GDM risk in pregnant women who had spontaneous preterm births (SPTBs).42 The 
results showed a significant association between carriers of the mutant ff FokI genotype 
and the risk for GDM in SPTB patients compared to patients who had normal deliveries 
(OR = 4.71, CI 95% = 1.1–22.30; P = 0.044). The frequency of the ff genotype was 
higher in the SPTB group than their counterparts (23% vs. 4.7%). The authors suggested 
that FokI VDR could be a biomarker for GDM.42  
On the contrary, the third study, which was conducted in Saudi Arabia, did not 
show any significant association between VDR FokI polymorphism and the risk of GDM 
when the investigators compared 112 GDM patients and 218 controls in their cross-
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sectional study.41 The previous findings of the studies should be interpreted cautiously. It 
should be stressed that El-Beshbishy et al.41 and Aslani et al.26 used fasting blood glucose 
levels alone to screen for GDM. However, the application of other criteria, such as the 
International Association of Diabetes and Pregnancy Study Groups’ criteria, for the 
diagnosis of GDM results in an increased prevalence of GDM since it includes pregnant 
women with hyperglycemia.43 Therefore, there might be a chance that the authors missed 
high-risk patients, and GDM incidence may have been under-reported and could have 
affected the study outcomes. It was also not clearly indicated in the previous studies if 
investigators controlled for risk factors such as obesity, a family history of diabetes, or a 
history of microsomia, as the latter two factors were significantly associated with GDM 
patients only in Aslani et al.’s study.26  
To conclude, further studies with sufficient statistical power and on different 
ethnicities are warranted in order to confirm the potential of genetic biomarkers for the 
prediction of GDM in different populations. These prospective studies should take into 
consideration the inclusion of GDM risk factors while controlling for them to 
independently observe to what extent the FokI VDR gene polymorphism is the culprit in 
increasing the risk of GDM.  
2.2.1.3 FokI VDR Gene Polymorphisms and Metabolic Syndrome  
As mentioned in the previous chapter, MS is a serious health concern, and its 
prevalence is rising significantly in Saudi Arabia.44,45 It is also more common in females 
than in males.44 Disappointingly, despite the increasing prevalence of MS in Saudi 
Arabia, especially in women, no study to date has detected the role of the VDR gene FokI 
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polymorphisms in the pathogenesis of maternal MS and its components in MS during 
pregnancy. However, a few studies have examined the association between VDR gene 
polymorphisms and MS in adults. Aslani et al., for example, found that the frequency of 
the ff genotype was twofold more frequent in postpartum Iranian women with MS when 
compared to the healthy participants during postpartum follow-ups (P = 0.09, OR = 2.1, 
95% CI = 0.90–4.89).26 On the contrary, another recent study from the same population 
in Iran by Shab-Bidar and colleagues did not observe any significant association between 
FokI and MS in adult males or females.46 Other studies from Brazil,47 north China,48 and 
the United Arab Emirates are also in line with the previous findings. This evident 
variation and inconsistency between different studies on VDR FokI polymorphism and 
MS could be attributed to environmental factors in different populations.25 Moreover, the 
frequency distribution of the genotypes and alleles of the VDR gene polymorphisms 
differ substantially among different ethnic groups and within the same studied 
population, as previously noted in the Iranian population.26,46 Such heterogeneity in the 
distribution of alleles and genotypes leads to different susceptibility to specific diseases.49 
Iyer et al. explained that in Saudi Arabia, genetic factors such as allele distributions and 
the exchange of gene pools through crossbreeding with neighboring countries can have a 
large effect on the findings of studies.50 Accordingly, larger and more carefully designed 
prospective studies are needed that adjust for factors that might interfere with the 
underlying etiology of the disease.  
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CHAPTER 3 
PURPOSE OF THE STUDY 
 
3.1 Research Aims and Hypotheses 
As mentioned in CHAPTER 2, vitamin D receptor (VDR) polymorphism could 
be associated with increased risk of chronic disease resulting from defects in gene 
activation. The presence of the FokI f allele (mutant) has been shown to reduce 
transcriptional activity and affect vitamin D responsiveness. This, in turn, might lead to 
vitamin D deficiency and extra-skeletal health complications; yet, there is very limited 
research examining the association of the FokI VDR polymorphism with adverse 
pregnancy outcomes. The present research will investigate this association; particularly 
how maternal FokI VDR gene polymorphism affects metabolic health outcomes in 
pregnancy. The following chapter explains the aims and hypotheses of this research in 
greater detail.  
Aim 1:  
The first aim is to investigate the association between FokI VDR gene 
polymorphism and serum 25(OH)D levels in first-trimester pregnant Saudi women while 
controlling for lifestyle and environmental risk factors that are known to alter vitamin D 
status, such as dietary intake of vitamin D, sun exposure indices, physical activity, 
educational level, and place of residence.  
Hypothesis 1: 
We hypothesized that pregnant Saudi women carrying the ff genotype of the FokI 
VDR polymorphism will have an increased risk of vitamin D deficiency compared to 
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those carrying the FF and Ff genotypes.  
Aim 2:  
The second aim is to determine whether there was a difference in gestational 
diabetes mellitus (GDM) risk factors among the VDR FokI genotypes carried by pregnant 
Saudi women in their second trimester, via an oral glucose tolerance test (OGTT) 
administered at 24–28 weeks of pregnancy. We will also study the effect of different 
FokI VDR genotypes on glucose intolerance by measuring fasting blood glucose, fasting 
insulin, and glycated hemoglobin. We will also calculate Homeostasis model of insulin 
resistance and of beta cell function using HOMA-IR and HOMA_, respectively. 
Hypothesis 2: 
We predicted that pregnant Saudi women carrying the ff genotype of the FokI 
VDR polymorphism will have increased glucose intolerance and a greater risk of GDM 
compared to those carrying the FF and Ff genotypes.  
Aim 3:  
The final aim is to assess whether the FokI VDR genotypes are associated with 
Metaboilc Syndrome (MS), or its components, in pregnant Saudi women. We will also 
study the metabolic impact of the ff genotype versus the wild FF genotype on various MS 
risk factors by measuring blood pressure, lipid and glycemic profiles, and body mass 
index (BMI).  
Hypothesis 3: 
We expect that pregnant Saudi women carrying the ff genotype of the VDR FokI 
polymorphism will be at higher risk of MS; elevated blood pressure; glucose 
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intolerance/gestational diabetes; dyslipidemia; and elevated lipid-profile biomarkers, such 
as total cholesterol, low-density lipoprotein (LDL), triglycerides (TG), and low high-
density lipoprotein (HDL) cholesterol.  
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CHAPTER 4 
MANUSCRIPT 1: THE INFLUENCE OF FOKI VITAMIN D RECEPTOR GENE 
POLYMORPHISMS ON VITAMIN D STATUS AMONG PREGNANT SAUDI 
WOMEN  
 
4.1 Abstract 
• Background: Vitamin D deficiency is highly prevalent among pregnant Saudi 
women, ranging from 86.4 % to 90.5%. It has been associated with adverse maternal 
and offspring outcomes. Numerous factors, including genetics, play significant roles 
in altering vitamin D status. Previous genomic studies have associated vitamin D 
receptor (VDR) gene polymorphism with serum 25-hydroxyvitamin D levels in 
adults. However, the genetic determinant of VDR gene polymorphisms and maternal 
vitamin D status in pregnancy have not been clarified yet.  
• Aim: The objective of this study was to investigate the association between FokI 
VDR gene polymorphism and serum 25-hydroxyvitamin D levels in pregnant Saudi 
women in their first trimester, while controlling for lifestyle and environmental risk 
factors that are known to alter vitamin D status.     
• Materials and Method: A cross-sectional study was conducted on 345 pregnant 
Saudi women who visited antenatal clinics of three hospitals in Riyadh, Saudi Arabia 
(King Khaled University Hospital [KKUH], King Salman bin Abdulaziz Hospital, 
and King Fahad Medical City [KFMC]) between December 2013 and January 2016. 
In the first antenatal visit, information was collected regarding socio-economic status 
and anthropometric and biochemical data, including serum 25 hydroxy-vitamin D 
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(25(OH)D) levels, dietary intake of calcium and vitamin D, physical activity, and sun 
exposure indices. The Fokl VDR genotypes of each woman were determined by 
allele-specific polymerase chain reaction (PCR).  
• Results: About 79% of the Saudi women studied were vitamin D deficient (25(OH)D 
< 50 nmol/L). Full body coverage with clothing, low physical activity, residence in 
North Riyadh, indoor work, and timing of sun exposure were found to be the key 
factors predisposing pregnant women toward vitamin D deficiency in the Kingdom of 
Saudi Arabia. In addition, the risk of being vitamin D deficient was associated with 
the FokI VDR genotype. The frequencies of genotypes FF, Ff, ff, and combined Ff+ff 
in women with vitamin D deficiency were 60.1%, 33.3%, 6.6%, and 39.9%, 
respectively, while in the non-deficient group they were 55.6%, 36.1%, 8.3%, and 
44.4%, respectively. Taking the FF genotype as a reference, the Ff genotype and the 
combined variant genotype (Ff+ff) showed a significant decrease in the risk of 
developing vitamin D deficiency after adjusting for confounding factors (FF vs. Ff, 
OR = 0.44, 95% CI = 0.20–0.94, P = 0.035, FF vs. Ff+ff, OR = 0.42, 95% CI = 0.20–
0.88, P = 0.022). Furthermore, individuals carrying the f allele were protected against 
vitamin D deficiency (OR = 0.51, 95% CI = 0.29–0.91, P = 0.021).  
• Conclusion: Our study is the first to evaluate the association between FokI VDR 
gene polymorphism and vitamin D status in pregnant Saudi women while controlling 
for major risk factors. Our findings indicated that the FF genotype and the F allele of 
FokI VDR genotype polymorphisms is an important determinant of an individual’s 
susceptibility to vitamin D deficiency in pregnant Saudi women after adjusting for 
confounding factors that have an effect on vitamin D status, such as age, BMI, 
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physical activity, full body clothing coverage, job status, residential area, and 
education.   
 
4.2 Introduction 
Vitamin D deficiency during pregnancy is of epidemic proportions, occurring in 
nearly 20% to 95% of pregnant women around the world.1,2 There is a substantial body of 
evidence in the literature that indicate the serious adverse consequences of low maternal 
vitamin D status on maternal and fetal health, including both skeletal and non-skeletal 
outcomes.3,4 Aside from the adverse skeletal effects, vitamin D deficiency during 
pregnancy has been linked to a number of maternal and fetal problems, including 
preeclampsia, gestational diabetes, caesarean section, bacterial vaginosis, postpartum 
depression, neonatal hypoglycemia, small-for-gestational age infants, and preterm 
birth.1,5-8 
It is expected that the Saudi population will have adequate vitamin D status since 
cutaneous vitamin D production is primarily determined by sun exposure. Saudi Arabia 
has the highest number of sunny days per year, with an average sunlight of 2,200 
kWh/m2 and more solar radiation hitting the earth there due to the country’s location 
within the earth’s equatorial sun belt.7 Unfortunately, numerous studies have 
demonstrated that vitamin D deficiency has become an epidemic among the Saudi 
population, specifically in the young and middle-aged groups of healthy Saudi adults, and 
in females more than males.6,10 It is estimated that between 80–100% of Saudi women 
have suboptimal levels of vitamin D during the reproductive phase of their lives.11-13 
Higher prevalence of vitamin D deficiency among Saudi women appears to be a 
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predisposition for further deterioration of the vitamin D status, particularly among 
pregnant females because of the increased nutritional demands of the growing fetus.14 
Two recently published studies found that the prevalence of vitamin D deficiency was 
about 86% in pregnant Saudi women 10,15 and 88% among neonates.15 Both of these 
studies, as well as other studies, used serum 25-hydroxyvitamin D (25(OH)D) < 50 
nmol/L as a cut-off point for vitamin D deficiency.10,15-17 Serum 25(OH)D is the main 
circulating metabolite of vitamin D and the most reliable biomarker of vitamin D 
adequacy,18 reflecting both dietary vitamin D intake and cutaneous vitamin D 
production.19  
Factors such as age, race, gender, skin pigmentation, physical activity, sun 
exposure, season, geographic location, latitude, obesity, and dietary/supplemental vitamin 
D intake have all been previously reported to influence serum 25(OH)D levels.20,21 Other 
factors related to Saudi cultural practices and customs, including complete coverage of 
the body and limited outdoor activities play an important role in hindering the positive 
effect of the abundant sunlight on vitamin D status.10  
Obviously, there are many factors that influence the levels of circulating 
25(OH)D other than the ones mentioned earlier. Hussain et al. found that the prevalence 
of vitamin D deficiency was more common and severe in Saudis than in non-Saudis 
living in the same city of Riyadh, Saudi Arabia.12 This observation might be explained by 
the influence of genetic variants such as vitamin D receptor polymorphisms that play a 
role in vitamin D metabolism and disease susceptibility.10,20,22 In fact, genome wide 
association (GWA) studies have revealed that the genetic variation significantly 
contributes to variability in serum 25(OH)D concentration, with estimates of heritability 
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ranging from 29% to 80%.23-25 
Vitamin D receptor (VDR) is one of the candidate genes involved in meditating 
the transcription of vitamin D-dependent target genes26 by binding to the active hormonal 
form of vitamin D (1,25-dihydroxyvitamin).27 VDR is known to be expressed in almost 
every tissue.10 Several single nucleotide polymorphisms (SNPs) have been identified in 
the VDR sequence, including a FokI endonuclease site (rs10735810, merged into 
rs2228570).28 The FokI VDR variant, which is located in an alternate  upstream 
transcriptional initiation site of the VDR gene, specifically in exon 2 in the 5′-coding 
region, is the only known VDR polymorphism that is not linked to any of the other VDR 
variants. In addition, the VDR protein products differ with one variant (f) establishing an 
alternate start site resulting in a VDR protein that is 3 amino acids longer than the other 
shorter VDR variant (F). The longer f variant form of VDR has been shown to be less 
active in some in vitro test systems, thus giving it a potentially unique role. 24,29 The FokI 
mutation produces a longer f-VDR protein that is 427 amino acid long and a shorter F-
VDR protein variant that is 424 amino acids long, which is reported to be more active 
and effective than the longer protein variant. 26 However, the functional significance of 
the FokI VDR polymorphism as a genetic risk factor in various disease outcomes is 
inconsistent.30  
While there is increasing evidence in the literature associating FokI VDR gene 
polymorphisms with an increased risk of a range of adverse health outcomes, it is not yet 
clear whether the FokI VDR polymorphism contributes to maintaining serum 25(OH)D 
adequacy. The role of the FokI VDR polymorphism and other genetic variants related to 
vitamin D metabolic pathways have been greatly evaluated in regards to the responses of 
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serum 25(OH)D levels to vitamin D supplementation, with contradicting results.31 The 
first study in the Saudi population that evaluated the genetic influence of FokI VDR as 
well as several single nucleotide polymorphisms (SNPs) in vitamin D-related genes on 
vitamin D status was reported by Sadat-Ali et al.32 They found that FokI VDR was 
significantly associated with vitamin D deficiency, compared to the population with 
normal vitamin D levels.32 Moreover, there are a limited number of studies that examined 
the effects of  dietary vitamin D intake, sun exposure, or other personal characteristics as 
probable modifiers that influence serum 25(OH)D concentrations. 20 Additionally, most 
of the studies that examined such a relationship were conducted on groups of adults with 
different kinds of diseases. Such a correlation was not investigated among pregnant 
women in Saudi Arabia, where plentiful sunlight is available throughout the entire year. 
Therefore, we conducted a cross-sectional study to investigate the association between 
the FokI VDR gene polymorphism and serum 25(OH)D levels in pregnant Saudi women 
while controlling for environmental and lifestyle variables linked to Saudi culture that 
were previously known to influence vitamin D status. 
 
4.3 Methods 
4.3.1 Study Design and Sample Population 
This study is part of a large prospective cohort study called “Vitamin D and 
Pregnancy in Saudi Women.” Our cross-sectional study is a subset of these study 
participants, consisting of 345 pregnant Saudi women who visited an antenatal clinic at 
one of three different Saudi hospitals: King Khaled University Hospital (KKUH), King 
Salman Bin Abdulaziz Hospital, and King Fahad Medical City (KFMC) in Riyadh, the 
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capital of Saudi Arabia, between December 2013 and January 2016. The study has full 
ethical approval from the three hospitals to collect samples and patient data and approval 
from the Ethics Committee of the College of Science, King Saud University in Riyadh 
(Appendix A). Written informed consent was obtained from each patient (Appendix B).  
4.3.1.1 Inclusion and Exclusion Criteria 
Healthy pregnant Saudi women in their first trimester (8–12 weeks) aged 18 to 40 
years, with no previous history of diabetes mellitus (type I or II), were recruited. Subject 
exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks; taking 
vitamin D supplements during pregnancy; unwillingness to deliver at any of the three 
hospitals; taking oral glucocorticoids; using drugs known to interfere with vitamin D or 
calcium absorption or parathyroid disorders; using any cardiac medication or diuretics; 
suffering from chronic hypertension or malabsorption syndrome; having chronic medical 
conditions or preexisting liver, kidney, calcium, and/or parathyroid conditions; or serious 
chronic disease conditions (epilepsy, cancer, or other malignancy). 
4.3.1.2 Recruitment and Data Collection 
Recruitment banners and brochures were placed in prenatal clinics in all three of 
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients 
during their first prenatal appointment. Patients who met the criteria and consented to 
contribute to the present study were provided the appropriate information. During their 
early pregnancy visit, prospective candidates were asked to sign consent forms that 
included information about their participation in the study, such as the completion of a 
questionnaire regarding demographic data, procurement of blood samples for biomarker 
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measurement and DNA for genetic analyses, and anthropometric measurements. 
Permission for data collection from their medical records and stored blood stocks from a 
bio-bank were also obtained. Additionally, the participants were informed of their right to 
withdraw from the study at any point without it affecting their usual medical care.  
The study tools included anthropometric measurements, blood biochemical tests, 
and an interview questionnaire. The interview questionnaire included questions regarding 
socio-economic information, clinical measurements, and past medical and treatment 
history. It also contained a food frequency questionaire (FFQ) and questions on sun 
exposure and physical activity.  
4.3.2 Anthropometric Measurements 
Anthropometric measurements were taken in the first antenatal visit. These 
measurements included weight (kg) and height (cm), used for calculating body mass 
index (BMI) (kg/m2); reported pre-pregnancy weight (kg); and pre-pregnancy BMI 
(kg/m2). Body weight, without shoes and in lightweight clothing, was measured to the 
nearest 0.1 kg with a stadiometer (Digital Pearson Scale, ADAM Equipment Inc., USA). 
Based on pre-pregnancy weight as self-reported during the prenatal visit, the pregnant 
women were classified according to the WHO BMI definitions as follows: underweight: 
< 18.5 kg/m2; normal weight: 18.5–24.9 kg/m2; overweight: 25.0–29.9 kg/m2; or obese: 
≥  30.0 kg/m2.33 Height, to the nearest 0.5 cm, was measured during the early pregnancy 
visit using only (Digital Pearson Scale), with the women standing upright without shoes. 
Pre-pregnancy BMI was calculated from pre-pregnancy body weight recall and the 
measured height.  
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4.3.3 Interview and Physical Activity Questionnaire 
The interview questionnaire was adapted from a previously published 
epidemiological survey in Saudi Arabia that included questions about socio-economic 
details, past medical and treatment history, and sun exposure (Appendix C). 34-37 At the 
early pregnancy visit, all socio-economic and clinical measurements were recorded, 
including the visit date, age of the subject, place of birth, gestational age, maternal 
education status, occupation, and area of residence. Clinical data included date of LMP 
and estimated date of delivery (EDD). The participants were asked about parity 
(nulliparous or ≥ 1 multiparous). The season of the sampling was recorded. For the 
analysis of the season in relation to vitamin D status, the months of the year were divided 
into two periods. April to October was classified as summer, and November to March as 
winter.38                                                    
Furthermore, they were asked about sun exposure (yes/no) and other sun exposure 
indices such as exposure to the sun at work (indoor or outdoor work), timing of the 
exposure (e.g., noon), clothing (full body coverage vs. some parts of the body exposed), 
and the use of sunscreen (yes/no). Noon was defined in this study to be from 10:00 a.m. 
to 2:00 p.m. 
Physical activity was also assessed through a well-known and validated 
questionnaire, namely an Arabic short version of an International Physical Activity 
Questionnaire (IPAQ).39 The short IPAQ has been validated in various studies among 
different populations, including pregnant subjects.40,41 IPAQ evaluates physical activity 
during periods of leisure, work, and commute. It also assesses the intensity of an activity 
as vigorous, moderate, low-intensity physical activity/walking, or sitting. Each subject 
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was assisted in recalling her physical activities over the previous week. For each type of 
activity, frequency and duration were recorded in days per week and minutes or hours per 
day. This study excluded moderate and high activity because few women carried out such 
activities during pregnancy. The present study analyzed low-intensity physical activity 
and minutes spent sitting per week, similar to other studies using IPAQ in pregnancy.42 
Low-intensity physical activity in minutes per week was applied as a continuous and 
categorical variable at either less than or over 210 minutes/week.43 
4.3.4 Dietary Data Collection and Processing 
The dietary tool applied for measuring the participants’ food intake was the FFQ, 
which has been used previously in Saudi Arabian studies. 35,37 The subjects were 
interviewed separately, and the data were gathered by applying a pre-designed 
questionnaire to measure aspects of food consumption among the expectant mothers over 
the course of one week. The main purpose of this was to assess calcium, vitamin D, fat, 
and protein intake, as well as any other nutrients that may affect the absorption or 
excretion of vitamin D and calcium. Responses to the dietary questionnaire were 
facilitated through food models, cups and spoons of various sizes, cans, and approximate 
portions, using hand gestures to help the participants recall the amount of food consumed.  
The FFQ consisted of eight parts pertaining to: (1) bran, starch, and grains; (2) 
meat and fish; (3) fats and oils; (4) dairy products; (5) fruits and vegetables; (6) 
traditional dishes; (7) sweets and soft drinks; and (8) coffee and tea. Starches and grains 
mainly referred to any bran food that could have reduced calcium absorption.44 Fruits and 
vegetables included those high in calcium and any that may have reduced calcium 
absorption.45 Dairy fats (whole fat, low fat, skim milk, or other products) and fat added 
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during cooking may also affect calcium absorption.46 Finally, data on supplement intake 
(yes/no) were collected, including multivitamins, folic acid, iron, vitamin D, and cod 
liver oil.  
Nutrient intake was calculated using U.S. Department of Agriculture (USDA) 
software (27th edn, 2014), along with Nutribase software (11th edn, 2014), which utilizes 
food macro- and micro-nutrient composition. For traditional Saudi food, an Arabic food 
analysis program was used (1st version, 2007). The assessment of everyday food intake 
was conducted as total intake of macro- and micro-nutrients, especially vitamin D and 
calcium. Dietary nutrient values were compared with the dietary reference intake (DRI) 
of micro-nutrients during pregnancy, such as vitamin D and calcium.47 Additionally, 
vitamin D and calcium intake were presented continuously and categorically as above 
600 IU/day and 1,000 mg/day of vitamin D and calcium, respectively. 
4.3.5 Biochemical Assessment 
Blood samples (10 ml) were collected using a sterile vacutainer blood collection 
apparatus. Whole blood, serum, and ethylene diamine tetra-acetic acid (EDTA) plasma 
were collected from the participants. All samples were aliquoted and stored in a freezer at 
-80 oC to facilitate their availability for subsequent chemical analysis. All the lab tests 
were performed on the serum. The plasma was stored if needed for further analysis. The 
samples were stored and analyzed in the Biomarkers Research Program (BRP) 
laboratory. 
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4.3.5.1 Primary Outcome Measures 
Our main outcome measure was to investigate the association between FokI VDR 
gene polymorphism and serum 25(OH)D levels in pregnant Saudi women while 
controlling for confounding factors, which affect vitamin D status. 
4.3.5.2 Assessment of Circulating 25(OH)D and Biochemical Parameters 
During the first antenatal visit, random blood samples were collected to measure 
total 25(OH)D, calcium, phosphorus, and alkaline phosphatase. Total 25(OH)D was 
measured in an ECLIA assay, (Cobas e 411; Roche Diagnostics GmbA, Mannheim, 
Germany). The BRP laboratory is a participating entity in the Vitamin D External Quality 
Assessment Scheme (DEQAS). Since no international consensus exists for vitamin D 
deficiency cut-off points during pregnancy, vitamin D was categorized according to 
25(OH)D concentrations as follows: < 50 nmol/L considered to be a deficiency and ≥ 50 
nmol/L considered to be non-deficient.16,17 
Serum calcium and phosphorous were measured using a routine laboratory 
chemical analyzer (Konelab, Finland). Meanwhile, bone-specific alkaline phosphatase 
(BAP) was measured using the LIAISON XL immunoassay (DiaSorin, Italy).  
4.3.5.3 DNA Extraction and Quantification 
Genomic DNA was extracted from whole blood using innuPREP blood mini kits 
(Analytik Jena, Germany) by following the manufacturer’s instructions. In brief, 200 µl 
of the whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and 
Proteinase K. The contents were mixed using a vortex and incubated at 60 0C for 10 
minutes. The required amount of binding solution was added to the tube and transferred 
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to a spin filter column with a receiver tube and centrifuged for 1 minute at 12,000 rpm. 
The column-bound DNA was washed using the kit’s washing solution C, followed by 
washing solution BS. As a final step, the spin filter was placed in a 1.5 ml elution tube, 
and 200 µl of elution buffer that was pre-warmed to 60 0C was added. After 
centrifugation, the collected DNA was stored at -20 0C for further analysis. DNA 
concentration and purity (260/280) was determined using a Nano-Drop 
spectrophotometer.  
4.3.5.4 FokI VDR SNP Genotyping  
The FokI SNP (rs 2228570), previously reported as (rs10735810)20 (Exon 2, 
C[F] > T[f]), is located in the VDR coding region and can be evaluated by allelic 
discrimination real-time PCR using pre-designed TaqMan genotyping assay from 
Applied Biosystems, Foster City, CA, USA (assay ID: C_12060045_20). Amplification 
reactions were performed in a volume of 10 µL containing 1X TaqMan genotyping 
Master Mix (Applied Biosystems), 1X mix of unlabeled PCR primers and TaqMan MGB 
probes, and 30 ng of template DNA. All amplifications and detections were conducted in 
96-well PCR plates using a Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad, 
Milan, Italy). Thermal cycling was initiated with a denaturation step of 10 min at 95 °C, 
followed by 45 cycles of 15 s at 95 °C and 90 s at 60 °C. After PCR was completed, 
allelic discrimination was analyzed using the Bio-Rad CFX Manager Software (Version 
1.6, Bio-Rad). Genotype assignment was determined by plotting the end point relative 
fluorescent units (RFU) for one fluorophore (allele 1 on the x-axis) against the RFU for 
the other fluorophore (allele 2 on the y-axis) on the allelic discrimination. All PCR 
reactions were set up in a dedicated PCR area with dedicated PCR pipettes and reagents. 
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4.3.6 Statistical Analysis 
The sample size was estimated for adequate statistical power. The significant 
differences in serum 25(OH)D levels according to FokI VDR genotype were based on an 
expected  effect size of 0.25,48 and the required sample size at 95% CI was 243, with 95% 
power. 
The data were analyzed using SPSS version 21.0 statistical software (SPSS, Chicago, IL, 
USA). Quantitative normal variables were expressed as mean ±SD, while quantitative 
non-normal variables were expressed as medians (Q1-Q3). Categorical variables were 
expressed as frequencies and percentages (%). Pearson’s chi-square test was used to 
determine the differences between categorical variables. Comparisons between groups 
were performed using the independent sample t-test and the Mann-Whitney U test for 
normal and non-normal variables, respectively. Unadjusted and adjusted odds ratios were 
determined using logistic regression analysis. P-value < 0.05 is considered significant.  
4.4 Results 
4.4.1 Demographics and Biochemical Characteristics According to Vitamin D Status 
in Early Pregnancy  
Table 4.1 presents the characteristics of the deficient and non-deficient groups of 
pregnant women. The population sample was categorized into either deficient (< 50 
nmol/L) or non-deficient (≥ 50 nmol/L) groups for statistical analysis. 49,50 The 
prevalence of vitamin D deficiency (< 50 nmol/L) in early pregnancy was 79.1% 
(273/345). 
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The mean age of women with vitamin D deficiency was similar to that of non-
deficient women (28.7 ± 5.4 vs. 29.4 ± 5.4 years, P = 0.320). Pre-pregnancy BMI, BMI 
in early pregnancy, and parity also failed to reveal any differences between the two 
groups. The biochemical profile of the pregnant women, such as calcium and alkaline 
phosphatase levels, did not show any significant differences between the groups. 
However, the non-deficient subjects had significantly higher serum phosphorus and 
25(OH)D levels than the deficient subjects, (1.3 ± 0.5 vs. 1.2 ± 0.4 mmol/L, P = 0.029) 
and (67.8 ± 12.9 vs. 27.0 ± 10.6 nmol/L, P < 0.001), respectively.  
Interestingly, the percentage of women engaged in low-intensity physical activity 
such as walking was significantly higher in the non-deficient group than in the deficient 
group (78% vs. 43.8%, P < 0.001), respectively. Furthermore, pregnant women who were 
non-deficient in vitamin D were more likely to be educated and have a graduate or 
postgraduate degree than those in the deficient group (70.4% vs. 56.0%, P = 0.028), 
respectively. Moreover, the rate of employment was higher in the non-deficient group 
compared to the deficient group, although this was not statistically significant (38.9% vs. 
29.5%, P = 0.127). Similarly, vitamin D, calcium, and multivitamin intake did not reveal 
any statistically significant differences between the deficient and non-deficient groups.  
The percentage of women living in North Riyadh was significantly higher 
amongst the non-deficient subjects compared to their counterparts (33.3% vs. 15.9%, P < 
0.001). Meanwhile, a higher percentage of pregnant women who were deficient in 
vitamin D lived in West Riyadh compared to the non-deficient group, but this figure did 
not reach statistical significance (18.8% vs. 29.8%, P = 0.069).  
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We did not observe any differences between vitamin D non-deficient and 
deficient groups in exposure to sun, use of sunscreen, and blood being drawn in the 
summer or winter. Nevertheless, the amount of exposure to the sun at noon was 
significantly higher amongst the non-deficient subjects compared to their deficient 
counterparts (72.2% vs. 22.7%, P < 0.001), respectively. Likewise, the percentage of 
women who tend to work indoors was higher amongst the deficient participants 
compared to the non-deficient subjects, (98.5% vs. 66.7%, P < 0.001), respectively. 
Moreover, the percentage of subjects covering their whole body with clothing was 
significantly higher in the deficient group compared to their counterparts, (33.3% vs. 
2.8%, P < 0.001), respectively. 
4.4.2 Risk Factors for Vitamin D Deficiency in Pregnancy  
We further conducted a multivariate logistic regression analysis to assess the risk 
factors for vitamin D deficiency while adjusting for confounding factors (Table 4.2). 
Significant independent variables that increased the risk of vitamin D deficiency included 
full body coverage with clothing (OR 19.64, 95% CI 2.52-152.68, P = 0.004), and 
working indoors (OR 132.0, 95% CI 10.9-1600.7, P < 0.001).  
On the contrary, the variables that appeared to confer some protection against 
vitamin D deficiency in early pregnancy were higher serum phosphorus levels (OR 0.27, 
95% CI 0.10-0.76, P = 0.013), low-intensity physical activity/walking (≥ 210 
minutes/week) (OR 0.19, 95% CI 0.08-0.44, P < 0.001), time of sun exposure at noon 
(OR 0.13, 95% CI 0.06-0.32, P <0.001), and living in North Riyadh (OR 0.32, 95% CI 
0.14-0.75, P = 0.009).  
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Moreover, having a graduate or bachelor’s degree, and a higher serum calcium 
levels (OR 0.42, 95% CI 0.17-1.02, P = 0.054), (OR 0.11, 95% CI 0.01-1.18, P = 0.068), 
respectively, appeared to be protective factors against vitamin D deficiency, but did not 
reach significant levels.  
4.4.3 FokI VDR Gene Polymorphism and Vitamin D Deficiency 
As shown in Table 4.3, the difference in the occurrence of the various FokI VDR 
genotypes in vitamin D deficient and non-deficient participants was statistically 
significant. The FokI VDR genotypes are normally expressed as homozygous genotype 
“FF,” heterozygous genotype “Ff,” and mutant homozygous genotype “ff.” The 
frequencies of genotypes FF, Ff, ff, and combined Ff+ff in women with vitamin D 
deficiency were 60.1%, 33.3%, 6.6%, and 39.9% respectively, while in the non-deficient 
group they were 55.6%, 36.1%, 8.3%, and 44.4%, respectively. We did not observe any 
statistically significant associations between FokI VDR polymorphisms and serum 
25(OH)D levels, but after adjusting for important covariates such as age, BMI, low-
intense physical activity, full body clothing coverage, job status, residential area, and 
education, we detected a statistically significant association between VDR genotype and 
risk of vitamin D deficiency.  
After correcting for the potential confounding variables, and using the FF 
genotype as a reference, the Ff genotype and the combined variant genotype (Ff+ff) 
showed a significant decrease in the risk of developing vitamin D deficiency (FF vs. Ff, 
OR = 0.44, 95% CI = 0.20–0.94, P = 0.035; FF vs. Ff+ff, OR = 0.42, 95% CI = 0.20–
0.88, P = 0.022). Furthermore, individuals with the f allele were protected against vitamin 
D deficiency (OR = 0.51, 95% CI = 0.29–0.91, P = 0.021). However, no significant 
  60 
association was found between the ff genotype and vitamin D deficiency (FF vs. ff, OR = 
0.36, 95% CI = 0.08–1.52, P = 0.163). 
4.5 Discussion 
In our study, vitamin D deficiency was evident in 79.1% of our study sample. 
Although numerous studies have reported a high prevalence of vitamin D deficiency in 
the Saudi population across different ages, 35, 51,52 only a limited number of studies have 
assessed the prevalence of vitamin D deficiency in pregnant Saudi women. 6,10,15, 53 For 
example, Al-Ajlan et al. found that 68% of Saudi pregnant women were vitamin D 
deficient.53 Al Foda et al. 15 and Al-Sheikh et al.10 found a higher prevalence of vitamin D 
deficiency reaching 86%.10,15 Besides Saudi Arabia, vitamin D deficiency during 
gestation seems to be a global health concern, as it has been reported in many other 
countries such as the UAE (78%),54 India (62%),55 Korea (77.3%),56 Belgium (44.6%),57 
Switzerland (63%),58 and Canada (39%).59  
Despite the abundant sunshine all year in Saudi Arabia, our results indicated that 
lifestyle patterns and traditional clothing play an important role in decreasing sun 
exposure, thus significantly decreasing vitamin D levels and the risk of vitamin D 
deficiency. Saudi women wear black veils, or what are known as abaya, to cover their 
entire bodies due to religious and cultural beliefs. The present study, supported by others, 
indicates that pregnant women who fully cover their body are at greater risk of 
developing vitamin D deficiency. 11,60  
Moreover, we found higher levels of vitamin D among educated pregnant women 
compared to their less educated counterparts. This observation has been stated in 
different studies reporting that vitamin D levels vary in adults according to their 
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educational acheivement, with a higher level of education decreasing the risk of vitamin 
D deficiency.61,62 
We also noticed that the area of residence, particulary North Riyadh, had a 
significantly positive impact on vitamin D status compared to other areas. In other words, 
pregnant women residing in North Riyadh had higher serum 25(OH)D levels than women 
residing in other areas such as south, west, and east of Riyadh. We speculate that this part 
of the capital city is more likely to be affluent and has highly educated residents.  
Pregnant women performing low-intensity physical activity such as walking were 
also shown to have higher vitamin D levels compared to those performing low-intensity 
physical activity in the deficient group. Similarly, Al-Faris et al. also noted that pregnant 
women involved in daily outdoor activity during the early stages of pregnancy were more 
likely to have adequate vitamin D levels.6 These observations may be attributed to two 
reasons. First, increased physical activity causes greater mobilization of vitamin D from 
burned fat deposits.63 Second, engaging in an outdoor asctivity means greater sun 
exposure, thus triggering vitamin D synthesis. 64 
In our present study, we did not detect any significant associations between 
vitamin D levels and the season in which the blood was drawn from the samples when 
comparing the deficient and non-deficient pregnant women. However, this result was 
expected due to several reasons. Firstly, women tend to cover their whole bodies with 
clothing due to cultural and religious reasons.10 Secondly, due to the extreme hot weather 
in the summer, Saudis generally avoid sun exposure.6,53 Thirdly, a large proportion of the 
workforce works indoors in Saudi Arabia. The latter two explanations confirm our 
finding that working indoors and the amount of sun exposure, especially at noon, were 
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also critical in determining vitamin D levels and corresponded significantly with risk of 
having vitamin D deficiency in our population. Our results were in line with the findings 
of Al-Shahrani et al.65 They reported that the time of day plays a major role in vitamin D 
production, as they observed that summer production of pre-vitamin D3 increased 
between the peak hours of 10:00 a.m. to 12:00 p.m.65 
We did not observe a significant difference in dietary intake of vitamin D and 
calcium between deficient and non-deficient participants, as they were shown to be very 
low in both groups in our study, as well as in other studies conducted in Saudi Arabia.6,66 
In the present study, we found that about 25% of the entire sample were taking 
multivitamins in their first trimester. Consistently, other studies from various countries 
have reported the use of multivitamin supplementation during pregnancy, ranging from 
7.5% to 63.1%. 6,57,67 
It has been previously noted that vitamin D intake during pregnancy, whether 
from food or from supplements, is inadequate for meeting the optimum demands of the 
mother and the growing fetus.68 Previous studies have reported that less than 10% of the 
daily vitamin D requirement could be met through dietary sources of vitamin D.69,70 
In Saudi Arabia, dietary sources of vitamin D tend to be inadequate, and currently 
food fortification is extremely scarce.70 In addition, globalization has brought dramatic 
changes to dietary and lifestyle patterns, with a shift toward unhealthy diets.6,60 Since our 
study was conducted in the capital city of Riyadh, the consumption of vitamin D-rich fish 
was usually uncommon due to the geographic nature of the area, which lacks access to 
the sea or rivers.11 
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Interestingly, in our study we observed the novel finding of an association 
between FokI VDR gene polymorphism and the risk of vitamin D deficiency in pregnant 
Saudi women after adjusting for lifestyle and environmental factors that are known to 
alter vitamin D levels. Our results showed a significant difference in the genotype 
distribution between vitamin D deficient and non-deficient pregnant women. Our results 
indicated that FF genotype individuals have a significantly higher risk for vitamin D 
deficiency compared to those carrying the Ff genotype and the combined genotype 
(Ff+ff). Based on our data, subjects carrying the FokI F allele had a significantly higher 
prevalence of vitamin D deficiency than subjects with f alleles.   
There is consistent evidence that FokI VDR gene polymorphism is significantly 
associated with 25(OH)D levels in adult patients with Multiple Sclerosis (MS),18,71,72 
Systemic Lupus Erythematosus (SLE),73 Ulcerative Colitis,29 Crohn’s Disease,79 and 
Autism Spectrum Disorder (ASD) in children.48 
Three studies investigated the association between FokI polymorphism and serum 
25(OH)D levels in MS patients and found results that were similar to our findings. 
Agnello et al. observed that MS patients with the ff genotype had significantly higher 
levels of serum 25(OH)D compared to FF and Ff carriers.71 In addition, Orton et al. 
reported the same finding in a study on twins with MS.18 Similarly, another study by 
Smolders et al. demonstrated that lower serum 25(OH)D levels were associated with the 
homozygous FF genotype compared to the homozygous ff genotype carriers.72 Another 
study conducted in Turkey by Coskun et al. reported that the ff genotype was associated 
with higher serum 25(OH)D levels in children with ASD compared to the homozygous 
FF genotype.48 In addition, two studies conducted in patients with SLE living in Brazil73 
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and Egypt74 found that carriers of the wild type homozygous FF genotype in comparison 
with the mutant homozygous ff genotype had significantly lower serum 25(OH)D. 
Intriguingly, Yao et al. conducted a randomized double-blinded, placebo-
controlled trial and found that carriers of the f allele responded better to vitamin D 
treatment (2000 IU/d) than F allele carriers in the Chinese population with vitamin D 
deficiency.27 In fact, when compared to other common polymorphisms in vitamin D 
metabolism genes, ff FokI genotype was associated with a greater increase in 25(OH)D  
in week 20 of the treatment, but the treatment was still unable to correct vitamin D 
deficiency in 25% of participants who were carrying other mutant genes. 27 
These results, as well as our findings regarding the mutant f allele’s protective 
role against vitamin D deficiency should be interpreted cautiously. Monticielo et al. 
explained that the underlying justification for such an observation could be that the 
mutant f allele may be associated with VDR dysfunction since it is longer and less active 
than the F allele, thus causing an increased synthesis of serum 25(OH)D from vitamin D. 
73 However, there are definitely other described genetic factors along the vitamin D 
metabolic pathway that influence the production, elimination, and transportation of serum 
25(OH)D concentration, which we did not measure and may contribute to residual 
confounding in our study.  
If we delve into the underlying mechanism of vitamin D metabolism, we notice 
that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) binds to the VDR, and the activated VDR 
regulates the rate of transcription of vitamin D-responsive genes.75 VDR-1,25(OH)2 D 
complex is considered a negative regulator of vitamin D-25-hydroxylase enzyme (also 
known as CYP27A1), which catalyzes the 25-hydroxylation of vitamin D. 71 
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Furthermore, it is well known that FokI VDR polymorphism can alter the translation 
initiation sites of  the VDR gene.48,71 The short VDR variant (F allele) is associated with 
a higher transcriptional activity than the long variant (f allele).48 According to this 
evidence, the authors attributed the observation of higher vitamin D levels in individuals 
with the ff genotype to the following explanation: Since the F allele variant of the FokI 
VDR genotype is more active, it is more likely to enhance the inhibitory effect of the 
VDR on CYP27A1 than the f allele, causing reduced serum 25(OH)D levels. 71,72   
Interestingly, there are other studies that have reported an association between 
FokI VDR polymorphism and vitamin D status, but their findings contradict ours. These 
studies show that the ff genotype could be a risk factor for vitamin D deficiency based on 
the fact that this mutant genotype could alter the metabolic feedback loops or affect the 
speed at which 25(OH)D is metabolized.18 Thus, individuals carrying the homozygous 
major genotype FF have a significantly better increase in serum 25(OH)D levels than 
those who carry the ff genotype.76 This assumption led Al-Daghri and colleagues to 
speculate that FokI genotypic variants might require different threshold concentrations of 
25(OH)D levels to exhibit feedback effects. The following section will shed light on the 
studies that contrast our findings.  
Two studies conducted in Egypt found a significant association between ff 
genotype carriers and low values of serum 25(OH)D when compared to FF genotype in 
type 2 diabetic (T2DM) patients.77,78 In agreement with the previous results, two studies 
conducted in China also evaluated the association between FokI VDR polymorphism and 
vitamin D status among patients with inflammatory bowel disease (IBD) and found 
similar outcomes.79,80 Both studies demonstrated a significant association between 
  66 
vitamin D deficiency and the combined mutant genotype (Ff+ff) of FokI in the Chinese 
patients with ulcerative colitis (UC)29 and Crohn’s Disease (CD).79 Moreover, the 
investigators observed a higher risk of UC 29 and CD 79 in patients when FokI VDR 
mutations and vitamin D deficiency were combined. Similarly, a very recent cross-
sectional study conducted among black and white South Africans found an increased risk 
of developing severe vitamin D deficiency (< 38 nmol/L) among chronic kidney disease 
(CKD) patients carrying Ff and combined Ff+ff genotypes compared to healthy 
participants.80  
Furthermore, two vitamin D supplementation studies conducted on type 2 diabetic 
(T2DM) patients reported that the lowest increase in serum 25(OH)D levels was detected 
in patients with ff genotypes.26,76 With that knowledge, Al Daghri et al. 76 supplemented 
their patients with 2,000 IU vitamin D3 daily for 12 months without a control or placebo 
group, while Neyestani et al. monitored the daily intake of vitamin D-fortified yogurt 
with 500 IU vitamin D/250 mL for 12 weeks.26 Both authors suggested that high-risk 
patients carrying ff genotype might be considered “low responders,” as they need higher 
doses of vitamin D supplements than their counterparts in order to achieve sufficient 
levels and benefit the most from the treatment.26,76 
To our knowledge, only one study has explored the effect of FokI VDR 
polymorphism on serum 25(OH)D levels in healthy Saudi subjects.32 Sadat-Ali et al. 
found that vitamin D deficiency was quite prevalent among 283 Saudis, reaching 87%, 
and that carriers of the GG genotype of FokI VDR (which corresponds to FokI ff 
genotypes in our study) had an increased risk of both vitamin D insufficiency and 
deficiency when compared to controls, 32 a study that contradicts ours. The investigators 
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addressed a major limitation in their study that they did not control for confounders such 
as environmental and individual factors that may alter vitamin D levels. 32 It is worth 
mentioning that we did not see any significant associations between FokI VDR 
polymorphism and vitamin D deficiency in our logistic regression model until we 
adjusted for risk factors such as age, BMI, physical activity, clothing, job status, 
residential area, and education level. It seems that these factors have masked the genetic 
influence on vitamin D status, and this could be the case with Sadat Ali et al.’s findings 
as well.  
While there is robust evidence linking FokI VDR polymorphism to serum 
25(OH)D concentrations, many studies have failed to replicate these finding in different 
populations. Neither Li et al. 81 nor Robein et al. 20 found a significant association 
between FokI VDR gene polymorphism and vitamin D deficiency in the Chinese 
population, even though Robein et al. 20 controlled for confounding factors such as 
dietary vitamin D intake and number of hours spent indoors at work. Also, Engelman et 
al. did not observe any effect of FokI on vitamin D levels in the African-American or 
Hispanic populations.82 Similarly, no association was detected among Saudi 83 and 
Emirates 84 participants with Metabolic Syndrome (MS).  
Although there is a vast body of literature stating that pregnancy offers a window 
of opportunity to prevent adverse fetal programming, we only found one study that 
evaluated the association between FokI VDR polymorphism and vitamin D levels in 
Iranian pregnant women. 85 Aslani et al. did not detect any significant differences in 
25(OH)D levels between carriers of the F and f alleles among healthy pregnant women 
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and gestational diabetes mellitus (GDM) patients in their second trimester (17.27 ± 13.56 
vs. 16.86 ± 9.79 nmol/L, P = 0.7). 85  
Possible explanations for the non-significant association between VDR FokI and 
vitamin D status in the previous studies could be attributed to the following reasons: 
smaller study populations and the failure to adjust for risk factors that alter serum 
25(OH)D, such as vitamin D intake, use of supplements, latitude, seasonal variations, sun 
exposure, and other factors that affect vitamin D status. 20 Additionally, most of the 
research to date has assessed the association between 25(OH)D and FokI VDR on non-
healthy subjects, and the lack of association could be related to disease state confounders. 
To the best of our knowledge, this is the first investigation to assess VDR FokI 
polymorphism and vitamin D levels in a group of pregnant women with prevalent 
vitamin D deficiency in Saudi Arabia. We also extensively studied important confounders 
that have a significant effect on altering vitamin D status.  
We acknowledge that there are some limitations to the current study. First, the 
cross-sectional nature of the study cannot confirm a causal link between vitamin D levels 
and VDR FokI, and further prospective design studies are required to support our 
findings. Second, we did not study polymorphisms of other VDR genotypes and other 
genes involved in the vitamin D metabolic pathway such as Vitamin D-binding protein, 
Vitamin D 25-hydroxylase, and CYP27A1 that are thought to be associated with vitamin 
D status.31 Third, despite several adjustments, factors related to sun exposure and the use 
of sunscreen were subjected to recall bias.  
Despite the aforementioned limitations of this study, the finding in our study may 
assist in identifying “at-risk” populations through screening for FokI VDR 
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polymorphisms in conjunction with screening vitamin D serum levels in pregnant 
women. Moreover, since vitamin D is a potentially modifiable risk factor, these results 
encourage a prospective study of the use of vitamin D supplementation in pregnant 
women who are vitamin D deficient and the monitoring of its effectiveness in increasing 
vitamin D levels while evaluating genes related to the metabolic pathway.  
4.6 Conclusion 
As far as we know, this is the first cross-sectional study to evaluate the 
association between FokI polymorphisms in the VDR gene and serum 25(OH)D levels in 
pregnant Saudi women with vitamin D deficiency compared to non-deficient subjects. 
We also demonstrated the first association between the f allele and the reduced risk of 
vitamin D deficiency when controlling for lifestyle and environmental factors that play a 
major role in altering vitamin D status. The observed higher levels of serum 25(OH)D in f 
allele carriers may be a compensatory response due to reduced VDR activity and 
distorted signaling pathways.  
In conclusion, vitamin D deficiency was highly prevalent among 79% of pregnant 
Saudi women in their first trimester. Full body coverage with clothing, lower levels of 
physical activity, residence in areas other than North Riyadh, work indoors, and the 
amount of exposure to sunlight were found to be major risk factors for vitamin D 
deficiency in pregnant Saudi women. 
Our findings also indicated that the VDR gene FokI FF genotype and the F allele 
might be important determinants of an individual’s susceptibility to vitamin D deficiency 
in pregnant Saudi women, thus leaving them unprotected with the risk of developing 
adverse skeletal and non-skeletal health outcomes. However, allele f and genotype Ff 
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seemed to play a protective role, but the role of genotype ff is still unclear because of its 
limited frequency.  
It is important to take this finding into consideration in future prospective studies 
that are targeted to assess 25(OH)D levels. Therefore, possible alterations in vitamin D 
intake are needed to ameliorate the untoward effects of VDR FokI polymorphisms on 
vitamin D status in this vulnerable vitamin D deficient group carrying a variant of the F 
allele. If genotypes are truly associated with vitamin D status, serum concentrations of 
25(OH)D required to reduce adverse health outcomes may need to be individualized for 
each patient.  
Future studies on healthy subjects are required to clarify the primary genetic 
predictors of 25(OH)D concentrations, including the assessment of genes involved in 
vitamin D metabolism. However, our study indicates the need for proper adjustment for 
important confounders that are known to alter vitamin D status to appreciate the effects of 
genotype on vitamin D levels.
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Table 4.1: Demographic and biochemical characteristics of vitamin D deficient vs. non-deficient subjects 
 
Parameters 
 
Overall 
Non-Deficient  
50nmol/L 
Deficient 
<50 nmol/L 
 
P-
values 
N 345 72 (20.9) 273 (79.1) --- 
Age (years) 28.8 ± 5.4 29.4 ± 5.4 28.7 ± 5.4 0.320 
BMI (kg/m2) 28.2 ± 6.3 28.6 ± 6.6 28.2 ± 6.3 0.626 
Pre-pregnancy BMI (kg/m2) 27.2 ± 6.1 27.5 ± 6.7 27.1 ± 5.9 0.591 
Parity # 1.4 ± 1.7 1.3 ± 1.7 1.4 ± 1.7 0.492 
Biochemical Parameters 
Calcium (mmol/L) 2.2 ± 0.2 2.2 ± 0.2 2.2 ± 0.2 0.638 
Phosphorus (mmol/L) 1.2 ± 0.4 1.3 ± 0.5 1.2 ± 0.4 0.029 
Alkaline phosphatase (mmol/L) 9.5 ± 3.2 9.5 ± 2.8 9.5 ± 3.3 0.992 
25(OH) D (nmol/L) 35.5 ± 20.0 67.8 ± 12.9 27.0 ± 10.6 0.000 
Physical Activity 
Low-intense PA (<210 mint/wk) (yes) 144 (50.9) 46 (78.0) 98 (43.8) <0.001 
Sitting (minutes/week) 1200(600-
1800) 
1200 (450 – 1500) 
1200 (600 – 
1800) 
0.709 
Diet 
Vitamin D intake (>600 IU/d) 10 (3.1) 4 (5.8) 6 (2.4) 0.433 
Calcium intake (>1000 mg/d) 21 (6.6) 6 (8.7) 15 (6.0) 0.147 
Multivitamin intake 62 (21.9) 13 (24.5) 49 (21.3) 0.609 
Education and employment 
University graduate (or Higher) (yes) 199 (59.1) 50 (70.4) 149 (56.0) 0.028 
Employment (yes) 107 (31.5) 28 (38.9) 79 (29.5) 0.127 
Area of living 
Living in north Riyadh (yes) 64 (19.6) 23 (33.3) 41 (15.9) <0.001 
Living in west Riyadh (yes) 90 (27.5) 13 (18.8) 77 (29.8) 0.069 
Sun exposure Indices 
Blood sample collection season 111 (32.4) 23 (32.9) 88 (32.2) 0.921 
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(Summer) 
Sun exposure (yes) 91 (26.4) 20 (27.8) 71 (26.0) 0.762 
Coverage with clothing (whole body) 93 (27.0) 2 (2.8) 91 (33.3) <0.001 
Use of sun screen (yes) 28 (8.1) 6 (8.3) 22 (8.1) 0.939 
Nature of work (indoors) 317 (91.9) 48 (66.7) 269 (98.5) <0.001 
Time of sun exposure (at noon)  114 (33.0) 52 (72.2) 62 (22.7) <0.001 
Note:  Data presented as Mean ± SD for continuous variables and N (%) presented for categorical variables;  
# indicates non-normal variables; P-value<0.05 considered significant.  
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Table 4.2: Predictors of vitamin D deficiency among pregnant women in early pregnancy 
Parameters Univariate Analysis Adjusted Model 
OR (95% CI) P-
value 
OR (95% CI) * P-value* 
Age (years) 0.98 (0.93 – 1.02) 0.319 1.00 (0.92 – 1.08) 0.909 
BMI (kg/m2) 0.99 (0.95 – 1.03) 0.625 0.97 (0.92 – 1.03) 0.288 
Pre-pregnancy BMI (kg/m2) 0.99 (0.55 - 1.03) 0.590 0.97 (0.91 – 1.03) 0.283 
Parity 1.06 (0.90 – 1.25) 0.491 1.13 (0.85 – 1.50) 0.403 
University graduate or postgraduate 0.54 (0.30 - 0.94) 0.030 0.42 (0.17 – 1.02) 0.054 
Employment 0.66 (0.38 – 1.13) 0.128 0.67 (0.31 – 1.47) 0.319 
Living in North Riyadh 0.38 (0.21 - 0.69) 0.002 0.32 (0.14 - 0.75) 0.009 
Living in West Riyadh 1.35 (0.97 - 1.88) 0.072 1.42 (0.91 – 2.22) 0.119 
Calcium (mmol/L) 0.70 (0.16 – 3.02) 0.637 0.11 (0.01 – 1.18) 0.068 
Phosphorus (mmol/L) 0.42 (0.21 – 0.83) 0.012 0.27 (0.10 – 0.76) 0.013 
Alkaline phosphatase (mmol/L) 1.00 (0.92 – 1.09) 0.992 0.96 (0.83 – 1.11) 0.596 
Low-intense PA (<210 mint/wk) (yes) 0.22 (0.11 – 0.43) <0.001 0.19 (0.08 – 0.44) <0.001 
Vitamin D intake (>600 IU/d) 0.40 (0.11 – 1.46) 0.165 0.30 (0.02 – 4.52) 0.383 
Calcium intake (>1000 mg/d) 0.67 (0.25 – 1.80) 0.427 2.94 (0.30 – 28.35) 0.351 
Blood collection season (Summer) 0.97 (0.56 – 1.70) 0.921 2.49 (0.90 – 6.89) 0.080 
Sun exposure (yes) 0.91 (0.51 – 1.64) 0.762 2.23 (0.88 – 5.67) 0.090 
Coverage with clothing (whole body) 17.5 (4.20 – 72.98) <0.001 19.64 (2.52 – 152.68) 0.004 
Use of sun screen (yes) 0.96 (0.37 – 2.47) 0.939 1.65 (0.42 – 6.48) 0.474 
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Nature of work (indoors) 33.63 (11.17 – 101.23) <0.001 132.0 (10.9 – 1600.7) <0.001 
Time of sun exposure (at noon)  0.11 (0.06 - 0.20) <0.001 0.13 (0.06 - 0.32) <0.001 
Note: *P-value adjusted for Age, BMI at visit 1, Low-intense physical activity, Whole body cloth coverage, Job Status,  
Residential Area, Education, total-cholesterol-HDL ratio, Calcium intake (mg/day), Vitamin D intake (IU/day).  
P-value<0.05 considered significant.  
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Table 4.3: The genotype distribution of FokI VDR gene polymorphisms among participants  
FokI 
Genotype 
All Deficient 
(<50 
nmol/L) 
Non 
Deficient 
(>50 
nmol/L) 
OR (95 % CI) P-Value Adj. OR 
(95%CI) 
Adjusted 
P-value* 
FF 204(59.1) 164 (60.1) 40 (55.6) Reference 
Ff 117 (33.9) 91 (33.3) 26 (36.1) 0.85 (0.50 – 1.49) 0.577 0.44 (0.20 – 
0.94) 
0.035 
ff 24 (7.0) 18 (6.6) 6 (8.3) 0.73 (0.27 – 1.96) 0.535 0.36 (0.08 – 
1.52) 
0.163 
FF 204(59.1) 164 (60.1) 40 (55.6) Reference 
Ff + ff 141 (40.9) 109 (39.9) 32 (44.4) 0.83 (0.49 – 1.40) 0.488 0.42 (0.20 - 0.88) 0.022 
F 525 (76.1) 419 (76.7) 106 (73.6) Reference 
f 165 (23.9) 127 (23.3) 38 (26.4) 0.85 (0.56 – 1.29) 0.434 0.51 (0.29 – 
0.91) 
0.021 
Note: *P-value adjusted for Age, BMI, low-intense physical activity, whole body cloth coverage, Job Status, residential Area, and education 
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CHAPTER 5 
MANUSCRIPT 2: FOKI VITAMIN D RECEPTOR GENE POLYMORPHISMS, 
GLUCOSE INTOLERANCE AND GESTATIONAL DIABETES RISK IN SAUDI 
WOMEN 
 
5.1 Abstract 
• Background: Gestational diabetes mellitus (GDM) is one of the major complications 
of pregnancy. GDM is common in pregnancies around the world (1% to 14%), with 
alarmingly high rates among Saudi women (39%). The reported prevalence of 
vitamin D deficiency is also higher in pregnant Saudi women (85%). Previous studies 
have linked vitamin D deficiency in pregnancy with a 1.6-times increased risk of 
developing GDM. The presence of the mutant f allele of the FokI vitamin D receptor 
(VDR) polymorphism has been shown to reduce vitamin D responsiveness. We 
expect that carriers of the ff genotype have a greater risk of GDM. 
• Aim: This study examined whether there was a difference in GDM risk associated 
with the various genotypes of the FokI VDR polymorphism in pregnant Saudi women 
during their second trimester. 
• Materials and Methods: A cross-sectional study of 368 pregnant Saudi women, 
including 108 GDM patients and 260 healthy subjects, was conducted in the antenatal 
clinics of three hospitals in Riyadh, Saudi Arabia (King Khaled University Hospital 
[KKUH], King Salman bin Abdulaziz Hospital, and King Fahad Medical City 
[KFMC]) between December 2013 and January 2016. The oral glucose tolerance test 
(OGTT) was administered at 24–28 weeks’ gestation. We also measured fasting 
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blood glucose, insulin, and HbA1C. The homeostasis models of insulin resistance and 
beta cell function were calculated using the HOMA-IR and HOMA-, respectively. 
The FokI genotype of each woman was determined through allele-specific 
polymerase chain reaction (PCR).  
• Results: About 29% of the study sample were diagnosed with GDM. The GDM 
patients were older, heavier, and had higher pre-pregnancy BMIs than the healthy 
subjects. As expected, the fasting blood glucose (FBG), fasting insulin, HbA1C, 
HOMA-IR, and HOMA- levels were also higher in the GDM patients. Among the 
GDM patients, the frequencies of the genotypes FF, Ff, ff, and combined Ff+ff were 
60.2%, 33.3%, 6.5%, and 39.8%, respectively; among the healthy subjects, the 
frequencies of these genotypes were 61.1%, 31.5%, 6.9%, and 38.4%, respectively. 
While we could not determine a significant association between the FokI VDR 
polymorphism and GDM risk, we found that serum 25-hydroxyvitamin D was 
significantly and inversely associated with fasting blood glucose and HbA1C within 
the group of patients carrying the ff minor allele genotype (r=-0.49, P=0.014 and r=-
0.45, P= 0.026, respectively). Vitamin D deficiency was highly prevalent among the 
study sample, reaching up to 85.3%. This condition was also significantly associated 
with GDM (P=0.016) and glucose indices, such as fasting insulin, HOMA-IR and 
HOMA-. 
• Conclusion: Our study suggests that, within the Saudi population, the glucose-
lowering effects of a higher vitamin D level may be dependent upon the FokI 
genotype. 
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5.2 Introduction 
Gestational Diabetes Mellitus (GDM), defined as “carbohydrate intolerance of 
variable severity, with onset or first recognition during pregnancy”,1 is one of the more 
common complications of pregnancy. The global prevalence of GDM, which is from 1% 
to 14% of all pregnancies, depends on the population studied and the GDM diagnostic 
tests applied.2 GDM can cause serious maternal and fetal morbidity and mortality. Short-
term maternal complications of GDM include increased risk of maternal hypertension, 
pre-eclampsia, infection, cesarean delivery and premature birth, and in newborns 
hypoglycemia, macrosomia, shoulder dystocia or birth injury, increased intensive 
neonatal care, hyperbilirubinemia, respiratory distress syndrome, and polycythemia.3,4 
Long-term adverse maternal health outcomes of GDM include a 70% increase in the risk 
of developing Type 2 Diabetes (T2DM) within 10 years after delivery5, and a 35 to 80% 
increased risk of developing GDM in a future pregnancy.6 In addition, offspring of  
mothers with GDM are at increased risk of developing obesity, T2DM and cardiovascular 
disease during early childhood.7 The pathogenesis of GDM remains unclear, 8 but likely 
is attributed to both genetic and lifestyle factors.  
The role of vitamin D deficiency as a potentially modifiable nutritional risk factor 
for GDM has been highlighted in the literature. For example, a recent meta-analysis 
found that reduced vitamin D status was associated with a 45% increase in GDM risk. 8 
Further support for a role of vitamin D status in blood glucose control in women with 
GDM has been supplied by two vitamin D supplementation studies.9,10 One recent 
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randomized, double-blind placebo-controlled clinical trial found that a very high-dose of 
vitamin D supplementation (50,000 IU) every 2 weeks significantly reduced levels of 
insulin resistance in pregnant Chinese women with GDM .9 Similarly, another 
randomized placebo-controlled trial found a significant reduction in fasting plasma 
glucose, serum insulin levels and HOMA insulin resistance in 56 Iranian women with 
GDM compared with the placebo group after supplementing them with calcium (1,000 
mg/d) and vitamin D (50,000 IU/d) twice during the study period.10  
In spite of bountiful sunlight in Saudi Arabia, vitamin D deficiency is common 
and reported to affect 72% of women of childbearing age.11 A cross-sectional study found 
that out of 160 pregnant Saudi women, 90% of the study sample were either vitamin D 
deficient (25(OH)D ≤50 nmol/L) or vitamin D insufficient (25(OH)D = 50–74 nmol/L). 12 
Similarly, another cross-sectional study of 1000 pregnant Saudi women reported that 
86% were vitamin D deficient (mean: 30.5 ± 19.6 nmol/L).13 This alarmingly high rate of 
vitamin D inadequacy needs to be carefully evaluated because many studies have linked 
vitamin D deficiency with adverse metabolic outcomes for both mother and their 
newborns. 14,15,16  
In addition, the prevalence of GDM among Saudi women is also exceedingly 
high, ranging between 10% to 51% depending on the diagnostic tool.15 Important risk 
factors for GDM in Saudi women that have been identified include obesity, and the 
tradition of Saudi women to become pregnant at an older age.16 Other commonly 
observed risk factors for GDM include: a family history of diabetes, gestational weight 
gain, history of GDM in previous pregnancies, a history of delivering a large baby 
(macrosomia).15,16  
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The suggested physiological mechanism behind the association of vitamin D 
status and risk of GDM is that the vitamin D receptor (VDR) is present in almost every 
tissue of the human body, including β-cells of the pancreas.9 The active hormonal 
metabolite of vitamin D (1,25-dihydroxyvitamin D) binds to the VDR of pancreatic β 
cells and promotes insulin secretion and thereby may influence glucose homeostasis.9, 17 
Activation of the vitamin D receptor by its ligand can be modulated by many cellular 
factors, including single nucleotide polymorphisms (SNP) in the VDR gene itself, such as 
the ff FokI SNP (rs 2228570); previously reported as (rs10735810).18 This VDR 
polymorphism is of particular interest because in vitro studies indicate that the f allele 
results in a nucleotide change in the gene sequence that results in the formation of a 
second upstream start site that results in the expression of a VDR protein that is 3 amino 
acids longer than the VDR coded by the F FokI VDR allele.19 The longer VDR has been 
shown to be less responsive to 1,25-dihydroxyvitamin D than the shorter F allele version 
in activating target gene expression.20 Thus, we hypothesized that Saudi mothers with 
poorer vitamin D status plus expression of the longer, less effective f version of the VDR 
protein would be at greatest risk of any adverse effects of vitamin D deficiency on 
glucose intolerance and the risk of GDM.   
To our knowledge, only a few studies have investigated the association between 
the FokI VDR polymorphisms and GDM in Iran,21 Saudi Arabia,22,23 and most recently in 
Brazil,23 but the findings were inconsistent and inconclusive due to the variability of the 
population and ethnic groups studied. A significant association was found between 
mutant ff FokI genotype carriers and the risk of GDM when compared with healthy 
subjects in Iranian and Brazilian population.21,24 Nevertheless, El-Beshbishy et al. and Al-
  91 
Ghamdi failed to observe such an association in Saudi pregnant women.22,23   
The current study was designed to determine to what extent the f allele of the FokI 
VDR gene polymorphism is a genetic biomarker associated with increased risk of GDM 
in Saudi women. We reasoned that the ability of vitamin D status to modulate glucose 
metabolism would be impaired in women with the ff FokI genotype. Our working 
hypothesis was that Saudi pregnant women carrying the (f) minor allele FokI VDR 
genotype will have an increased signs of glucose intolerance and a greater risk of 
developing GDM.  
5.3 Methods 
5.3.1 Study Design and Sample Population 
This study is a part of a large prospective cohort study called “Vitamin D and 
Pregnancy in Saudi Women”. Our cross-sectional study is a subset of these study 
participants and consisted of 368 pregnant Saudi women including 108 GDM patients 
and 260 healthy pregnant women who visited an antenatal clinic in their second trimester 
(24-28 weeks of gestation) at one of three different hospitals; King Khaled University 
Hospital (KKUH), King Salman bin Abdulaziz Hospital and King Fahad Medical City 
(KFMC) in Riyadh, the capital city of Saudi Arabia, between December 2013 and 
January 2016. The study has full ethical approval from the three hospitals to collect 
samples and patients data and also an approval was obtained from the Ethics Committee 
of the College of Science, King Saud University in Riyadh (Appendix A). Written 
informed consent was obtained from each patient (Appendix B).  
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5.3.1.1 Inclusion and Exclusion Criteria 
Healthy pregnant Saudi women aged 18 to 40 years with no previous history of 
diabetes mellitus (type I or II) were enrolled in the study prior to 16 weeks of gestation. 
Subject exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks; 
women were excluded from the study if they were taking vitamin D supplements during 
pregnancy; unwillingness to deliver at the three hospitals; taking oral glucocorticoids; 
using drugs known to interfere with vitamin D or calcium absorption or parathyroid 
disorders; using any cardiac medication or diuretics; suffering from chronic hypertension 
or malabsorption syndrome; having chronic medical conditions or preexisting liver, 
kidney, calcium, and /or parathyroid conditions; or serious chronic disease conditions 
(epilepsy, cancer, other malignancy). 
5.3.1.2 Recruitment and Medical Screening  
Recruitment banners and brochures were placed in prenatal clinics in all three of 
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients 
at their first prenatal appointment. Patients who met the criteria and consented to 
contribute in the present study were given the appropriate information. At their early 
pregnancy visit, prospective candidates were asked to sign consent forms that included 
information about their participation in the study, such as answering a questionnaire 
about demographic data collection, procurement of blood samples for biomarker 
measurement and DNA for genetic analyses, and anthropometric measurements. 
Permission for data collection from their medical records and stored blood stocks ifrom a 
bio-bank were also obtained (Appendix A). The participants were also informed of their 
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right to withdraw from the study at any point, without it affecting their usual medical 
care.  
 5.3.2 Anthropometric Measurements 
Anthropometric measurements were taken from the participants between 24 and 
28 weeks gestation. These measures included weight (kg) and height (cm), used for 
calculating BMI (kg/m2); reported pre-pregnancy weight (kg) and pre-pregnancy BMI 
(kg/m2). Body weight, without shoes and wearing lightweight clothing, was measured to 
the nearest 0.1 kg  (Digital Pearson Scale, ADAM Equipment Inc., USA). Height, to the 
nearest 0.5 cm, was measured at the early pregnancy visit only using the Digital Pearson 
Scale, while standing upright without shoes. Pre-pregnancy BMI was calculated from 
pre-pregnancy body weight recall and measured height.  
5.3.3 Interview Questionnaire 
At the second trimester visit (24-28 weeks of gestation), clinical data was 
collected. Pregnant women were questioned about GDM risk factors, such as parity 
(nulliparous or ≥ 1 multiparous), pre-pregnancy weight, previous miscarriage (yes/no), 
previous history of GDM, and family history of diabetes or any other family medical 
history. Participants were also asked about pregnancy-related symptoms, such as nausea, 
vomiting, morning sickness, frequent urination, headaches, abdominal bloating, 
constipation, acute respiratory or gastrointestinal viral or bacterial infections, any 
hospitalisation or medication prescribed, and the presence of any pregnancy-related 
complications. 
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5.3.4 Biochemical Assessment 
During the antenatal visit between 24 and 28 weeks of gestation, participants were 
asked to fast > 10 hours for blood withdrawal. Blood samples (10 ml) were collected 
using sterile vacutainer blood collection apparatus. Whole blood, serum, and ethylene 
diamine tetra-acetic acid (EDTA) plasma were collected from the participants. All 
samples were aliquoted and stored in a -80ºC freezer for subsequent analyses. All the lab 
tests were performed on serum, except hemoglobin A1C (HbA1C), which was performed 
on whole blood. The blood samples were stored and analyzed at the King Saud University 
Biomarkers Research Program (BRP) Laboratory. It should be noted that the Biomarker 
Research Program (BRP) Laboratory is a participating entity in the vitamin D External 
Quality Assessment Scheme (DEQAS), and Quality Assurance (QA) standards are 
maintained by ISO 9000 and 17025. The QA department audits the BRP Laboratory at 
regular intervals.  
5.3.4.1 Primary Outcome Measures 
Our main outcome is the metabolic impact of the mutant ff FokI VDR genotype 
versus the wild type FF FokI VDR genotype on glucose intolerance and risk of GDM, 
measured by oral glucose tolerance test (OGTT) administered at 24-28 weeks gestation. 
For the OGTT, women were asked to fast for at least 10 hours, and a fasting blood 
sample was obtained and then a 75 g glucose drink was consumed (within a period of five 
minutes). Further blood collections took place at the 60- and 120-minute time points to 
assess glucose tolerance. Serum glucose (PG) was measured by using routine laboratory 
analysis (Konelab, Finland).  The International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) guidelines were applied to diagnose GDM based on the (fasting 
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≥5.1 mmol/l and or 1 h post glucose ≥10mmol/l h and/or 2 h post glucose load 
≥8.5mmol/l) .25 
5.3.4.2 DNA Extraction and Quantification 
Genomic DNA was extracted from whole blood using innuPREP blood ini kits 
(Analytik Jena, Germany) following the manufacturer’s instructions. Briefly, 200µl of 
whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and 
Proteinase K. The content was mixed by vortex and incubated at 600C for 10 minutes. 
The required amount of binding solution was added to the tube and transferred to a spin 
filter column with receiver tube and centrifuged for 1 minute at 12000 rpm. Washing of 
the column-bound DNA was performed using the kit’s washing solution C followed by 
washing solution BS. In a final step, the spin filter was placed into a 1.5ml elution tube 
and 200µl of pre-warmed (at 600C) elution buffer was added. After centrifugation, the 
collected DNA was stored at -20◦C for further analysis. DNA concentration and purity 
(260/280) was determined using a Nano-Drop spectrophotometer.  
5.3.4.3 FokI SNP Genotyping  
The Fok-I SNP is in the VDR coding region (rs 2228570); previously reported as 
(rs10735810) and can be evaluated by allelic discrimination real-time PCR using pre-
designed TaqMan genotyping assay from Applied Biosystems, Foster City, CA, USA 
(assay ID: C_12060045_20). Amplification reactions was performed in a volume of 10 
µL containing 1X TaqMan genotyping Master Mix (Applied Biosystems), 1X mix of 
unlabeled PCR primers and TaqMan MGB probes, and 30 ng of template DNA. All 
amplification and detection was conducted in 96-well PCR plates using a Bio-Rad 
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CFX96 Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Thermal cycling was 
initiated with a denaturation step of 10 min at 95 °C, followed by 45 cycles of 15 s at 95 
°C and 90 s at 60 °C. After PCR was completed, allelic discrimination was analyzed 
using the Bio-Rad CFX Manager Software (Version 1.6, Bio-Rad). Genotype assignment 
was determined by plotting the end point relative fluorescent units (RFU) for one 
fluorophore (allele 1 on the x-axis) against the RFU for the other fluorophore (allele 2 on 
the y-axis) on the allelic discrimination. All PCR reactions were set up in a dedicated 
PCR area with dedicated PCR pipettes and reagents. 
5.3.4.4 Other Measures 
From the whole blood, HbA1C was measured using a point-of-care device (Accu-
Check Active, Roche Diagnostics, Mannheim, Germany). Fasting serum insulin was 
measured by COBAS e 411 Analyzer (Roche Diagnostics). The homeostasis model of 
insulin resistance (HOMA-IR) and homeostasis model of beta cell function (HOMA-β), 
were calculated to evaluate insulin resistance and basal pancreatic β-cell function using 
the following equations:  
(HOMA-IR) = fasting insulin (μU/ml) × fasting FPG (mmol/l)/22.5 14    
(HOMA-β) = 20 × fasting insulin(μU/ml)/[FPG(mmol/l) − 3.5] 14  
Higher HOMA-IR values indicated greater insulin resistance, while lower HOMA-β 
values indicated greater beta-cell dysfunction, as validated against gold standards.26 
We also measured serum 25-hydroxyvitamin D (25(OH)D), which is the most 
reliable indicator of vitamin D status 27 through an electro-chemiluminescence binding 
assay 2012 (ECLIA) (Roche Diagnostics GmbA, Mannheim, Germany) and 
commercially available IDS kits (IDS Ltd, Boldon Colliery, Tyne & Wear, UK). The 
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inter- and intra-assay coefficients of variation (CV) for the 25(OH)D ELISA is 5.3% and 
4.6%, respectively, with 100% cross-reactivity to 25(OH)D3 and 75% cross-reactivity to 
25(OH)D2. According to US Endocrine Society guidelines, the cutoff values for vitamin 
D deficiency is defined as serum 25(OH)D less than 50nmol/L. 27 
5.3.5 Statistical Analysis 
The power analysis for this study is based on results from Aslani et al.21 Using the 
G*Power Calculator for sample size effect size=0.22 α=0.05, power (1-β) = 0.95 and 
degrees of freedom=2, the total estimated sample size=321. Data were analyzed using 
SPSS statistical software (version 21.0, IBM). The normality of all quantitative 
variables was tested before performing the analysis, using Shapiro-Wilk Test. 
Quantitative normally distributed variables were presented as mean ± standard deviation 
(SD), while quantitative non-normally distributed variables were presented in median 
(25th and 75th) percentiles. Categorical data were presented as frequencies and 
percentages (%). Pearson’s chi-square test was used to determine the differences between 
categorical variables. Comparisons between groups were performed using the 
independent sample t-test and the Mann-Whitney U test for normal and non-normal 
variables, respectively. The Pearson’s and Spearman’s rank correlation coefficients were 
determined to assess the linear relationship between quantitative variables for normally 
and non-normally distributed variables, respectively. Unadjusted and adjusted odds ratios 
were determined using logistic regression analysis to identify the risk factors associated 
with categorical outcome variables. Generalized multivariate analysis was also done to 
compare mean differences adjusted for age, BMI. A P-value of < 0.05 and 95% CI was 
finally applied to report statistical significance and the precision of the estimates. 
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5.4 Results 
5.4.1 Demographic and Biochemical Characteristics of GDM vs. Normal Subjects  
Table 5.1 presents the anthropometric and biochemical characteristics of the 
GDM and non-GDM groups of pregnant women. The prevalence of GDM was 29.3% 
(n=108/368). There was a significant difference in age, current BMI, and pre-pregnancy 
BMI between the GDM and normal subjects. GDM patients were significantly older and 
heavier than normal pregnant women (P< 0.01 and <0.01, respectively). Moreover, GDM 
patients were more obese (53.4%) compared to healthy pregnant women (30.2%), 
(P<0.001) (Figure 5.1). Compared with non-GDM group, fasting blood glucose (FBG), 1 
h and 2 h OGTT, HbA1C, fasting insulin, HOMA_IR, and HOMA-β in the GDM subjects 
were significantly increased. These significant increases remained even after adjusting 
for age and BMI.  Although, medium serum 25(OH)D was low, but not different in the 
GDM and normal subjects (33.9 vs. 32.9 nmol/L, respectively P = 0.686), vitamin D 
deficiency however, was significantly higher in GDM group (93.2%) compared to normal 
subjects (82.2%) (P =0.013) (Figure 5.1). 
Interestingly, there were no significant differences between GDM and normal 
subjects in regards to parity, family history of diabetes, and previous history of 
miscarriage. However, previous history of GDM was significantly higher in GDM than 
non-GDM groups (25.7% vs. 3.1%, respectively P < 0.01) (Figure 5.1). 
5.4.2 Risk Factors for GDM in Pregnancy  
We further conducted a multivariate logistic regression analysis to assess the risk 
factors for GDM while adjusting for confounding factors (Table 5.2). Significant 
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independent variables that increased the risk of GDM included previous history of GDM 
(OR 9.25, 95% CI 3.14-27.22, P < 0.001), fasting insulin (OR 1.07, 95% CI 1.03-1.11, P 
< 0.001), HOMA_IR (OR 1.07, 95% CI 1.03-1.11, P < 0.001), obesity (OR 2.08, 95% CI 
1.09-3.95, P =0.026) and vitamin D deficiency (OR 2.96, 95% CI 1.22-7.19, P = 0.016). 
Although HbA1C was significantly higher in GDM than non-GDM group, it did 
not appear to be a risk factor for GDM. In fact, it lost its significance after adjusting for 
confounding factors (OR 1.50, 95% CI 0.74-3.02, P = 0.263). 
5.4.3 FokI VDR Polymorphism and GDM 
 
As shown in Table 5.3, the difference in the occurrence of the various FokI VDR 
genotypes in GDM and non-GDM participants was not significant. The FokI VDR 
genotypes are normally expressed as homozygous genotype “FF,” heterozygous 
genotype “Ff,” and mutant homozygous genotype “ff.” The frequencies of FF, Ff, ff, and 
combined Ff+ff genotypes were 61.1% (225), 32.1% (118), 6.8% (25), and 39.8% (43) 
respectively, in the study population. Taking the FF genotype as a reference, the odds 
ratio for the risk of having GDM was not significant among the different FokI VDR 
genotypes, even after adjusting for important covariates such as age, BMI, family history 
of diabetes, obesity, previous history of GDM, fasting serum insulin, HbA1C and vitamin 
D deficiency. The frequencies of genotypes FF, Ff, ff, and combined Ff+ff in women 
with GDM were 60.2%, 33.3%, 6.5%, and 39.8% respectively, while in the control group 
were 61.1%, 31.5%, 6.9%, and 38.4% respectively. The prevalence of F and f alleles for 
the FokI VDR polymorphisms in the two groups was also not significant (allele F vs. f; 
P=0.495), even after adjustments of covariates. 
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5.4.4 Biochemical Characteristics of the Subjects Depending on FokI VDR 
Genotypes and Alleles 
Table 5.4 shows that women carrying the f allele had higher OGTT levels at 2 
hours than subjects carrying the F allele (P= 0.017). Similarly, OGTT levels at 2 hours 
were significantly higher in combined FokI genotype Ff+ff than the FF genotype carriers 
(P= 0.019) (data not shown). Yet, we did not detect any significant association between 
other different biochemical variables and FokI VDR genotypes in all subjects.  
5.4.5 Vitamin D Status and Glucose Indices 
Table 5.5 presents the clinical and biochemical characteristics of vitamin D 
deficient versus non-deficient subjects. Vitamin D deficient subjects had significantly 
higher fasting insulin, HOMA_IR and HOMA1-β (P= 0.024, 0.007, 0.041, respectively). 
5.4.6 Correlation Between Vitamin D and Other Parameters in Genotypes 
Serum 25(OH)D was significantly and inversely associated with fasting blood 
glucose (FBG) (r= -0.49, P=0.014) (Figure 5.2) and HbA1C (r = - 0.45, P=0.026) (Figure 
5.3) in women carrying the ff FokI genotype. Moreover, there was a significant and 
positive association between serum 25(OH)D and HOMA1-β (r = 0.20, P<0.05) in 
patients carrying the f allele. 
5.5 Discussion 
Vitamin D deficiency was evident in 85.3% of our study sample. Despite the 
abundance of sunlight in Saudi Arabia, many previous studies have similarly reported a 
high prevalence of vitamin D deficiency among the Saudi population, with a higher rate 
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observed in younger females, especially in pregnant women and their offspring.12,13 In 
line with our finding, both Al-Sheikh et al.13 and Foda et al.28 found that 86% of pregnant 
Saudi women, were vitamin D deficient. Several factors related to Saudi customs may 
play a role in vitamin D status, such as limited outdoor activities due to extremely high 
temperatures during the daytime as well as the tradition of wearing dark clothing that 
covers the whole body, thus preventing sun exposure and blocking the cutaneous 
production of vitamin D. Low consumption of foods containing vitamin D may be 
another important risk factor for vitamin D deficiency in Saudi Arabia.12,13 
Poor vitamin D status is a known risk factor for glucose intolerance and the 
development of T2DM.29 VDR gene polymorphisms are candidate single nucleotide 
polymorphisms associated with vulnerability to a variety of conditions and diseases, 
including glucose intolerance and T2DM.18 Among the most common VDR 
polymorphisms studied, only the FokI VDR polymorphism has been shown to affect the 
VDR protein structure.30 This polymorphism (denoted by f) results in a cytosine-to-
thymine (C→T) nucleotide change in exon 2 of the coding region of the VDR gene, thus 
creating a second upstream start site due to a codon change from ACG to ATG.19, 20 This 
start codon change causes the expression of a VDR protein that is 3 amino acids longer 
(427 versus 424 amino acids), which has been shown to have reduced transactivation 
ability.19, 20 Therefore, we hypothesized that pregnant women with the ff genotype of the 
FokI polymorphism (all long VDR proteins) would be more likely to have impaired 
glucose tolerance than those with the FF genotype (all short VDR proteins). We also 
predicted that poor vitamin D status, in combination with the ff genotype, would be 
associated with a greater degree of glucose intolerance (determined via an OGTT at 24 
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weeks’ gestation) and would be more likely to be diagnosed with GDM. However, our 
findings showed no significant associations between the FokI VDR polymorphism and 
the risk of GDM in pregnant Saudi women. In fact, the frequencies of FokI genotype and 
allele variants were almost identical in the wild-type (FF) carriers, ff homozygotes, and 
Ff heterozygotes among the GDM and control groups.  
While previous studies have demonstrated the potential role of the FokI VDR 
polymorphism in the pathogenesis of GDM, they remain scarce and inconclusive. Our 
results agree with the following two studies conducted among the Saudi population.22,23 
In her small study, Al-Ghamdi did not observe any difference in the FokI VDR 
polymorphisms of 50 healthy, pregnant Saudi women and 50 GDM patients. 23 El-
Beshbishy et al., using a sample size similar to our own, also did not detect any 
significant differences in the FokI VDR polymorphisms of 112 GDM patients and 218 
healthy, pregnant Saudi women. 22   
In contrast, two studies found a significant association between the FokI VDR 
polymorphism and GDM. The first study was conducted by Aslani et al. on 303 pregnant 
Iranian women (142 GDM patients and 161 healthy subjects), which found that the ff 
genotype was more common in the GDM patients than in the healthy subjects 
(OR=1.783; 95% CI=0.774–4.107). 21 Interestingly, the healthy subjects had higher 
frequencies of the F allele (78.6% vs. 72.2%; P<0.06), suggesting that the F allele may 
contribute to decreasing the incidence of GDM.21 The authors attributed the reason for 
this association to the dysfunction of the f VDR variant. As the mutant f allele is longer in 
structure and 40% less active than the F allele, carriers of the f allele are therefore 
predisposed to a higher risk of GDM.21 The second study, which supports Aslani et al.’s 
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results, was recently conducted on a population from northeastern Brazil.24 The authors 
examined whether the FokI VDR polymorphism was associated with GDM risk in 
pregnant women with a history of spontaneous preterm births (SPTBs).24 The results 
revealed a significant association between the presence of the mutant ff genotype and 
GDM risk in SPTB patients, compared to patients who experienced normal deliveries 
(OR=4.71; CI 95%=1.1–22.30; P=0.044), as the frequency of the ff genotype was higher 
in the SPTB group (23% vs. 4.7%).24 The authors therefore suggested that the FokI VDR 
polymorphism could be a biomarker for GDM.24  
These previous findings should be interpreted with caution, however, as El-
Beshbishy et al.22 and Aslani et al.21 measured fasting blood glucose alone to screen for 
GDM. The application of other criteria for the diagnosis of GDM, such as those of the 
International Association of Diabetes and Pregnancy Study Groups (IADPSG), results in 
an increased prevalence of GDM due to the inclusion of pregnant women with 
hyperglycemia.25 Therefore, there is a possibility that the authors missed the high-risk 
patients, thus under-reporting the incidence of GDM, which may have affected the study 
outcomes. It was also not clearly indicated whether the previous investigators controlled 
for risk factors such as obesity, a family history of diabetes, or a history of microsomia, 
as only Aslani et al.21 found the latter two factors to be significantly associated with 
GDM risk. Furthermore, the contradictory evidence of the previous studies could be 
explained by the small sample size, the heterogeneity of the analyzed samples, and the 
intra-individual variability in vitamin D status, which might have influenced the 
expression of VDR gene polymorphisms.30 It should be noted that Aslani et al.21 were the 
only investigators who measured the serum 25(OH)D levels; however, they did not study 
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the effect of vitamin D deficiency in combination with the genotype of the FokI VDR 
polymorphism on the patients’ glucose intolerance or GDM risk. 
Although our study did not result in a significant association between the FokI 
VDR polymorphism and the risk of GDM, we did find that carriers of the f allele had 
higher levels of blood glucose at two hours into the OGTT than carriers of the F allele. 
Moreover, in carriers of the ff genotype, serum 25(OH)D was found to be significantly 
and inversely associated with fasting blood glucose and HbA1C. These observations might 
be explained by the fact that the VDR is expressed in many human tissues, including 
those involved in the regulation of glucose metabolism, such as pancreatic β cells.8,19 The 
VDR is also known to alter glucose homeostasis via the insulin-like growth factor 
system.8,12 Although the role of vitamin D and the VDR in regulating glucose 
homeostasis remains unclear, our results in the Saudi population suggest that the glucose-
lowering effects of a higher vitamin D level may be dependent upon the FokI genotype.  
It is well known that vitamin D may enhance insulin sensitivity by stimulating the 
expression of insulin receptors, thereby increasing insulin response to facilitate glucose 
transport.31 In our results, we found evidence that supports the adverse effect of vitamin 
D deficiency on glucose tolerance and insulin sensitivity, as the levels of fasting insulin, 
and HOMA-IR were significantly higher in vitamin D-deficient subjects. These 
observations are congruent with other published studies reporting an association between 
lower serum 25(OH)D levels and higher HOMA-IR, which suggests that vitamin D 
deficiency during pregnancy may be related to insulin resistance and could therefore 
increase the risk of GDM.32–35 Our findings are also in agreement with a recently 
published study that revealed a significant association between poor vitamin D status and 
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fasting blood glucose (P=0.002) or insulin sensitivity (P=0.001) in healthy Czech 
adults.30 
In our study, although there were no observed, significant differences in vitamin 
D levels between the GDM and healthy subjects, even after adjusting for the cofounders 
of age and BMI, vitamin D deficiency appeared to be a risk factor for GDM. In fact, we 
found that the vitamin D-deficient subjects were 2.3 times more likely to develop GDM 
compared to their healthy counterparts (OR=2.29, 95%; CI=0.79–6.65; P=0.016). Our 
results are consistent with two previous studies that linked vitamin D deficiency with 
GDM36,37 as well as a meta-analysis, which associated vitamin D deficiency in pregnancy 
with a 1.6-times increased risk of GDM.38 However, in other studies, particularly in 
Saudi Arabia,13 the Czech Republic,39 Turkey,32 India,40 and Britain,41 no associations 
were reported between vitamin D deficiency and the risk of GDM. Other factors that can 
potentially impact the results include geographical location, ethnicity, study design, 
sample size, lack of adjustment for confounding factors, heterogeneity of dietary factors, 
and differences in socio-economic status.42,43 
GDM is considered a serious public health issue, as it has been associated with 
higher incidences of perinatal mortality and morbidity.40 The prevalence of GDM in 
Saudi Arabia has risen steadily over the past two decades, from 12.5% in 200011 to 18.7% 
in 201344 and 24% in 2015.45 These alarmingly large increments were measured using the 
2013 criteria of the ADA and the WHO.11,44,45 In our study, using the latest GDM 
diagnosis criteria of the IADPSG, we identified 108 participants (29.3%) with GDM. 
This rate appears to be high, and it corresponds well with the rising trend of GDM in 
Saudi Arabia; however, it should be noted that the IADPSG criteria includes pregnant 
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women with hyperglycemia as well as GDM patients, which may have affected the 
prevalence of GDM observed in our study population.46,47 Three other studies conducted 
in Saudi Arabia used the same IADPSG criteria and, congruent with our results, found a 
high prevalence of GDM in their respective samples, amounting to 39.6%,48 36.6%,49 and 
39.4%.16 These rates are extremely high when compared to the overall prevalence of 
GDM (17.8 %) found in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
cohort.50 The HAPO was a large, multicenter, multinational, epidemiologic cohort study 
of 23,957 pregnant women at 24–32 weeks’ gestation, who were similarly diagnosed 
using the IADPSG criteria.4 According to the literature, GDM has genetic and 
environmental influences.51 In addition to ethnic variation within a population, the most 
commonly reported risk factors for GDM in pregnant women include weight, parity, 
advanced maternal age, having delivered a macrosomic infant, having a previous history 
of GDM, and having a family history of diabetes.49,54 Likewise, our study found that 
having a previous history of GDM, fasting insulin, HOMA-IR, obesity, and vitamin D 
deficiency (as discussed earlier) are strong, significant predicators of GDM. The 
association between having a previous history of GDM and the recurrence of GDM has 
been confirmed as well; as earlier studies found that GDM recurs in at least 30% of 
women with prior history.53 Our findings are also supported by studies in different 
countries that found a significant association between pre-pregnancy obesity and GDM 
risk.49,54 
The association between GDM and HbA1C has been previously documented as 
well.14 While we also observed a strong, significant relationship between GDM and 
HbA1C, statistical significance was lost after adjusting for confounders.  
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We acknowledge that there are some limitations in our study, as cross-sectional 
studies are incapable of proving causation. In addition, our sample size was relatively 
small, especially in the group carrying the ff genotype of the FokI VDR polymorphism, 
thus making it difficult to assess the interaction between VDR gene polymorphisms and 
GDM risk. We also analyzed only one SNP of the VDR gene—albeit one that translates 
structurally diverse VDR proteins, which have different potentials in eliciting vitamin D-
mediated gene expression. While there are other documented risk factors that might have 
masked the relationship between the FokI VDR polymorphism and GDM risk, such as 
gestational weight gain,55 inflammation,56 low levels of vitamin B12,57 and low 
adiponectin,58 we only controlled for the classical risk factors. Nevertheless, our study is 
one of the few in Saudi Arabia that assesses the association between the FokI VDR 
polymorphism and GDM while considering the confounding factors of age, BMI, parity, 
obesity, vitamin D deficiency, previous history of GDM, and family history of diabetes. 
We had strict standards for recruitment, as we excluded all patients taking vitamin D 
supplements. The accuracy of our vitamin D measurements is assured through our use of 
the ECLIA method, which is the gold standard in liquid chromatography–mass 
spectrometry (LC–MS/MS), and our results were included in the Vitamin D External 
Quality Assurance Scheme (DEQAS). We were also able to measure multiple outcomes 
related to glucose intolerance, such as insulin and HbA1C, using the most accepted and 
cost-effective criteria worldwide (the IADPSG criteria).59 
5.6 Conclusion 
 
Contradictory results exist in the prevailing literature on the associations between 
VDR gene polymorphisms and GDM. While our study identified an effect on GDM risk 
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caused by vitamin D deficiency, we found no associations between the ff genotype of the 
FokI VDR polymorphism and the occurrence of GDM in the Saudi population. 
Regardless, our study is very encouraging, as it demonstrates that the glucose-lowering 
effects of a higher vitamin D level may be dependent upon the FokI genotype within the 
Saudi population. Our findings also confirm a high prevalence of GDM and vitamin D 
deficiency among pregnant Saudi women. A strong, significant association has been 
detected between vitamin D deficiency and GDM risk, along with other classical risk 
factors. 
Potential interactions between vitamin D status and genetic polymorphisms in the 
pathogenesis of GDM are far from being fully comprehended. Nevertheless, given the 
role of vitamin D status in pregnancy outcomes and disease conditions other than GDM, 
it would be prudent to recommend increased vitamin D supplementation among this 
vulnerable population of women. Further studies are warranted, with sufficient statistical 
power, subjects of diverse ethnic backgrounds, and the inclusion of both classical and 
atypical risk factors for GDM as well as other genes in the vitamin D metabolic pathway, 
to confirm the potential association of VDR gene polymorphisms with GDM in different 
populations.  
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Table 5.1: Demographic and biochemical characteristics of GDM vs. normal subjects  
 
Parameters All GDM Non GDM P-value P-Value 
adjusted 
for Age 
and BMI 
N 368 108 (29.3) 260 (70.7) 
Age (years) 29.1 ± 5.6 30.6 ± 6.0 28.4 ± 5.2  <0.001 
Parity 2.0 (1.0-4.0) 2.0(1.0-5.0) 2.0(1.0-3.0) 0.369 
Current-BMI (kg/m2) 28.2 ± 6.1 30.3 ± 6.4 27.3 ± 5.9 <0.001 ------ 
Pre-Pregnancy-BMI 
(kg/m2) 
26.9 ± 5.9 28.7 ± 5.9 25.9 ± 5.4 
<0.001 ------ 
FBG (mmol/L) 4.5 (4.1-5.0) 5.3 (4.8-5.6) 4.3 (3.9-5.6) <0.001 <0.001 
OGTT_1hrs (mmol/L) 7.4 (5.8-8.9) 10.1 (7.6-10.7) 6.7 (5.3-7.8) <0.001 <0.001 
OGTT_2hrs (mmol/L) 6.3 (5.3-7.7) 8.8 (6.6-10.2) 5.9 (5.1-6.9) <0.001 <0.001 
HbA1C (%) 
 
4.8 ± 0.5 
 
5.0 ± 0.6 
 
4.7 ± 0.5 <0.001 <0.001 
Fasting Insulin (uU/ml) 7.5 (4.5-13.1) 9.7 (6.2-17.2) 6.5 (4.1-12.1) <0.001 0.003 
HOMA_IR 1.5 (0.9-2.5) 2.2 (1.3-3.9) 1.2 (0.7-2.2) <0.001 <0.001 
HOMA_ 141.9 (52.9-
325.6) 
371 (163.1-658.9) 100 (44.6-216.5) <0.001 <0.001 
25(OH)D (nmol/l) 33.4 (213-53.7) 33.9 (21.7-56.9) 32.9 (20.9-52.8) 0.772 0.686 
Note: GDM: gestational diabetes mellitus, BMI: body mass index; FBG: fasting blood glucose; OGTT: Oral Glucose Tolerance Test; 
HbA1C: haemoglobin A1c or glycated haemoglobin; HOMA_IR: homeostatic model assessment of insulin resistance; 
HOMA_: homeostatic model assessment of beta cell function. Normally distributed variables are presented as Means ± SD.  
Non-normally distributed variables such as parity, FBG, OGTT 1,and 2 hrs, Fasting Insulin, HOMA_IR, HOMA_, and vitamin D. 
are presented as Medians (25th and 75th percentile). P-value denotes significance at <0.05 and <0.01 
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Table 5.2: Predictors of GDM among pregnant women between 24-28 weeks gestation 
 
Parameters Univariate Analysis Adjusted Model 
OR (95% CI) P-value OR (95% CI) * P-value* 
Age (years) 1.05(1.00 - 1.10) 0.044 0.98(0.91 - 1.04) 0.448 
Parity 1.11(0.96 - 1.30) 0.170 0.86 (0.68 – 1.08) 0.191 
Current-BMI (kg/m2) 1.05(1.02 - 1.10) 0.002 1.04(0.99 - 1.09) 0.168 
Pre-Pregnancy-BMI (kg/m2) 1.06(1.03 - 1.10) 0.001 1.05 (0.99 – 1.11) 0.072 
Family history of Diabetes 1.13(0.63 - 2.00) 0.676 0.84(0.42 - 1.65) 0.607 
Previous history of GDM 10.96 (4.14 – 29.0) <0.001 9.25(3.14 - 27.22) <0.001 
History of Miscarriage 1.69(0.93 - 3.10) 0.087 1.36 (0.64 – 2.92) 0.426 
HbA1C (%) 2.44(1.51 - 3.92) <0.001 1.50 (0.74 – 3.02) 0.263 
Fasting Insulin (uU/ml) 1.07(1.03 - 1.10) 0.000 1.07 (1.03 – 1.11) <0.001 
HOMA_IR 56.8(12.66 - 254.60) <0.001 75.34 (15.32 – 370.60) <0.001 
HOMA_ 0.48(0.24 - 0.96) 0.038 0.76 (0.36 – 1.57) 0.453 
25(OH)D (nmol/l) 0.58(0.19 - 1.81) 0.352 1.00 (0.98 – 1.02) 0.966 
Vitamin D deficiency (<50nmol/L) 2.96(1.22 – 7.19) 0.046 2.29(0.79 - 6.65) 0.016 
Obesity 2.66(1.62– 4.36) <0.001 2.08 (1.09 – 3.95) 0.026 
Note: *P-value adjusted for age, pre-pregnancy BMI, family history of diabetes, previous history of GDM, HbA1C (%), and obesity. 
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Table 5.3: Comparison of the genotype and allele frequencies of the VDR FokI polymorphism in GDM  
                  and control groups 
 
Parameters GDM  Non-GDM Odd Ratio (95% 
CI) 
P-Value Adjusted OR 
(95% CI) 
Adjusted P-
Value N N=108 
(29.3%) 
N=160 
(70.7%) 
FokI- rs10735810 
FF 
Ff 
ff 
Ff+ff 
 
             F 
             f 
 
65 (60.2) 
36 (33.3) 
7 (6.5) 
43 (39.8) 
 
166 (76.9) 
50 (23.1) 
 
160 (61.1) 
82 (31.5) 
18 (6.9) 
100 (38.4) 
 
402 (77.3) 
118 (22.7) 
 
1 
0.96 (0.38-2.40) 
1.08 (0.66-1.76) 
1.06 (0.66-1.68) 
 
1 
1.03 (0.70-1.50) 
 
 
 
0.926 
0.755 
0.808 
 
 
0.704 
 
1 
1.26 (0.48-3.31) 
1.28 (0.76-2.14) 
1.29 (0.78-2.07) 
 
1 
1.51 (0.78-1.70) 
 
 
0.426 
0.289 
0.256 
 
 
0.368 
 
Note: OR: Odds ratio (95% CI), P-value adjusted for Age, Pre-pregnancy BMI, family history of diabetes, obesity, previous history of GDM,  
fasting serum insulin, Hbg A1c and vitamin D deficiency. 
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Table 5.4: Clinical and biochemical characteristics of the subjects depending on 
their alleles 
 
Parameters F f P-value 
N 568 168 
Age (years) 
29.2 ± 5.9 28.3 ± 5.3 
 
0.073 
Parity 2.0 (1.0-4.0) 2.0(1.0-3.0) 0.755 
Current-BMI (kg/m2) 28.5 ± 6.5 27.6 ± 5.7 0.121 
Pre-Pregnancy-BMI (kg/m2) 27.2 ± 6.2 26.3 ± 5.2 0.080 
FBG (mmol/L) 4.5 (4.1-4.9) 4.5 (4.1-4.9) 0.625 
OGTT_1hrs (mmol/L) 7.3 (5.8-8.8) 8.0 (5.9-9.5) 0.122 
OGTT_2hrs (mmol/L) 6.2 (5.2-7.7) 6.6 (5.8-7.8) 0.017 
HbA1C (%) 
 
4.8 ± 0.5 4.9 ± 0.7 0.099 
Fasting Insulin (uU/ml) 7.5 (4.4-12.9) 7.7 (5.6-15.6) 0.967 
HOMA_IR 1.5 (0.9-2.6) 1.3 (0.9-2.8) 0.975 
HOMA_ 141.7 (52.6-315.9) 136.9 (57.1-360.1) 0.772 
25(OH)D (nmol/l) 33.6 (22.4-53.7) 31.6 (19.3-52.2) 0.303 
Note: Data represented Mean ± SD and Median (1st and 3rd) percentile for Gaussian and non-Gaussian 
variables. P-Value denotes significance at <=0.05 and 0.01. 
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Table 5.5: Clinical characteristics of the vitamin D deficient and non-deficient 
pregnant Saudi women  
 
Parameters Vitamin D deficient 
25(OH)D<50 nmol/l 
 
Non- deficient 
25(OH)D >50 
nmol/l 
P-value 
N 260 (85.3) 108 (14.7) 
Age (years) 28.9 ± 5.7 29.4 ± 5.2 0.470 
Parity 2.0 (1.0-4.0) 1.0 (1.0-3.0) 0.202 
Current-BMI (kg/m2) 28.2 ± 6.5 28.1 ± 5.6 0.835 
Pre-Pregnancy-BMI 
(kg/m2) 
26.8 ± 6.1 26.9 ± 5.5 0.852 
FBG (mmol/L) 4.5 (4.1-4.9) 4.2 (3.9-5.1) 0.081 
OGTT_1hrs (mmol/L) 7.3 (5.8-8.7) 8.4 (6.7-9.5) 0.114 
OGTT_2hrs (mmol/L) 6.3 (5.3-7.4) 6.8 (5.6-9.1) 0.756 
HbA1C (%) 4.8 ± 0.5 4.8 ± 0.6 0.712 
Fasting Insulin (uU/ml) 7.6 (4.6-13.1) 6.3 (4.5-12.9) 0.024 
HOMA_IR 1.5 (0.9-2.5) 1.3 (0.9-2.7) 0.007 
HOMA_ 146.8 (59.3-319.9) 111.1 (56.8-348.3) 0.041 
25(OH)D (nmol/l) 29.9 (20.1-46.7) 66.7 (43.4-85.3) <0.001 
Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and non-Gaussian 
variables. P-Value Denotes significance at P <0.05 and 0.01 
 
 
 
 
 
 
 
 
 
 
  114 
Figure 5.1 Demographic and biochemical parameters in relation to GDM status 
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Figure 5.2 Correlations between Log vitamin D (nmol/L) in ff FokI genotypes versus (A) FBG, (B) HbA1C 
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Figure 5.3 Correlation between Log vitamin D (nmol/L) in f FokI allele versus 
HOMA_ 
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CHAPTER 6 
MANUSCRIPT 3: VITAMIN D, VITAMIN D RECEPTOR POLYMORPHISM, 
AND METABOLIC SYNDROME IN PREGNANT SAUDI WOMEN 
 
6.1 Abstract 
• Background: Metabolic Syndrome (MS) is a serious health concern and its 
prevalence is rising significantly in Saudi Arabia. It is also more common in females 
than in males. Pregnant women with MS have a higher risk of developing gestational 
diabetes (GDM) and preeclampsia during pregnancy and a great increased risk of 
future chronic diseases such as cardiovascular disease (CVD) and Type 2 diabetes 
mellitus (T2DM). In addition, it has been previously reported that complications 
during pregnancy may contribute negatively to the health of the unborn infant from 
gestation to adulthood and cause an increased risk for morbidity and mortality. 
Previous studies have linked Vitamin D receptor (VDR) gene polymorphism to MS in 
adults. However, the association between VDR gene polymorphisms with maternal 
MS and its components in pregnancy has not yet been clarified.  
• Aim:  The objective of this study was to investigate the association of the FokI VDR 
genotype as a risk factor for MS and its components in pregnant Saudi women.  
• Materials and Method: A cross-sectional study of 368 pregnant Saudi women (44 
with MS and 324 without MS) who visited antenatal clinics of three hospitals in 
Riyadh, Saudi Arabia (King Khaled University Hospital [KKUH], King Salman bin 
Abdulaziz Hospital, and King Fahad Medical City [KFMC]) between December 2013 
and January 2016. Fasting serum glucose, HbgA1C, insulin, HDL-C, LDL-C, TG, TC, 
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25(OH) D and blood pressure were measured in the second trimester (at 24-28 weeks 
of pregnancy. The Fokl VDR genotype of each woman was determined by allele-
specific polymerase chain reaction (PCR).  
• Results: About 12% of the study population had MS. FokI VDR genotyping 
frequencies for FF, Ff, and ff genotypes were 62.7% (203), 31.5% (102), and 5.9% 
(19), respectively, in healthy pregnancies and 50.0% (22), 36.4% (16), and 13.6% (6), 
respectively, in patients with MS. The minor FokI ff genotype was a significant risk 
factor for MS (OR = 2.91; 95% CI, 1.05-8.1; P= 0.039).  
• Conclusion: This observation suggests that the presence of the ff FokI VDR genotype 
is genetic marker of MS risk in pregnant Saudi women. However, we did not find a 
significant association between FokI VDR genotype and components of MS in these 
pregnant women.    
 
6.2 Introduction 
Metabolic syndrome (MS) is a cluster of abnormal metabolic health disorders that 
includes 3 or more of the following 5 characteristics: elevated blood pressure, central 
obesity, dyslipidemia, high cholesterol and elevated fasting blood sugar.1 MS is a 
growing worldwide health problem and is a risk factor for developing cardiovascular 
disease (CVD) and type 2 diabetes mellitus (T2DM).2 The prevalence of MS has been 
rising globally and increasing from about 20% to 40% in the adult population.3 In the 
United States, for example, about 25% of the adult population suffers from MS,4 whereas 
in Saudi Arabia, the prevalence of MS is much higher, ranging between 13.6 and 57%.5 
Differences in the prevalence estimates of MS in different geographic areas may by 
  126 
affected by gender variations in the population studied, different targeted populations or 
age groups studied, as well as possible differences in the criteria used in its definition.5 
Moreover, a recent study from Saudi Arabia revealed that 43.42% of the total cohort of 
12,126 study participants, aged 18 years and above, had two or more risk factor 
components for MS.6   
The prevalence of MS in general is higher in females than in males.4 Al-Nozha 
and colleagues, found a higher ratio of MS in Saudi females than in males, 42%, and 
37.2%, respectively.7 A systematic review conducted by Aljefree and Ahmed in the Gulf 
countries found a high prevalence of CVD and its associated risk factors, particularly 
obesity among women in this area.8 Another large cohort study in Saudi Arabia; Riyadh 
Mother and Baby Study (RAHMA), found that more than 68% of the 14,568 pregnant 
women studied were either overweight or obese and 24% of the total cohort developed 
gestational diabetes. 9 The prevalence of these two risk factors for MS; namely, obesity 
and gestational diabetes were among the highest in the world.9 
Identification of MS in pregnant women is important because they are at 
increased risk of developing maternal complications, such as preeclampsia and coma, as 
well as adverse perinatal effects, such as malformations, neonatal hypoglycemia, neonatal 
macrosomia, jaundice, and preterm birth.1,4,10 Moreover, Rodie et al. reviewed different 
studies related to complications during pregnancy and their outcomes and reported that 
multiple complications, such as preeclampsia, preterm birth and intra-uterine growth 
restriction, carries a seven-fold additive risk of future diseases, including maternal 
CVD.11 In addition, an increasing body of epidemiologic evidence indicates that offspring 
of high-risk pregnancies accompanied by complications and adverse birth outcomes are 
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at increased risk of developing MS, CVD, and T2DM later in life.1,10, Gosadi has 
reported that “CVD is one of the leading causes of death in the adult Saudi population 
where the increase in cardiovascular-related mortality is augmented by the rise in the 
prevalence of MS.”12 
The alarmingly pandemic rate of MS in Saudi Arabia and elsewhere can be 
attributed to many etiological factors. For example, in Saudi Arabia, rapid urbanization, 
globalization, and improvements in socioeconomic status have resulted in a significant 
change in lifestyle.13 A recent systematic review also found a very high prevalence of 
physical inactivity among Saudi women, ranging from 53.2% to 98.1%.14 These authors 
attributed the high prevalence of sedentary lifestyle and obesity in Saudi women to socio-
cultural factors like the banning of driving and physical education in girls’ public 
schools.14 The dietary pattern of the Saudi Arabian diet has also changed to a more 
Westernized diet with increased consumption of high-energy-dense foods and processed 
foods that are high in fat, sugar and salt.13 As a result, non-communicable diseases 
(NCD) such as obesity, diabetes, hypertension and high cholesterol have emerged as a 
significant problem, and are affecting a growing number of people in Saudi Arabia.13,15 
Rahim et al. reported that in Arab countries there were more than one million deaths in 
the year of 2008 from NCD, which accounted for 60% of all deaths.16 Although all these 
risk factors in addition to aging are considered to be primary etiological factors for 
developing MS, genetic predisposition could be another important factor in the prediction 
of risk for MS.3 
The activity of 1,25-dihydroxyvitamin D, the active hormonal form of vitamin D, 
is mediated through the cellular vitamin D nuclear receptor (VDR) protein.17 VDR is 
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expressed in most body tissues and has been shown to be important in calcium 
homeostasis and bone metabolism, as well as other non-calcemic actions.18,19 Single 
nucleotide polymorphisms (SNPs) are common in the genome and can sometimes affect 
gene expression or function. The VDR gene has several recognized SNPs that could alter 
the functioning of the VDR.20 Among these VDR polymorphisms, the FokI VDR gene 
polymorphism has been of interest because it occurs in the transcription start codon, and 
its polymorphic form (f) results in a change in the start codon position such that the 
expression of the VDR protein is three amino acids longer than the wild-type (F) allele.17 
The longer VDR protein has been shown to be less active than the shorter wild-type 
version. This shorter FokI VDR allelic variation has also been found associated with 
various adverse disease outcomes in some epidemiologic studies.21,22 The association of 
FokI VDR genotypes with pregnancy complications has been studied, but has resulted in 
mixed findings.23 
Vitamin D status is largely dependent on sunlight exposure and is reflected in 
higher serum 25-hydroxyvitamin (25(OH)D), a biomarker of vitamin D status. However, 
it is evident that vitamin D deficiency is quite prevalent among pregnant women in Saudi 
Arabia, despite the abundance of sunlight all year around.24 Vitamin D deficiency itself 
has been linked to MS. Meta-analysis of cross-sectional studies found a significant 
inverse association between the level of serum 25(OH)D and the risk of MS.25 In another 
systematic review, it was observed that the highest levels of serum 25(OH)D were 
associated with a 43% reduction in CVD, T2DM and MS.18 
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 Several studies have examined the relationship between VDR gene 
polymorphisms and the risk for MS or its components in adults. These studies found that 
FokI VDR gene polymorphisms were associated with blood pressure, insulin resistance, 
BMI and lipid profile, but the findings from these studies in different ethnic groups 
remained inconclusive. 2,3,21,22, 26,27 To our knowledge, there have been no studies that 
have investigated the association between VDR gene polymorphisms and MS and its 
components among pregnant Saudi women. Given the endemic nature of low vitamin D 
status and vitamin D deficiency found in the Saudi population, this group may be 
particularly susceptible to vitamin D-related adverse events due to the presence of the 
relatively ineffective longer VDR protein found in women with the ff VDR genotype.  
Therefore, our study was designed to investigate the association of VDR FokI genotypes 
with the risk of MS and its individual components in pregnant Saudi women living in 
Riyadh, the capital city of Saudi Arabia. 
 
 
6.3 Methods 
6.3.1 Study Design and Sample Population 
This study is a part of a large prospective cohort study called “Vitamin D and 
Pregnancy in Saudi Women”. Our cross-sectional study is a subset of these study 
participants and consisted of 368 pregnant Saudi women, which included 324 healthy 
pregnant women and 44 pregnant women with MS, among subjects who visited an 
antenatal clinic in their second trimester (24-28 weeks of gestation) at one of three Saudi 
hospitals; King Khaled University Hospital (KKUH), King Salman bin Abdulaziz 
Hospital and King Fahad Medical City (KFMC) in Riyadh, the capital city of Saudi 
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Arabia, between December 2013 and January 2016. The study has full ethical approval 
from the three hospitals to collect samples and patient data and approval from the Ethics 
Committee of the College of Science, King Saud University in Riyadh. (Appendix A). 
Written informed consent was obtained from each patient (Appendix B).  
6.3.1.1 Inclusion and Exclusion Criteria 
Healthy pregnant Saudi women, aged 18 to 40 years, with no previous history of 
diabetes mellitus (type I or II) were enrolled in the study prior to 16 weeks of gestation. 
Subject exclusion criteria included: non-Saudi subjects; gestational age of over 16 weeks; 
if they were taking vitamin D supplements during pregnancy; unwillingness to deliver at 
any of the three hospitals; taking oral glucocorticoids; using drugs known to interfere 
with vitamin D or calcium absorption or parathyroid disorders; using any cardiac 
medication or diuretics; suffering from chronic hypertension or malabsorption syndrome; 
having chronic medical conditions or preexisting liver, kidney, calcium, and /or 
parathyroid conditions; or serious chronic disease conditions (epilepsy, cancer, other 
malignancy). 
6.3.1.2 Recruitment and Medical Screening  
Recruitment banners and brochures were placed in prenatal clinics in all three of 
the hospitals. Obstetricians were asked to introduce the research to their pregnant patients 
at their first prenatal appointment. Patients who met the criteria and consented to 
contribute in the present study were given the appropriate information. At their early 
pregnancy visit, prospective candidates were asked to sign consent forms that included 
information about their participation in the study, such as answering a questionnaire 
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about demographic data, procurement of blood samples for biomarker measurement and 
DNA for genetic analyses, and anthropometric measurements. Permission for data 
collection from their medical records and stored blood stocks from a bio-bank were also 
obtained (Appendix A). The participants were also informed of their right to withdraw 
from the study at any point without it affecting their usual medical care.  
 
6.3.2 Anthropometric Measurements 
Anthropometric measurements were taken from the participants between 24 and 
28 weeks gestation. These measures included weight (kg) and height (cm), used for 
calculating body mass index (BMI) (kg/m2); reported pre-pregnancy weight (kg) and pre-
pregnancy BMI (kg/m2). Systolic and diastolic blood pressures (mmHg) were also 
recorded.  
Body weight, without shoes and wearing lightweight clothing, was measured to 
the nearest 0.1 kg  (Digital Pearson Scale, ADAM Equipment Inc., USA). Based on pre-
pregnancy weight as self-reported during the prenatal visit, pregnant women were 
classified according to the WHO BMI definitions as follows: underweight: <18.5 kg/m2; 
normal weight: 18.5–24.9 kg/m2; overweight: 25.0 - 29.9 kg/m2; or obese: ≥ 30.0 kg/m2.28 
Height, to the nearest 0.5 cm, was measured at the early pregnancy visit only 
using a stadiometer (Digital Pearson Scale), while standing upright without shoes. Pre-
pregnancy BMI was calculated from pre-pregnancy body weight recall and measured 
height. Blood pressure (mm Hg) was measured using a mercury sphygmomanometer, 
while the patient was relaxed and seated. Per the criteria set out by the International 
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Society for the Study of Hypertension in Pregnancy, gestational HTN was identified as 
BP140/90 mm Hg.29  
6.3.3 Biochemical Assessment 
During the antenatal visit between 24 and 28 weeks of gestation, participants were 
asked to fast > 10 hours for blood withdrawal. Blood samples (10 ml) were collected 
using sterile vacutainer blood collection apparatus. Whole blood, serum, and ethylene 
diamine tetra-acetic acid (EDTA) plasma were collected from the participants. All 
samples were aliquoted and stored in a -80ºC freezer for subsequent analyses. All the lab 
tests were performed on serum, except hemoglobin A1C (HbA1C), which was performed 
on whole blood. The blood samples were stored and analyzed at the King Saud University 
Biomarkers Research Program (BRP) Laboratory. It should be noted that the Biomarker 
Research Program (BRP) Laboratory is a participating entity in the vitamin D External 
Quality Assessment Scheme (DEQAS), and Quality Assurance (QA) standards are 
maintained by ISO 9000 and 17025. The QA department audits the BRP Laboratory at 
regular intervals. Serum 25(OH)D was measured by electro-chemiluminescence binding 
assay 2012 (ECLIA) (Roche Diagnostics GmbA, Mannheim, Germany) and 
commercially available IDS kits (IDS Ltd, Boldon Colliery, Tyne & Wear, UK). The 
inter- and intra-assay coefficients of variation (CV) for 25(OH)D ELISA is 5.3% and 
4.6%, respectively, with 100% cross-reactivity to 25(OH)D3 and 75% cross-reactivity to 
25(OH)D2. According to US Endocrine Society guidelines, the cutoff values for vitamin 
D deficiency is defined as serum 25(OH)D less than 50 nmol/L, and for sufficiency 
serum 25(OH)D more than 75nmol/L. 30 
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6.3.3.1 Primary Outcome Measures 
Our main outcome measure was to study the metabolic impact of the ff FokI VDR 
genotype versus the FF wild type VDR genotype on the risk of MS. Participants were 
divided into two groups, cases with MS and controls without MS, according to the 
International Diabetes Federation (IDF) definition with some attention taken into 
account to accommodate to our study population of pregnant women.4 In particular, for a 
pregnant women to be defined as having MS according to IDF definition, she must have 
3 or more of the following risk factors: pre-pregnancy body mass index (BMI) > 30 
kg/m2; level of serum triglyceride(TG) ≥ 150 mg /dL; serum high-density lipoprotein 
(HDL-cholesterol level < 50 mg/dL; fasting serum glucose level ≥ 100 mg/dL, and blood 
pressure level ≥ 130/85 mm Hg. 4 Healthy pregnant control subjects were those who did 
not match the criteria employed for the selection of MS subjects.  
6.3.3.2 Other Measures 
After an overnight fast (>10 h), participants were requested to return to their 
prenatal clinics for blood withdrawal. A 6-mL sample of fasting venous blood was 
collected and transferred immediately to a non-heparinized tube for centrifugation. Serum 
was then transferred to a pre-labeled plain tube, stored in ice, and delivered to the 
Biomarker Research Center in King Saud University on the same day. Fasting serum 
samples were stored in a −20 °C freezer prior to analysis to facilitate availability for later 
analysis.  
Fasting serum glucose (FBG) and lipid profile (including total cholesterol (TC), 
triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density 
lipoprotein cholesterol (LDL-C) were all measured using a chemical analyzer (Konelab, 
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Vantaa, Finland). Dyslipidemia is defined by presence of one or more abnormal serum 
lipid biomarkers. The cut-off of dyslipidemia, according to IDF guidelines, was as 
follows: TC ≥ 5.2 mmol/L (200 mg/dl), LDL ≥ 3.4 mmol/L (130 mg/dl), HDL 
<1.3 mmol/L (50 mg/dl), or TG >1.7 mmol/L (150 mg/dl), or a combination thereof. 31 
From the whole blood, HbA1C was measured using point-of-care (POC) devices 
(Accu-Check Active, Roche Diagnostics, Mannheim, Germany). 
 Fasting serum insulin was measured by COBAS e 411 Analyzer (Roche 
Diagnostics). The homeostasis model of insulin resistance (HOMA-IR) was calculated to 
evaluate insulin resistance using the following equations: (HOMA-IR) = fasting insulin 
(μU/ml) × fasting FPG (mmol/l)/22.5. Higher HOMA-IR values indicated greater insulin 
resistance.31 
6.3.3.3 DNA Extraction and Quantification 
Genomic DNA was extracted from whole blood using innuPREP blood mini kits 
(Analytik Jena, Germany) following the manufacturer’s instructions. Briefly, 200µl of 
whole blood sample was added to a 1.5 ml reaction tube containing lysis buffer and 
Proteinase K. The content was mixed by vortex and incubated at 60 0C for 10 minutes. 
The required amount of binding solution was added to the tube and transferred to a spin 
filter column with receiver tube and centrifuged for 1 minute at 12000 rpm. Washing of 
the column-bound DNA was performed using the kit’s washing solution C followed by 
washing solution BS. In a final step, the spin filter was placed into a 1.5ml elution tube 
and 200µl of pre-warmed at 60 0C elution buffer was added. After centrifugation, the 
collected DNA was stored at -20 0C for further analysis. DNA concentration and purity 
(260/280) was determined using a Nano-Drop spectrophotometer.  
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6.3.3.4 FokI SNP Genotyping  
The FokI SNP is in the VDR coding region (rs 2228570); previously reported as 
(rs10735810) and can be evaluated by allelic discrimination real-time PCR using pre-
designed TaqMan genotyping assay from Applied Biosystems, Foster City, CA, USA 
(assay ID: C_12060045_20). Amplification reactions was performed in a volume of 10 
µL containing 1X TaqMan genotyping Master Mix (Applied Biosystems), 1X mix of 
unlabeled PCR primers and TaqMan MGB probes, and 30 ng of template DNA. All 
amplification and detection was conducted in 96-well PCR plates using a Bio-Rad 
CFX96 Real-Time PCR Detection System (Bio-Rad, Milan, Italy). Thermal cycling was 
initiated with a denaturation step of 10 min at 95 °C, followed by 45 cycles of 15 s at 95 
°C and 90 s at 60 °C. After PCR was completed, allelic discrimination was analyzed 
using the Bio-Rad CFX Manager Software (Version 1.6, Bio-Rad). Genotype assignment 
was determined by plotting the end point relative fluorescent units (RFU) for one 
fluorophore (allele 1 on the x-axis) against the RFU for the other fluorophore (allele 2 on 
the y-axis) on the allelic discrimination. All PCR reactions were set up in a dedicated 
PCR area with dedicated PCR pipettes and reagents. 
6.3.4 Statistical Analysis 
Data were analyzed using SPSS (version 21.0, IBM). Continuous data are 
presented as mean ± standard deviation (SD) for Gaussian variables and non-Gaussian 
variables are presented as median (25th and 75th) percentiles. Categorical data are 
presented as frequencies and percentages (%). All continuous variables were checked for 
normality using Kolmogorov-Smirnov test. Non-Gaussian variables were log-
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transformed prior to parametric analysis. Independent T-test, analysis of variance 
(ANOVA), Mann-Whitney and Kruskal-Walis H tests were used to compare mean 
differences in Gaussian and non-Gaussian variables. Odds-ratio and X2 tests were done 
using binary logistics and multinomial logistic regression. A p- value <0.05 was 
considered statistically significant.  
6.4 Results 
6.4.1 General Characteristics and Components of MS 
Table 6.1 presents the characteristics of the subjects with and without MS. In our 
study, the prevalence of MS was 12%. Pregnant women with MS were significantly older 
and have higher pre-pregnancy BMI than the controls (P< 0.02 and <0.01, respectively). 
The mean age of the 44 women with MS was 31 (±7) years, and the mean age of 324 
controls was 29 (±5) years. Moreover, median serum 25(OH)D was lower in the MS 
subjects than controls (29.9 and 33.7 nmol/L, respectively), but did not reach statistical 
significance (P=0.186), as both groups had high prevalence of vitamin D deficiency 
(P=0.199).  Compared with the controls, diastolic blood pressure, HbgA1C, fasting serum 
glucose, HOMA_IR, insulin, and TG were significantly higher in pregnant women with 
MS, while HDL cholesterol was significantly lower (1.6±0.4 vs. 1.3±0.5 mg/dl, 
P<0.001). These findings remained significant even after adjusting for age and pre-
pregnancy BMI. 
6.4.2 FokI VDR Gene Polymorphisms and MS Risk 
 
As shown in Table 6.2, the difference in the occurrence of the genotypes in FokI 
between individuals with MS and the control group was statistically significant even after 
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the adjustment for age. The FokI VDR genotypes are normally expressed as dominant 
homozygous genotype “FF”, heterozygous genotype “Ff”, and mutant homozygous 
genotype “ff”. The frequencies of genotype FF, Ff, and ff in women with MS were 50%, 
36%, and 14% respectively, while in the control group were 63%, 32%, and 6%, 
respectively, which suggests that the genotype ff is a risk factor for MS (OR = 4.17; 95% 
CI, 1.42-12.2, P=0.009) in pregnant Saudi women. The prevalence of F and f alleles for 
the FokI VDR polymorphisms in the two groups were statistically significant (allele F vs. 
f; P=0.017), which suggests that the f allele is a genetic risk factor for MS in this 
population.  
6.4.3 Clinical Characteristics of the FokI VDR Gene Polymorphisms in MS and 
Control Group 
The distribution of some clinical and biochemical variables according to FokI 
VDR genotype that were observed in MS participants and pregnant controls are shown in 
Table 6.3. The pregnant women without MS with the FF genotype had a higher pre-
pregnancy and current BMI than pregnant women with either the Ff or ff genotypes (P= 
0.021, 0.027, respectively). We did not observe any association between VDR genotype 
and individual components of MS in pregnant women.  
6.4.4 FokI VDR Gene Polymorphism x Components of MS  
We conducted a multinomial logistic regression to better understand the 
relationship between different genotypes and alleles of FokI VDR polymorphisms and 
obesity, hypertension, low HDL, hypertriglyceridemia, hypercholesterolemia, 
dyslipidemia, and GDM (Table 6.4). Taking the FF genotype as a reference, the odds 
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ratio for the risk of having any component of MS, was not significant among the different 
FokI VDR genotypes. However, pregnant women carrying the mutant homozygous ff 
genotype of the VDR FokI were more likely to have elevated blood pressure (OR = 1.85, 
95% CI: 0.79, 4.34), low HDL (OR = 1.14, 95% CI: 0.70, 1.87), dyslipidemia (OR = 
1.60, 95% CI: 0.63, 4.10), and GDM (OR = 1.08, 95% CI: 0.66, 1.76) suggesting that ff 
genotype could be a risk factor for these variables. Although we did not see statistically 
significant odds ratios, they were consistently in the same direction. 
The prevalence of maternal obesity in Saudi women was 27%. Moreover, 12%, 
29%, 63%, 55%, 34%, and 47% of participants had elevated blood pressure, GDM, 
hypercholesterolemia, hypertriglyceridemia, low HDL, and dyslipidemia, respectively 
(Figure 6.1).  
6.4.5 MS and Its Components x Vitamin D Status 
Pregnant women who had MS and carry ff genotype were found to have a very 
strong significant and inverse association between serum 25(OH)D and fasting serum 
glucose (r=-0.92) (Figure 6.2). In controls, we found a significant inverse association 
between serum 25(OH)D and diastolic blood pressure (DBP) regardless of genotype (r=-
0.16) (Figure 6.3). Additionally, in all controls carrying FF genotype, serum 25(OH)D 
was significantly associated with HDL-cholesterol, LDL-cholesterol, and total cholesterol 
(r= 0.22, 0.19, 0.25, respectively) (Figure 6.4).  
Table 6.5 presents the anthropometric and biochemical characteristics of vitamin 
D deficient versus non-deficient subjects. Vitamin D deficiency was prevalent among 
85% of our participants. Moreover, vitamin D deficient subjects had significantly higher 
fasting insulin, HOMA_IR and systolic blood pressure (SBP) (P= 0.007, 0.024, 0.032, 
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respectively). Whereas, HDL-C and TC were significantly higher among the non-
deficient vitamin D women compared to their counterparts (P= 0.001, 0.049, 
respectively).  
6.5 Discussion 
To our best knowledge, this study represents the first time that the associations 
between the FokI VDR gene polymorphism and MS, as well as its components, have 
been evaluated in pregnant Saudi women.  
We found that the FokI VDR polymorphism may have a strong influence on the 
emergence of MS. The f allele and the ff genotype seem to be risk factors for MS, while 
the F allele and the FF genotype appear to play a protective role. Our findings are in line 
with Aslani et al.,32 who found that the frequency of the ff genotype was two-fold in 
postpartum Iranian women with MS compared to healthy participants during the 
postpartum follow-up (OR=2.1; 95% CI: 0.90–4.89; P=0.09). On the contrary, another 
recent study on the same population in Iran did not observe any significant associations 
between the FokI VDR polymorphism and MS in adult males nor females.33 Results from 
other studies in northern China3, the United Arab Emirates (UAE)26, and Brazil2 are also 
consistent with this finding. The variations and inconsistencies between these studies 
could be attributed to the environmental factors in different populations.25 Moreover, the 
frequency of the VDR FokI genotypes and alleles differ substantially between ethnic 
groups and even within the same population samples,26 as previously observed in the 
contradictory findings regarding the Iranian population. Such heterogeneity in allele and 
genotype distribution leads to varying susceptibility to diseases.22  
There are very few studies on MS in pregnancy. In our study, the prevalence of 
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MS among pregnant women was 12%. Another study recently conducted in the UAE 
found that the prevalence of MS among adults was 14.6%.26 Furthermore, 66% of our 
study population was either overweight or obese. This finding is congruent with another 
large cohort study performed in Saudi Arabia, in which 68% of pregnant women were 
found to be either overweight or obese.9 According to a recent report by the World Health 
Organization (WHO), the prevalence of obesity and overweight among females aged 15 
years or older in Saudi Arabia is approximately 65.9%, which is one of the highest in the 
Eastern Mediterranean Region, and this figure is predicted to rise to 78% by the year 
2022.34 The increasing prevalence of obesity among females in Saudi Arabia is 
concerning due to the myriad of adverse health outcomes it can cause in mothers and 
their offspring.35 Obesity is a risk factor for many maternal and neonatal complications, 
including increased incidence of GDM, hypertension, cesarean-section delivery, fetal 
macrosomia, shoulder dystocia, and perinatal mortality.1,36 In addition, obesity in 
pregnancy has a negative effect on fetal metabolic programming, thereby causing a long-
term, adverse metabolic condition in the child, such as obesity, diabetes, and CVD.36,37 
A significant body of evidence has revealed associations between obesity and 
vitamin D deficiency. Since vitamin D is fat-soluble, it becomes sequestered in fat cells 
in a form that is not bioavailable.38 Obese individuals tend to have a higher body fat 
percentage, thus reducing the circulating level of serum 25(OH)D.21,38 Another known 
causation linked to obesity and vitamin D deficiency is the reduction of cutaneous 
vitamin D synthesis as a result of decreased sunlight exposure due to clothing habits or 
limited outdoor activity.39,40 In our study, 85% of pregnant women were found deficient 
in vitamin D (25[OH]D <50 nmol/L). This rate exceeds Al-Faris’s report in 201624 that 
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50% of pregnant Saudi women living in Riyadh were vitamin D deficient, but Al-Ajlan et 
al.’s41 results contained the highest rate; they found that 94% of pregnant Saudi women 
had vitamin D deficiency or insufficiency (25[OH]D <50 nmol/L). 
Previous studies have reported a link between the FokI VDR polymorphism and 
obesity. In Egypt, Mackawy and Badawi27 found that the ff genotype was associated with 
higher waist circumference in diabetic patients with MS, compared to the FF genotype in 
the same group. Similarly, Zaki et al.21 reported higher frequencies of the mutant allele f 
in obese Egyptian women with vitamin D deficiency, compared to healthy obese women 
with sufficient levels of vitamin D. In their preliminary study on obese Pakistanis, Haris 
and Baig42 observed a potential association between the ff genotype and obesity. Zhao et 
al.3 also found that the FF genotype was associated with lower BMI, compared to the ff 
and Ff genotypes, in Chinese adults with MS. Aslani et al.32 also found a significant 
association between the f allele and pre-pregnancy obesity in pregnant Iranian women. In 
our study, however, the control-group carriers of the FF genotype presented higher pre-
pregnancy BMI than the pregnant women carrying the Ff and ff genotypes. This indicates 
that the ff genotype may be a protective factor against obesity, but the level of association 
did not reach statistical significance. A possible explanation for the variation between 
these studies could be related to ethnicity and environmental factors. 
 It is well known that vitamin D plays a powerful role in regulating blood pressure 
by suppressing renin biosynthesis for the modulation of the renin–angiotensin system 
(RAS).43 Vitamin D also has anti-hypertensive properties by enhancing endothelial 
vasodilation as well as reducing advanced glycation products and oxidative stress.41 We 
found that vitamin D deficient subjects had significantly higher systolic blood pressure 
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than non deficient (P=0.032). Similarly, a cross-sectional study found that low levels of 
serum 25(OH)D may be correlated with high blood pressure and increased rates of 
incident hypertension.44 We also found a significant inverse correlation between serum 
25(OH)D and diastolic blood pressure across all genotypes in the control group (non-MS 
patients) (r=-0.16). It is also notable that carriers of the mutant genotype ff demonstrated 
a higher incidence of hypertension (>130/85) compared to carriers of the homozygous 
and heterozygous genotypes. While these results are not statistically significant, they are 
consistent with Zaki et al.’s 21 findings, who reported that obese Egyptian women 
carrying both genotypes Ff and ff showed significantly higher blood pressure compared to 
those with the common homozygous genotype FF. Two studies found a significant 
association between the FF genotype and the risk of high blood pressure; one study 
linked the FF genotype to higher systolic blood pressure in Emirati women,26 while the 
other study associated the FF genotype with hypertension in Indian adults.19 Both studies 
attributed the cause of hypertension or elevated blood pressure to the effect of FF 
homozygotes enhancing the production of renin and angiotensin II. In contrast to these 
findings, Cottone et al.45 did not detect any significant associations between blood 
pressure and the FokI VDR polymorphism, nor between blood pressure and serum 
25(OH)D levels, in hypertensive Italian patients. A meta-analysis concluded that vitamin 
D supplementation is ineffective in lowering systolic or diastolic blood pressure and thus 
should not be used as an anti-hypertensive agent.46 Such discrepancies in previous studies 
may be related to genetic differences in the sample populations or their exposure to 
different environmental factors. Until future research determines a significant association 
between the FokI VDR polymorphism and maternal hypertension, it should be stressed 
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that pregnant women with hypertension are at increased risk of delivering a premature 
baby as well as other serious complications, such as a defect in endothelial-dependent 
vascular function, compared to healthy pregnant women.10 These issues should be 
carefully addressed when defining high risk pregnancies, and preventative measures 
should be undertaken.  
The expression of VDR has been detected in various human tissues and cells, 
including adipocytes.27 Vitamin D is known to interact with VDR in adipose tissue, 
thereby forming the vitamin D-VDR axis, which is important for the metabolic activation 
of vitamin D.26 Any change in the axis caused by, for example, vitamin D deficiency or 
VDR polymorphism could affect the lipid profile through many different mechanisms.47 
Vitamin D can directly affect adipocyte differentiation and metabolism through the 
stimulation of parathyroid hormone secretion, thus depressing lipolysis.39,48 Additionally, 
vitamin D increases intestinal calcium absorption, which reduces the formation and 
secretion of TG by the liver, thereby causing a decrease in serum TG levels.49 It has also 
been found that vitamin D raises the concentrations of apolipoprotein A-1, which is the 
main protein component in HDL-C.50 Vitamin D can also indirectly influence lipid 
metabolism by improving insulin secretion and sensitivity.51 All these hypothesized 
mechanisms contribute to a favorable lipid profile with a decreased risk of CVD. 52 
Consistent with this notion, many studies have associated VDR gene 
polymorphism with dyslipidemia.26,27,50,52 Schuch et al.2 found that participants who did 
not have MS and who were carrying the mutant, homozygous genotype (ff) had 
significantly higher TG levels and lower HDL levels compared to those with the 
heterozygous (Ff) or normal homozygous (FF) genotypes. Other authors have reached 
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reciprocal outcomes. Mackawy et al.27 observed higher plasma TC, TG, and LDL-C with 
lower HDL-C levels in diabetic, non-MS carriers of the ff genotype compared to carriers 
of the FF genotype. Additionally, Hasan et al.26 reported higher serum TC levels in 
Emirati carriers of the ff genotype compared to other genotypes of the FokI VDR 
polymorphism. These previous studies are in line with our findings, which revealed that 
all participants carrying the mutant, homozygous genotype were at higher risk of 
developing dyslipidemia compared with those carrying the normal homozygous and 
heterozygous genotypes. However, these results are not statistically significant. 
Moreover, all pregnant women with MS, regardless of their genotypes, expressed 
significant associations between HDL and serum 25(OH)D levels. Similarly, in the 
control group (non-MS), the serum 25(OH)D level was found to be significantly 
associated with HDL, LDL, and TC in all pregnant carrying FF genotypes. Surprisingly, 
we found that non-deficient vitamin D women had higher lipid profile compared to 
vitamin D deficient women. Our unexpected result was similar to the finding of Al-Ajlan 
et al,41 who reported that in the subgroup of vitamin D-deficient, pregnant Saudi women, 
their serum vitamin D levels were significantly and positively correlated with their serum 
TG and TC levels. One possible explanation for this outcome, as speculated by the 
researchers, could be the combination of vitamin D deficiency, which was highly 
prevalent among the study sample, with the high metabolic demands of pregnancy.41 It 
has been known that as pregnancy progresses, there is a marked increase in plasma lipid 
concentrations, which mimics the markers of MS.4, 35 While increased lipid levels are 
considered normal physiological changes during pregnancy, maternal hyperlipidemia 
could cause serious health issues in the fetus by disrupting normal placentation and 
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damaging the vessel wall via increased oxidative stress.11 Previous studies have shown a 
strong relationship between hyperlipidemia and increased incidence of preterm birth, 
which is considered a leading cause of prenatal morbidity and mortality.53,54 
As previously mentioned, the presence of VDR in human tissue, including 
pancreatic -cells, inspired many researchers to study the association between VDR gene 
polymorphism and glucose homeostasis.26,32 In Brazil, Schuch et al.2 observed  
significantly higher -cell secretion (HOMA-) in individuals carrying the f allele than 
those carrying the F allele. Both Schuch et al.2 and Zaki et al.21 reported a significant 
association between the ff genotype and a higher HOMA-IR, compared to the FF and Ff 
genotypes of the FokI VDR polymorphism, in Brazilian and Egyptian populations, 
respectively. Similarly, Mackawy et al.27 found that diabetic Egyptian patients with MS 
who carried the ff genotype presented higher insulin levels and HOMA-IR than those 
with the FF and Ff genotypes. These outcomes support our finding of a statistically 
significant and inverse correlation between serum 25(OH)D levels and fasting serum 
glucose in pregnant women carrying ff genotype in MS group.  
There are very few studies available that examined the effect of the FokI VDR 
polymorphism on GDM. A link between the FokI VDR polymorphism and GDM risk 
was conducted among Iranian32 and Saudi populations,55 with contradictory results. In 
Iran, Aslani et al.32 found that the frequency of the ff genotype in GDM patients was 
higher than in normal pregnant women (10.6% vs. 6.2%). A higher frequency of the F 
allele was also observed in healthy subjects (P=0.06), suggesting that the F allele may 
represent a protective factor against GDM.33 In Saudi Arabia, El-Beshbishy et al.55 also 
found a higher frequency of the F allele (56.4% vs. 35.7%) and a lower frequency of the f 
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allele (43.6% vs. 64.3%) in their control group compared to their GDM group, but the 
results were not statistically significant (P=0.100). The authors concluded that there was 
no significant association between the FokI VDR polymorphism and GDM in the Saudi 
population.55 The present results agree with El-Beshbishy et al.,55 as we did not observe 
any statistically significant associations between GDM and the FokI VDR polymorphism. 
However, a logistic regression analysis revealed that carriers of the ff genotype are at 
higher risk of developing GDM, compared to carriers of other genotypes of the FokI 
VDR polymorphism (odds ratio=1.27; 95% CI: 0.76–2.14; P=0.360, after adjustments for 
age and BMI). In support of the present findings, Al-Daghri et al.56 found a statistically 
significant association between the F allele and a reduced risk of developing T2DM 
among the Saudi population (P=0.02). It is well known that GDM mimics T2DM in its 
pathology, as both conditions cause defects in insulin secretory response.57 We speculate 
that a larger cohort study with sufficient statistical power is necessary to affirm the 
potential of VDR genetic variation in predicting GDM.  
The pathophysiological mechanisms of the previous associations are still unclear. 
It has been hypothesized that vitamin D plays a role in glucose homeostasis through 
several underlying pathways; for example, the active hormonal metabolite of vitamin D 
(1,25-dihydroxyvitamin D) binds to the VDRs of pancreatic β-cells, which stimulates 
insulin secretion and regulates the balance between the extracellular and intracellular 
calcium pools.57 Thus, calcium is an important co-factor for insulin-mediated intracellular 
functions in insulin-responsive tissues, as any changes in intracellular calcium may cause 
peripheral insulin resistance.58 In addition, the VDR affects glucose homeostasis via the 
insulin-like growth factor system;23 any genetic changes in the VDR might contribute to 
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the pathogenesis of GDM via alterations in calcium metabolism and modulation of 
insulin secretion.27 GDM can have serious consequences with lasting metabolic changes 
for both mother and offspring.1 Long-term cohort studies have reported that women with 
GDM have an 35–65% increased risk of developing T2DM later in life, and their 
offspring are more likely to develop obesity and T2DM in childhood and adulthood.1,57 
In our study, vitamin D deficiency was evident in 85% of the sample population. 
Our results are in line with Al Foda et al.59 and Al-Sheikh et al.60 who reported a high 
prevalence of vitamin D deficiency amounting to 86%. We did not detect any significant 
difference between MS and controls in regards to vitamin D deficiency, as both groups 
had high prevalence of vitamin D deficiency.   
We acknowledge that there are some limitations in our study. Due to the limited 
frequency of mutant ff genotype, we were not able to observe an association between 
FokI and components of MS. We strongly believe for future prospective studies, a 
sufficient statistical power is vitally needed, especially when studying the effect of 
mutant ff FokI genotype on MS and its components. In addition, we analyzed the VDR 
gene at only one SNP—albeit one that translates structurally diverse VDR proteins, 
which vary in their potential to elicit vitamin D-mediated gene expression. Unfortunately, 
we did not control for confounding factors such as dietary habits, physical activity or 
other lifestyle factors, which may impact the risk of MS. Despite these limitations, and to 
our best knowledge, this study is the first to examine the relationships between the FokI 
VDR polymorphism and MS, as well as its components, among pregnant Saudi women; 
in fact, no previous study has investigated such associations in pregnancy among any 
population. Accuracy can also be assured in our vitamin D measurements, as we 
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investigated the role of vitamin D status and correlated it with different variables related 
to the components of MS in all FokI genotypes. Unlike previous epidemiological studies, 
detailed and valid data for each MS component, such as blood pressure, and the fasting 
serum samples, including the lipid, glucose, and insulin concentrations, were precisely 
measured and not self-reported.  
 
6.6 Conclusion 
The past few years have seen dramatic changes to the lifestyle of Saudi Arabians, 
which have led to notable increases in the prevalence of MS, especially among pregnant 
women, associated with an increased incidence of CVD, T2DM, GDM, and dyslipidemia 
in the Saudi population. Despite this, there is a marked lack of research on the genetic 
risk factors, such as VDR gene polymorphism, in MS occurrence among this population,  
and no study has examined such associations during pregnancy.  
To address this issue, we conducted a study to observe the effect of the FokI VDR 
polymorphism on the pathology of MS and its components among pregnant Saudi 
women. We found a statistically significant association between the FokI VDR 
polymorphism, specifically in carriers of the ff genotype, and an increased risk of MS 
among the sample. This association could be a prognostic tool for predicting the risk of 
developing MS in pregnancy. 
Knowledge of the associations between the FokI VDR polymorphism and the risk 
of MS is crucial for many reasons. One is that the early diagnosis of MS during 
pregnancy allows for the identification of patients who are at risk of developing CVD and 
other adverse metabolic changes.61 Another reason is that early intervention, such as 
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vitamin D supplementation, can be used to treat this condition and mitigate its adverse 
effects on mothers and their offspring.  
The results of our study suggest that the FokI VDR polymorphism may affect the 
components of MS, namely obesity, dyslipidemia, and GDM, but the correlation is not 
statistically significant. Our findings warrant further investigations using larger cohorts as 
well as future associative studies on other VDR gene polymorphisms. 
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Table 6.1 Demographic and biochemical characteristics of MS vs. normal subjects 
Parameters All Metabolic 
Syndrome 
Control P-value* P-value**  
N 368 44 (12.0) 324 (88.0) 
Age (years) 29.1±5.6 31.3±6.9 28.7±5.3 0.02 
Pre-pregnancy 
BMI 
(kg/m2) 
26.9±5.9 33.3±4.1 25.9±5.5 <0.001 
Current BMI 
(kg/m2) 
28.2±6.2 34.7±4.5 27.5±5.9 <0.001 0.956 
Parity 2 (1-4) 2(1-5) 2(1-4) 0.210 0.539 
SBP (mmHg) 113.3±12.9 119.1±15.7 112.3±12.1 0.020 0.272 
DBP (mmHg) 66.9±9.2 71.7±11.4 66.1±8.5 0.010 0.030 
HbA1C (%) 4.8±0.5 5.1±0.7 4.8±0.8 <0.001 0.005 
FBG (mmol/L) 4.6 ± 1.0 5.6±1.5 4.5±0.8 <0.001 <0.001 
HOMA_IR 1.5 (0.9-2.5) 3.1 (1.7-5.2) 1.3 (0.9-2.3) <0.001 <0.001 
Insulin (uU/ml) 7.5 (4.5-
13.1) 
14.2(7.9-22.8) 6.9(4.1-11.9) <0.001 0.003 
HDL-C (mmol/L) 1.5±0.4 1.3±0.5 1.6±0.4 <0.001 <0.001 
LDL-C (mmol/L) 3.9±1.3 3.9±1.4 3.9±1.3 0.698 0.269 
TC (mmol/L) 6.2±1.2 6.4±1.3 6.2±1.5 0.271 0.084 
TG (mmol/L) 1.8(1.4-2.3) 2.6(2.1-3.4) 1.7(1.3-2.2) <0.001 <0.001 
25(OH)D 
(nmol/L) 
33.4(21.3-
53.7) 
29.9(17.9-44.6) 33.7(21.7-54.4) 0.232 0.186 
Vitamin D 
deficiency 
(<50nmol/L) 
314 (85.3) 38 (86.4) 276 (85.2) 0.291 0.199 
Note: Pre-preg BMI: Pre-pregnancy body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure; FBG: fasting blood glucose; HbA1C: haemoglobin A1c or glycated haemoglobin; HDL: High-
density lipoprotein Cholesterol; LDL: low-density lipoprotein Cholesterol; TC: Total Cholesterol, TG: 
Triglycerides. Data Presented as Mean ± SD and Median (25th -75th) percentiles for Gaussian and Non 
Gaussian variables. *P-value adjusted for age & pre-pregnancy BMI; significant at 0.05 and 0.01 levels. 
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Table 6.2 The genotype distribution of VDR FokI polymorphisms in MS and control groups 
 
 
 
 
 
 
 
 
 
Note: ORs: Odds ratio (95% CI); *P-value significant at < 0.05, **P-value adjusted for age and significant at <0.05,0.01 
 
 
FokI 
Genotype 
All MS Control β OR (95 % CI) *P-
Value 
Adjusted OR ** P-Value 
 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
 
225 (61.1) 
118 (32.1) 
25 (6.8) 
143 (38.9) 
 
568 (77.2) 
168 (22.8) 
 
 
22 (50.0) 
16 (36.4) 
6 (13.6) 
22 (50.0) 
 
60 (68.2) 
28 (31.8) 
 
 
203 (62.7) 
102 (31.5) 
19 (5.9) 
121 (37.3) 
 
508 (78.4) 
140 (21.6) 
 
 
0.37 
1.07 
0.52 
 
 
0.53 
 
1 
1.45 (0.73-2.88) 
2.91 (1.05-8.1) 
1.68 (0.89-3.16) 
 
1 
1.69 (1.04-2.75) 
 
 
 
0.291 
0.039 
0.109 
 
    0.034 
 
 
1 
1.42 (0.71-2.9) 
4.17 (1.42-12.2) 
1.76 (0.92-3.36) 
 
1 
1.84 (1.05-1.14) 
 
 
0.307 
0.009 
0.090 
 
0.017 
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Table 6.3 Clinical characteristics of the FokI VDR genes polymorphisms in MS and 
control groups 
Parameters FF Ff ff P-value 
Metabolic Syndrome 
N 22 16 6 
Age (years) 29.1±5.4 28.5±5.3 26.8±3.6 0.190 
Pre-preg BMI 
(kg/m2) 
34.2±4.8 33.3±2.6 30.3±4.3 0.127 
Current BMI 
(kg/m2) 
35.3±4.8 34.8±3.1 32.6±6.3 0.430 
Parity 2.0(1.0-5.0) 3.0(1.0-7.0) 4.0(2.0-6.0) 0.635 
SBP (mmHg) 111.9±12.3 112.9±11.4 112.3±14.2 0.870 
DBP (mmHg) 65.6±8.3 67.2±9.1 65.3±7.9 0.471 
HbA1C (%) 4.7±0.4 4.8±0.6 4.8±0.4 0.645 
FBG (mmol/L) 4.5±0.9 4.4±0.7 4.5±0.3 0.594 
HOMA_IR 3.7 (1.9-5.3) 3.7(1.7-5.9) 2.1(1.1-2.7) 0.132 
Insulin (uU/ml) 7.4 (4.1-12.3) 6.4 (4.2-10.9) 6.4 (3.6-17.9) 0.907 
HDL-C (mmol/L) 1.6±0.4 1.5±0.4 1.6±0.4 0.949 
LDL-C (mmol/L) 3.8±1.3 3.9±1.2 3.7±1.0 0.749 
TC (mmol/L) 6.2±0.6 6.2±1.4 6.2±1.2 0.996 
TG (mmol/L) 2.7 (2.1-3.2) 2.5 (2.2-3.4) 3.3 (2.2-3.4) 0.761 
25(OH)D 
(nmol/l) 
29.9 (18.0-46.9) 37.3(20.4-60.6) 22.2(15.7-28.3) 0.234 
Control 
N 203 102 19  
Age (years) 32.4±7.1 31.8±6.6 26.3±5.5 0.144 
Pre-pregnancy BMI 
(kg/m2) 
26.6±5.9 24.7±4.3 25.9±5.7 0.021 
Current BMI 
(kg/m2) 
27.9±6.3 25.9±4.7 27.0±5.9 0.027 
Parity 2.0(1.0-4.0) 2.0(1.0-3.0) 1.0(1.0-2.0) 0.439 
SBP (mmHg) 120.1±15.3 119.3±15.5 112.0±22.5 0.720 
DBP (mmHg) 70.8±11.6 73.4±10.3 69.7±18.5 0.796 
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HbA1C (%) 5.1±0.6 5.0±0.8 5.2±0.9 0.840 
FBG (mmol/L) 5.4±1.5 6.2±1.6 5.0±0.9 0.156 
HOMA_IR 1.4 (0.8-2.3) 1.2 (0.8-2.1) 1.3 (0.8-3.6) 0.616 
Insulin (uU/ml) 16.2 (9.3-22.7) 15.5 (6.7-24.7) 7.9 (6.0-11.7) 0.081 
HDL-C (mmol/L) 1.3±0.5 1.4±0.5 1.2±0.2 0.802 
LDL-C (mmol/L) 4.1±1.6 3.7±1.2 4.1±0.9 0.744 
TC (mmol/L) 6.4±1.3 6.4±1.4 6.6±0.9 0.922 
TG (mmol/L) 1.7 (1.3-2.2) 1.7 (1.2-2.2) 1.6 (1.4-2.3) 0.729 
25(OH)D 
(nmol/l) 
34.3(23.2-54.5) 31.4(18.8-52.1) 40.4(23.2-85.1) 0.090 
Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and non-
Gaussian variables. P-value significance at 0.05. 
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Table 6.4 Risk predictions for different genotypes and alleles of FokI VDR gene polymorphisms in relation to metabolic 
syndrome and its components 
Parameters Yes β OR (95 % CI) P-Value 
Obesity (≥ 30 kg/m2) 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
101 
66 (65.3) 
28 (27.4) 
7 (7.4) 
35 (34.8) 
 
160 (28.3) 
42 (25.1) 
 
 
 
0.030 
-0.363 
-0.291 
 
 
-0.169 
 
1 
1.03 (0.40-2.63) 
0.70 (0.41-1.18) 
0.75 (0.46-1.22) 
 
1 
0.84 (0.56-1.27) 
 
 
0.950 
0.179 
0.245 
 
 
0.844 
Elevated Blood Pressure (> 130/85) 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
44 
19 (46.2) 
19 (46.2) 
6 (7.7) 
25 (53.9) 
 
57 (10.3) 
31 (14.7) 
 
 
0.464 
0.616 
0.592 
 
 
0.409 
 
1 
1.59 (0.32-7.89) 
1.85 (0.79-4.34) 
1.81 (0.79-4.11) 
 
1 
1.51 (0.80-2.83) 
 
 
0.571 
0.157 
0.157 
 
 
0.205 
Low HDL-C (< 1.3 mmo/l) 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
126 
76 (60.0) 
42 (33.0) 
8 (7.0) 
50 (40.0) 
 
194 (33.8) 
58 (35.8) 
 
 
0.072 
0.133 
0.122 
 
 
0.087 
 
1 
1.07 (0.44-2.66) 
1.14 (0.70-1.87) 
1.13 (0.71-1.79) 
 
1 
1.09 (0.75-1.59) 
 
 
0.877 
0.595 
0.604 
 
 
0.652 
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Hypertriglyceridemia (> 1.7 mmol/l) 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
202 
127 (62.8) 
60 (29.6) 
15 (7.5) 
75 (37.1) 
 
314 (55.6) 
90 (53.6) 
 
 
0.131 
-0.240 
-0.175 
 
 
-0.079 
 
1 
1.14 (0.49-2.65) 
0.79 (0.50-1.23) 
0.84 (0.55-1.28) 
 
1 
0.92 (0.65-1.31) 
 
 
0.761 
0.297 
0.419 
 
 
0.656 
Hypercholesterolemia ( > 5.7 mmol/l) 
FF 
Ff 
ff 
Ff+ff 
 
F 
f 
233 
137 (58.5) 
78 (33.6) 
18 (7.9) 
96 (41.5) 
 
352 (62.1) 
114 (68.1) 
 
 
0.501 
0.237 
0.282 
 
 
0.265 
 
1 
1.65 (0.66-4.12) 
1.27 (0.79-2.03) 
1.33 (0.85-2.07) 
 
1 
1.31 (0.90-1.89) 
 
 
0.283 
0.324 
0.214 
 
 
0.158 
Dyslipidemia 
FF 
Ff 
ff 
Ff+ff 
 
F 
                                     f 
171 
88 (51.5) 
69 (40.5) 
14 (8.0) 
83 (48.5) 
 
245 (71.6) 
97 (29.4) 
 
 
-0.004 
0.470 
0.088 
 
 
0.101 
 
1 
1.00 (0.57-1.75) 
1.60 (0.63-4.10) 
1.09 (0.65-1.84) 
 
1 
1.11 (0.72-1.71) 
 
 
0.324 
0.989 
0.740 
 
 
0.648 
 
 
GDM 
FF 
Ff 
ff 
Ff+ff 
 
F 
                                      f 
108 
65 (60.2) 
36 (33.3) 
7 (6.5) 
43 (39.8) 
 
166 (76.9) 
50 (23.1) 
 
 
-0.04 
0.06 
      0.06 
       
 
  0.03 
 
1 
0.96 (0.38-2.40) 
1.08 (0.66-1.76) 
1.06 (0.66-1.68) 
 
1 
1.03 (0.70-1.50) 
 
 
0.926 
0.755 
0.808 
 
 
0.704 
           Note: Data Represented unstandardized β, odd ratio and (95 % CI). P-value significant at < 0.05.
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Table 6.5: Clinical characteristics of the vitamin D deficient vs. non-deficient 
pregnant Saudi women  
 
Parameters Vitamin D deficient 
25(OH)D<50 nmol/l 
 
Non-deficient 
25(OH)D >50 
nmol/l 
 
P-value 
N 260 (85.3) 108 (14.7) 
Age (years) 28.9 ± 5.7 29.4 ± 5.2 0.470 
Pre-preg BMI 
(kg/m2) 
26.8 ± 6.1 26.9 ± 5.5 0.852 
Current BMI 
(kg/m2) 
28.2 ± 6.5 28.1 ± 5.6 0.835 
Parity 2.0 (1.0-4.0) 1.0 (1.0-3.0) 0.202 
SBP (mmHg) 114.6 ± 12.9 110.8 ± 12.4 0.032 
DBP (mmHg) 67.7 ± 9.1 65.5 ± 9.2 0.070 
HbA1C (%) 
 
6.3 (5.3-7.4) 6.8 (5.6-9.1) 0.756 
FBG (mmol/L) 4.5 (4.1-4.9) 4.2 (3.9-5.1) 0.081 
HOMA_IR 7.6 (4.6-13.1) 6.3 (4.5-12.9) 0.024 
Insulin (uU/ml) 1.5 (0.9-2.5) 1.3 (0.9-2.7) 0.007 
HDL-C (mmol/L) 1.5 ± 0.4 1.6 ± 0.4 0.001 
LDL-C (mmol/L) 3.8 ± 1.3 3.9 ± 1.3 0.671 
TC (mmol/L) 6.1 ± 1.5 6.4 ± 1.4 0.049 
TG (mmol/L) 1.80(1.4-2.3) 1.90 (1.5-2.4) 0.684 
25(OH)D 
(nmol/l) 
29.9 (20.1-46.7) 66.7 (43.4-85.3) <0.001 
Note: Data represented Mean ± SD and Median (25th and 75th) percentile for Gaussian and non-Gaussian 
variables. P-Value Denotes significance at P <0.05 and 0.01. 
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Figure 6.1 Presence of metabolic disorders among pregnant Saudi women in their 
second trimester  
 
 
  
Figure 6.2 Correlation between Log vitamin D (nmol/L) in ff FokI genotypes versus 
FBG in MS subjects 
 
                        
12% 12%
27% 29%
34%
47%
55%
63%
85%
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Figure 6.3 Correlation between Log vitamin D (nmol/L) and diastolic blood pressure (DBP) in controls, 
 regardless of their FokI genotype 
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Figure 6.4 Correlations between Log vitamin D (nmol/L) in FF FokI genotypes 
versus (A) HDL-C, (B) LDL-C, (C) TC in controls 
                                 
                               
 
                              
A 
B 
C 
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CHAPTER 7 
CONCLUSION AND FUTURE DIRECTIONS 
 
7.1 Conclusion 
This is the first study to examine the metabolic impact of the ff VDR genotype 
versus the FF wild type VDR in pregnant Saudi women, who are known to be vitamin D 
deficient. We thoroughly investigated the genetic influence of FokI VDR polymorphism 
on vitamin D deficiency, gestational diabetes, glucose intolerance, and metabolic 
syndrome while controlling for classic confounders that may mask the findings of our 
results. Our findings are important and encouraging because, if replicated and proved 
correct, they will advance the medical field by determining the possible culprit or 
predictor of adverse outcomes for both mother and infant. This new knowledge is 
significant because it will lead to significant changes in current obstetric and pediatric 
practice, facilitating early identification of any at-risk pregnancy and supplementing 
pregnant women with vitamin D. This in turn will reduce the risk of morbidity and 
mortality as well as reduce the economic burden of these chronic diseases. The following 
section highlights our major research results. 
❖ We have successfully identified unique predictors according to the following 
health problems Saudi women face during pregnancy: 
o Vitamin D Deficiency: FokI FF genotype and the F allele might be 
important predictors of an individual’s susceptibility to vitamin D 
deficiency in pregnant Saudi women, thus leaving them unprotected and at 
risk of developing adverse skeletal and non-skeletal health problems. 
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Other identified risk factors for vitamin D deficiency in our study sample 
included full-body clothing coverage, lower levels of physical activity, 
residence in areas other than North Riyadh, working indoors, and the 
amount of sunlight exposure. 
o Gestational Diabetes (GDM): vitamin D deficiency appeared to be a 
major risk for GDM in Saudi women. Although we did not detect any 
association between FokI VDR gene polymorphism and GDM, we found 
that the glucose-lowering effects of a higher vitamin D level may be 
dependent upon the FokI genotype within the Saudi population. Other 
identified risk factors for GDM in our study sample included previous 
history of GDM, fasting insulin, HOMA_IR, and obesity. 
o Metabolic Syndrome (MS): Our results indicate that the presence of the 
ff FokI VDR genotype is a genetic marker for MS risk in pregnant Saudi 
women. However, we did not find any significant association between 
FokI VDR genotype and components of MS in our subjects. This 
meaningful association could be a potential prognostic tool for predicting 
development of MS in pregnancy. 
 
❖ We have observed an alarmingly high prevalence of the following metabolic 
disorders in Saudi women:  
o Vitamin D deficiency was prevalent among 79% of pregnant Saudi 
women in their first trimester. Full-body clothing coverage, lower levels of 
physical activity, residence in areas other than North Riyadh, working 
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indoors, and the amount of exposure to sunlight were found to be major 
risk factors for vitamin D deficiency in pregnant Saudi women. 
o We noticed that in the second trimester, the prevalence of vitamin D 
deficiency increased to 85%. 
o Using IADPSG criteria, we found that about 29% of our participants were 
diagnosed with GDM. This rate is extremely high when compared to the 
overall prevalence of GDM (17.8 %) found in the Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) cohort using the same diagnostic 
criteria as ours. 
o Metabolic Syndrome was evident in 12% of our study population. To the 
best of our knowledge, no study has examined the prevalence of MS in 
pregnancy.  
▪ Prevalence of the components of MS: 66% of our study population 
were either overweight or obese. Moreover, 63%, 55%, 34% of 
participants had hypercholesterolemia, hypertriglyceridemia, and 
low HDL, respectively.  
 
7.2 Future Directions 
Based on our study results, we believe that a more thorough understanding of the 
association between FokI VDR gene polymorphism and metabolic health disorders 
during pregnancy, especially in a population with a high rate of vitamin D deficiency, is 
vital to improving current diagnoses and intervention strategies for both mother and 
child. Therefore, we recommend the following be addressed in future research: 
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❖ Our study indicates the need for sufficient statistical power, especially when 
studying the effect of mutant ff FokI genotype. Unlike the wild FF FokI genotype, 
mutant ff FokI genotype has a limited frequency, thus the role of genotype ff is 
still unclear. The results of our study suggest that FokI VDR gene polymorphism 
may influence MS components, namely obesity, dyslipidemia, and GDM, 
although the correlation was not statistically significant. Our findings warrant 
further investigation in larger cohorts to confirm the potential association. We 
believe that we could have observed a significant association between FokI VDR 
genotype and components of MS if the frequency of mutant ff were high. 
❖ Further research is warranted for investigating the association between FokI VDR 
genotype polymorphism and metabolic outcomes in pregnancy, with substantial 
need to adjust for important classical and non-classical confounders that are 
known to be risk factors for GDM, vitamin D deficiency, and MS. Controlling for 
such covariates will reveal the independent effects of genotype on adverse 
perinatal outcomes, if in fact any association truly exists. 
❖ We call for interventional trials such as supplementing pregnant women, 
especially deficient subjects, with high and safe doses of vitamin D while 
studying the responsiveness of different VDR genotypes. These kinds of trials are 
important as they help to better identify which genotype carrier will benefit the 
most from supplementation. Because we assume that carriers of the mutant ff 
genotype are considered high-risk patients, or “low responders,” they need higher 
doses of vitamin D supplements than non-carriers to achieve sufficient levels and 
benefit the most from treatment.  
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❖ Further studies on healthy subjects are required to identify the genetic predictors 
of 25(OH)D concentrations, as most of the research that investigated such an 
association was conducted with patients who had different diseases. There is a 
possibility that a specific disease could have masked the genetic influence of 
VDR on vitamin D status. 
❖ Through our literature review, we noticed that there are numerous genes involved 
in the vitamin D metabolic pathway, aside from VDR gene, that significantly 
impact vitamin D status and are worth studying. Vitamin D binding protein as 
well as 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1) are among those genes 
that showed significant association with vitamin D status. 
❖ We would like to shed light on a neglected issue yet to be assessed. No studies to 
date have investigated the genetic risk factors, such as VDR gene polymorphism, 
on the occurrence of MS during pregnancy. Examining such a relationship is vital 
for preventing short- and long-term adverse effects on both mother and baby.  
❖ Saudi Arabia has a young population, with more than half of the population 
younger than 25 years. Therefore, research is needed among this age group to 
develop strategies for primary care intervention. If these current high rates of 
vitamin D deficiency, GDM, obesity, MS, and dyslipidemia that we observed in 
our population are not reversed early in life, the future disease burden will soar in 
Saudi Arabia. 
❖ No genome-wide association studies (GWAS) have been conducted in Saudi 
Arabia. These kinds of studies are important for the detection of novel genetic 
variants that may play a role in the occurrence of adverse health outcomes in the 
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Saudi population. Understanding the pathophysiological mechanisms of genes 
related to the vitamin D metabolic pathway might bring insight into the genetic 
components of different diseases in the Saudi population, especially in women of 
child-bearing age. 
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APPENDIX C 
QUESTIONNAIRES 
First and Second visit questionnaires 
 
Research code: 
Date of filling of the 
form: 
Date of filling of the 
form: 
Name: 
Tel or Mobile No: 
Place of birth: 
Week of 
gestation…… 
Date of Birth (age): 
Mother anthropometrics  
❖ Ht....................cm               Current Wt.................kg                    
 Prepregnancy Wt.................. kg 
 Current BMI…………. kg/ m2  
 Before pregnancy BMI…………. kg/ m2   
 
 
❖ Blood Pressure:  ....................  
 
Sociodemographic Measurements 
Education Level 
 
Illiterate   Primary    Intermediate       
Secondary         University         Post 
graduate       
Family Income Per 
month 
No Income less than 5000 S.R     5000-
10000 S.R 
10000-20000 S.R           More than 20000 S. 
R 
Occupation 
 House wife      Retired      Student       
Teacher 
Employee Physician Businesswomen   
 Other (………) 
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Marital 
status 
 Married            Single 
Divorced           Widow 
Does your 
husband a 
relative? 
Yes     No                      
Relative degree     First degree    Second degree 
Living area 
 North Riyadh       West Riyadh 
East Riyadh          South Riyadh      Center Riyadh 
Skin color 
 North Riyadh      West Riyadh 
East Riyadh         South Riyadh      Center Riyadh 
Clinical Measurements 
Medical history: Family 
 HTN               Hyperlipidemia                           Heart disease                   
Osteoporosis 
  Asthma            Cancer                                       Liver Disease                     
 Kidney Disease 
 Others: …………………………………. 
 Diabetes       1st degree relatives       mother     father      siblings        
children    
                         2nd degree relatives      grandparents     uncle(mother) 
uncle(father)    grandchildren 
              
  GDM          1st degree relatives       mother    sister     daughter 
                         2nd degree relatives      grandmother     aunt(mother)      
aunt(father)   grandchildren 
   Obesity      1st degree relatives       mother     father      siblings        
children   
                         2nd degree relatives      grandparents    uncle(mother)    
uncle(father)  grandchildren              
 
Medical history: Subject 
HTN                      Hyperlipidemia                 Polycystic ovarian 
syndrome           Osteoporosis 
 Asthma         Anemia                    GDM                                IGT                       
  Obesity 
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Others: …………………………………. 
Age of menarche: …………. 
Menstrual cycle           Regular          Irregular 
Age at first pregnancy: …………. 
LMP (last menstrual period): …… EDD (expected date of delivery) by date: 
………    
Risk Factors: 
-The head circumference of last baby………………… 
-Usage of insulin or its alternatives  Yes     NO 
-Parity (how many times she got pregnant): …………… Number of 
children…………… 
- Previous caesarean section Yes     No, how many………. 
-Miscarriages if occurs?   Yes          No       If yes, how many 
times?...............Reasons……………  
-Preeclampsia                 Yes          No        -Gestational HTN         Yes       
   No 
 
If any occurred in the past:     Poly urea         Glycosuria              
Protein urea 
-Pregnancy symptoms:  
Nausea                             vomiting                       morning sickness       
headache          mood swings  
abdominal bloating           frequent urination       constipation                
 tender swallow breast 
-Pregnancy complications:  …………………………………………….. 
 
 
List of medications:  
Please a check on all medications used by the subject 
Anti-
Hyperlipidemics 
[    ] Atorvastatin 
– Lipitor, Torvast 
[    ] Mexiletine – Novo – Mexiletine 
[    ] Procainamide – Procan 
[    ] Propafenone – Rhythrnol, Nu, Apo, Gen, PMS 
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[    ] Cerivastatin – 
Lipobaby 
[    ] Fluvastatin – 
Lescol, Lescol XL 
[    ] Lovastatin – 
Mevacor, Altocor, 
Altoprev 
[    ] Mevastatin  [    
] Pitavastatin – 
Livalo, Pitava 
[    ] Pravastatin – 
Pravachol, 
Selektine, Lipostat 
[    ] Rosuvastatin 
– Crestor 
[    ] Simvastatin – 
Zocor, Lipex 
[    ] Simvastatin + 
Ezetimibe – 
Vytorin 
[    ] Atorvastatin 
+ Amlodipine – 
Caduet 
[    ] Simvastatin + 
Niacin – Simcor 
[    ] 
Cholestyramine [    
] Gemfibrozil 
[    ] Colestipol [    
] Benzafibrate, 
fenofibrate 
Cardiovascular 
drugs 
[    ] Digoxin 
[    ] Clonidine 
[    ] Methyldopa 
[    ] Diazoxide 
[    ] Hydralazine 
[    ] Isosarbide dinitrate 
[    ] Nitroglycerin 
[    ] Prazosin, Terazosin, Dozazosin 
[    ] Atenolol, Acebutolol, Bisoprolol, Labetalol, 
Metaoprolol, Nadolol, Oxprenolol, Pndolol, 
Propranolol, Sotalol, Timolol 
[    ]  Amlodipine, Felodipine, Nifedipine 
[    ] Diltiazem, Verapamil 
[    ] Captopril, Benazepril, Enalapril, Cilazapril, 
Perindopril, Quinapril, Ramipril, Lisinopril 
[    ] Candesartan, Irbesartan, Losartan, Telmisartan, 
Valsartan,  
[    ] Spironolactone   [    ] Hydrochlorothiazide 
[    ] Furosemide        [    ] Pentoxyphylline 
Other (Please specify) 
1. _______________________________
__ 
2. _______________________________
__ 
3. _______________________________
__ 
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[    ] Aspirin          
[    ] Warfarine         
[    ] Heparin  
[    ] Clopidogrel     
[    ] Amiodarone – 
Amiodarone, 
Cordarone 
[    ] 
Disopyramide – 
Rythmodan 
[    ] Flecainide 
acetate – Apo – 
Flecainide 
 
 
Second visit questionnaires 
Research code: 
Date of filling of 
the form: 
Date of filling of the form: 
Name: 
Tel or Mobile No: 
Place of birth: 
Week of 
gestation…… 
Date of Birth (age): 
Anthropometric Measurements 
  
❖ Ht....................cm               Current Wt.................kg                    
 Prepregnancy Wt.................. kg 
 Current BMI…………. kg/ m2  
 Before pregnancy BMI…………. kg/ m2   
 
❖ Blood Pressure:  ....................  
 
  182 
Clinical Measurements 
o Pregnancy symptoms:  
Nausea         vomiting           morning sickness        headache          
mood swings  
abdominal bloating           frequent urination     constipation      
tender swallow breast 
            
o Any complains or diagnosis……………………………… 
 
Gestational HTN        Anemia                     Viral or Bacterial illnesses 
Preeclampsia             Respiratory                 Gastrointestinal           
bacterial vaginosis 
 
Food Frequency Questionnaire 
Dietary intake of vitamin D and calcium Questionnaire 
Breakfast cereals and bread 
Daily 
 
Weekly Amount 
Cornflakes 1 2 3 1 2 3 4 5 6 M R No 
.......…  
Cup/ week 
Cornflakes 
with sugar and 
Coco Pops 
1 2 3 1 2 3 4 5 6 M R No 
……… Cup/ 
week 
 Weciabix, 
Shredded wheat 
1 2 3 1 2 3 4 5 6 M R No 
…........ 
Cup/ week 
 Bran flakes, 
Wheat flakes or 
Sultana 
1 2 3 1 2 3 4 5 6 M R No 
…........ 
Cup/ week 
 Brown Bread 1 2 3 1 2 3 4 5 6 M R No 
………..toas
t/ week or 
………..1/4 
loaf 
White Bread 1 2 3 1 2 3 4 5 6 M R No 
………..toas
t/ week or 
………..1/4 
loaf 
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White 
Bread(Samoli,bu
rger) 
1 2 3 1 2 3 4 5 6 M R No 
………..toas
t/ week or 
………..1/4 
loaf 
Shaboorah 
(bran or white) 
1 2 3 1 2 3 4 5 6 M R No 
………..piec
es/week 
*M (1-3 times per month), R(rarely), NO (don’t take it at all) 
Meat and Fish 
Daily 
 
Weekly Amount 
White fish 
(hamoor), fish 
fingers 
1 2 3 1 2 3 4 5 6 M R No 
 .......…  gm  
Fried / 
Grilled 
Oysters, shrimp 1 2 3 1 2 3 4 5 6 M R No 
.......… gm  
Fried / 
Grilled 
Canned fish 
(canned salmon, 
sardines,) 
1 2 3 1 2 3 4 5 6 M R No 
.......… 
piece  
With oil / 
water 
Tuna fresh or 
canned             
1 2 3 1 2 3 4 5 6 M R No 
Can/large
/small 
With oil / 
water 
Red meat ( 
.............) 
1 2 3 1 2 3 4 5 6 M R No 
….gm/wee
k 
With fat 
Little fat  
Without fat 
Chicken Type 
..............) ) 
1 2 3 1 2 3 4 5 6 M R No 
….gm/wee
k 
Skin/with
out skin 
Liver, brain 
and kidneys 
1 2 3 1 2 3 4 5 6 M R No 
….gm/wee
k 
With fat 
Little fat  
Without fat 
Egg 
How many eggs 
do you eat? 
1 2 3  1 2 3 4 5 6 M R No 
………Egg/ 
week 
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What kind of eggs do you eat?        yolk       White      Both 
Fats 
What kind of fats used in your food?           Ghee          Margarine         Butte 
            Vegetables oil 
Daily 
 
Weekly Amount 
How many 
times do you use 
veg oil? 
Type…. 
1 2 3 1 2 3 4 5 6 M R No 
........Spoon
/ week 
How many 
times do you use 
olive oil? 
1 2 3 1 2 3 4 5 6 M R No 
........Spoon
/ week 
How many 
times do you use 
butter or ghee? 
Type…. 
1 2 3 1 2 3 4 5 6 M R No 
........Spoon
/ week 
How many 
times do you eat 
Tahini? 
Type…. 
1 2 3 1 2 3 4 5 6 M R No 
........Spoon
/ week 
How many 
times do you 
usually have 
almonds or 
peanuts? 
Type…… 
1 2 3 1 2 3 4 5 6 M R No 
...........Cup
/ week 
*Table spoon (15 ml), cup (240 ml) 
 
Dairy And its Products 
Do you usually drink milk?  
 Yes                     No                                 
If milk is liquid of which type? 
  Cow            Camel                      Goat                 Sheep                    Other  
How many times do you drink fresh milk? 
Daily Weekly Amount 
Full fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
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Low fat 1 2 3 1 2 3 4 5 6 M R No 
………Cup/ 
week 
Skim fat 1 2 3 1 2 3 4 5 6 M R No 
…........Cup
/ week 
 How many times do you drink dried milk? 
Daily Weekly Amount 
Full fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Low fat 1 2 3 1 2 3 4 5 6 M R No 
………Cup/ 
week 
Skim fat 1 2 3 1 2 3 4 5 6 M R No 
…........Cup
/ week 
 How many time do you drink canned milk?      
Daily Weekly Amount 
Full fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Low fat 1 2 3 1 2 3 4 5 6 M R No 
………Cup/ 
week 
Full fat 1 2 3 1 2 3 4 5 6 M R No 
…........Cup
/ week 
Concentra
ted milk 
1 2 3 1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Chocolate  1 2 3 1 2 3 4 5 6 M R No 
………Cup/ 
week 
With 
Strawberry 
1 2 3 1 2 3 4 5 6 M R No 
…........Cup
/ week 
With 
Banana 
1 2 3 1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
other 1 2 3 1 2 3 4 5 6 M R No 
………Cup/ 
week 
How many times do you drink Laban?        
Daily Weekly Amount 
Full fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Low fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Skim fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
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How many times do you have yoghurt?                  
Daily Weekly Amount 
Full fat 1 2 3 
 
1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Low fat 1 2 3 1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
Skim fat 1 2 3 1 2 3 4 5 6 M R No 
.......… 
Cup/ week 
How many times do you have these products?      
Daily Weekly Amount 
Triangle 
Cheese  
1 2 3 
 
1 2 3 4 5 6 M R No 
……Piece/ 
week 
Kerry 
Cheese  
1 2 3 1 2 3 4 5 6 M R No 
……Piece/ 
week 
White 
Cheese 
1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Yellow 
cheese 
1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Fatty 
cheese 
1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Geshtah 1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Labnah 1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Cream 1 2 3 1 2 3 4 5 6 M R No 
……Spoon
/ week 
Mozzarell
a 
1 2 3 1 2 3 4 5 6 M R No 
……..gm/ 
week 
Tofu 1 2 3 1 2 3 4 5 6 M R No 
……Piece / 
week 
* Food spoon= 15 gm 
 
Vegetables and Fruits 
How many times do you eat the following? 
Daily Weekly Amount 
Orange 1 2 3 
 
1 2 3 4 5 6 M R No 
………One/ 
week 
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Fig 1 2 3 1 2 3 4 5 6 M R No 
………One/ 
week 
Dried 
fruits 
(raisins,pea
che) 
1 2 3 1 2 3 4 5 6 M R No 
….......Cup 
/ week 
(fresh or 
cooked) 
kale 
1 2 3 1 2 3 4 5 6 M R No 
……...Cup / 
week 
(fresh or 
cooked) 
celery 
1 2 3 1 2 3 4 5 6 M R No 
……...Cup / 
week 
Spinach 
(fresh or 
cooked) 
1 2 3 1 2 3 4 5 6 M R No 
…...…Cup / 
week 
  (fresh or 
cooked) 
broccoli 
1 2 3 1 2 3 4 5 6 M R No 
…...…Cup / 
week 
Mashroom 
(fresh or 
sundried) 
1 2 3 1 2 3 4 5 6 M R No 
……...Cup / 
week 
Potatoes 
(fried or 
cooked)  
1 2 3 1 2 3 4 5 6 M R No 
………One/ 
week 
Homos,len
tis 
1 2 3 1 2 3 4 5 6 M R No 
...……Cup / 
week 
Fool 
(black 
beans) 
1 2 3 1 2 3 4 5 6 M R No 
…..….Cup / 
week 
*Cup = 240 m 
Cultural Food and others 
 Weekly Amount 
How many times do 
you have Greesh per 
week? 
1 2 3 4 5 6 M R No 
……...Cup/ 
week 
How many times do 
you have Saleeq per 
week? 
1 2 3 4 5 6 M R No 
……...Cup/ 
week 
How many times do 
you have Harees per 
week? 
1 2 3 4 5 6 M R No 
….......Cup/ 
week 
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How many times do 
you have Marase or 
msabeb per week? 
1 2 3 4 5 6 M R No 
……...Cup/ 
week 
How many times do 
you have Pasta with 
cheese or milk 
(lasagna, fettuccine, 
bashamel  ( per week? 
1 2 3 4 5 6 M R No 
……...Cup/ 
week 
How many times do 
you have pizza per 
week? 
1 2 3 4 5 6 M R No 
...…...piece
s/week 
Sweets 
Daily 
 
Weekly Amount 
How many 
times do 
you have 
Ice cream? 
1 2 3 1 2 3 4 5 6 M R No 
……Piece/
week 
Type………
…    
How many 
times do 
you have 
carbonated 
beverages? 
1 2 3 1 2 3 4 5 6 M R No 
……Piece/
week 
Type………
…    
How many 
times do 
you have 
chocolate? 
1 2 3 1 2 3 4 5 6 M R No 
……Piece/
week 
Type………
…    
How many 
times do 
you have 
muffins or 
cake or 
donuts? 
1 2 3 1 2 3 4 5 6 M R No 
……Piece/
week 
Type………
…    
How many 
times do 
you have 
biscuits? 
1 2 3 1 2 3 4 5 6 M R No 
…....Piece/
week 
Type………
…    
How many 
times do 
you have 
cream 
caramel or 
custard? 
1 2 3 1 2 3 4 5 6 M R No 
……Piece/
week 
Type………
…   
Tea and Coffee 
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Daily 
 
Weekly Amount 
How many 
times do 
you drink 
red tea? 
1 2 3 1 2 3 4 5 6 M R No 
…..Cup/ 
week 
Type 
(……………) 
How many 
times do 
you drink 
green tea? 
1 2 3 1 2 3 4 5 6 M R No 
……Cup/ 
week 
Type 
(……………) 
Water 
 Daily Amount 
How many times do you 
drink water? 
1-3 
cups 
3-6 
cups 
6-12 cups 
More than 
12 cups 
Kind? Bottled Water 
water from 
Tanks 
 Tape water 
 
 
Current Season 
Summer              
Winter         
What is the extent of your exposure to the sun? 
 No exposure        
Daily Minutes (…. )   
Weekly Minutes (…….)  
What is the time of exposure to the sun?  
 at sunrise       at noon        
 before sunset 
What is the nature of your work? 
Outside/ directly under 
the sun 
Inside (in covered
rooms/ paces) 
What are the parts of the body most exposed to 
the sun?  
 
Face     
 hands   
Face and hands     
Face, hands and feet 
What is the extent of clothing cover to the 
body during exposure to the sun?  
 
Body except face  
      
Body except face and 
hands   
 Body except face, 
hands and feet       
The whole body  
Body except hands and 
feet 
Do you use sun protection creams? 
 
 Yes 
(type………………)     
 No     
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Physical activity (International Physical Activity Questionnaire) (IPAQ) 
READ:  I am going to ask you about the time you spent being physically active in the last 7 
days. Please answer each question even if you do not consider yourself to be an active 
person.  Think about the activities you do at work, as part of your house and yard work, to 
get from place to place, and in your spare time for recreation, exercise or sport. 
  
READ:  Now, think about all the vigorous activities which take hard physical effort that you 
did in the last 7 days.  Vigorous activities make you breathe much harder than normal and 
may include heavy lifting, digging, aerobics, or fast bicycling.  Think only about those 
physical activities that you did for at least 10 minutes at a time. 
 
1.  During the last 7 days, on how many days did you do vigorous physical activities? 
 
_____  Days per week    [VDAY; Range 0-7, 8,9]  
    8. Don't Know/Not Sure   
    9. Refused 
2.  How much time did you usually spend doing vigorous physical activities on one of those 
days?  
 
__ __  Hours per day     [VDHRS; Range: 0-16]  
__ __ Minutes per day [VDMIN; Range: 0-960, 998, 999]     
998. Don't Know/Not Sure   
999. Refused 
➔Interviewer probe: An average time for one of the days on which you do vigorous activity 
is being sought. If the respondent can't answer because the pattern of time spent varies 
widely from day to day, ask: "How much time in total would you spend over the last 7 days 
doing vigorous physical activities?” 
  
__ __  Hours per week           [VWHRS; Range: 0-112]     
__ __   Minutes per week     [VWMIN; Range: 0-6720, 9998, 9999]   
 9998. Don't Know/Not Sure   
 9999. Refused   
READ:  Now think about activities which take moderate physical effort that you did in the 
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last 7 days.  Moderate physical activities make you breathe somewhat harder than normal 
and may include carrying light loads, bicycling at a regular pace, or doubles tennis.  Do not 
include walking.  Again, think about only those physical activities that you did for at least 
10 minutes at a time. 
 
3.  During the last 7 days, on how many days did you do moderate physical activities? 
 
____ Days per week           [MDAY; Range: 0-7, 8, 9]      
8. Don't Know/Not Sure   
9. Refused  
 
4. How much time did you usually spend doing moderate physical activities on one of those days? 
 
__ __ Hours per day        [MDHRS; Range: 0-16]     
__ __   Minutes per day  [MDMIN; Range: 0-960, 998, 999]    
  998. Don't Know/Not Sure   
  999. Refused   
➔[Interviewer probe: An average time for one of the days on which you do moderate 
activity is being sought. If the respondent can't answer because the pattern of time spent 
varies widely from day to day, or includes time spent in multiple jobs, ask: “What is the total 
amount of time you spent over the last 7 days doing moderate physical activities?” 
 
__ __ Hours per week       [MWHRS; Range: 0-112]  
__ __ Minutes per week   [MWMIN; Range: 0-6720, 9998, 9999] 
 9998. Don't Know/Not Sure   
 9999. Refused 
READ:  Now think about the time you spent walking in the last 7 days.  This includes at 
work and at home, walking to travel from place to place, and any other walking that you 
might do solely for recreation, sport, exercise, or leisure. 
 
5.  During the last 7 days, on how many days did you walk for at least 10 minutes at a time? 
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____ Days per week    [WDAY; Range: 0-7, 8, 9]      
   8.   Don't Know/Not Sure   
   9.   Refused   
6. How much time did you usually spend walking on one of those days? 
 
__ __ Hours per day [WDHRS; Range: 0-16]       
__ __ Minutes per day [WDMIN; Range: 0-960, 998, 999]     
  998. Don't Know/Not Sure   
  999. Refused 
➔[Interviewer probe: An average time for one of the days on which you walk is being 
sought.  If the respondent can't answer because the pattern of time spent varies widely from 
day to day, ask: “What is the total amount of time you spent walking over the last 7 days?” 
 
__ __   Hours per week [WWHRS; Range: 0-112]     
__ __   Minutes per week [WWMIN; Range: 0-6720, 9998, 9999]   
 9998.  Don't Know/Not Sure   
 9999. Refused 
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READ: Now think about the time you spent sitting on week days during the last 7 days.  
Include time spent at work, at home, while doing course work, and during leisure time.  
This may include time spent sitting at a desk, visiting friends, reading or sitting or lying 
down to watch television. 
 
    7.  During the last 7 days, how much time did you usually spend sitting on a week day? 
 
__ __  Hours per weekday  [SDHRS; 0-16]                         
__ __ Minutes per weekday    [SDMIN; Range: 0-960, 998, 999] 
998. Don't Know/Not Sure   
999. Refused 
➔[Interviewer probe]: An average time per day spent sitting is being sought.  If the 
respondent can't answer because the pattern of time spent varies widely from day to day, 
ask: “What is the total amount of time you spent sitting last Wednesday?” 
 
__ __ Hours on Wednesday [SWHRS; Range 0-16]   
__ __ Minutes on Wednesday [SWMIN; Range: 0-960, 998, 999]  
998. Don't Know/Not Sure  
999. Refused    
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